Phthalazine derivatives as pyruvate kinase modulators
Novel pyruvate kinase modulators, particularly compounds of formula (Ia), address the limitations of existing treatments by improving ADME and PK profiles, effectively treating conditions like cancer, obesity, diabetes, and blood disorders through enhanced PK activity.
Patent Information
- Application Number
- JP2024526497
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-08
- Filing Date
- 2022-11-04
- Publication Date
- 2024-11-19
AI Technical Summary
Current pharmacological interventions for diseases associated with pyruvate kinase (PK) dysfunction, such as cancer, obesity, diabetes, and blood disorders, face challenges due to unfavorable ADME and PK profiles, limiting their effectiveness in treating conditions like cancer cell proliferation, insulin resistance, and hemolytic anemia.
Development of novel pyruvate kinase modulators, specifically compounds of formula (Ia), which are designed to activate PKM2 and/or PKLR, offering improved ADME and PK profiles, suitable for treating conditions like cancer, obesity, diabetes, and blood disorders.
The compounds effectively modulate PK activity, enhancing glycolysis and improving insulin sensitivity, reducing cancer cell proliferation, and addressing hemolytic anemia, with potential for better pharmacokinetic and safety profiles compared to existing treatments.
Smart Images

Figure 2024543028000001_ABST
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present invention relates to compounds and their use in the treatment or prevention of inflammatory diseases, diseases associated with an unwanted immune response, cancer, obesity, diabetic diseases, or blood disorders, as well as related compositions, methods, and intermediate compounds. [Background technology]
[0002] BACKGROUND OF THEINVENTION Pyruvate kinase (PK) is the final rate-limiting enzyme in glycolysis, catalyzing the conversion of phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP. In mammals, there are four PK isoforms derived from two separate genes (Alves-Filho et al., 2016). The products of the Pklr gene, PKL and PKR, are expressed in the liver and erythrocytes, respectively. PKM1 and 2 are alternatively spliced products of the Pkm gene. PKM1 is expressed in tissues with high energy demands, such as the heart, muscle, and brain, whereas PKM2 is expressed in embryonic tissues, cancer cells, and normal proliferating cells, such as lymphocytes and intestinal epithelial cells. PKM1 is a constitutively active enzyme, whereas PKM2 is a low activity enzyme that depends on allosteric activation by multiple endogenous regulators, including the upstream glycolytic intermediate fructose-1,6-bisphosphate (FBP). The binding of these allosteric regulators induces a conformational change that promotes tetramerization of PKM2, resulting in an increase in the final rate-limiting step of glycolysis. Pyruvate enters the TCA cycle in mitochondria, where it is used to generate ATP by oxidative phosphorylation. In the absence of allosteric activation, PKM2 adopts a dimeric or monomeric form with low enzymatic activity, leading to the accumulation of glycolytic intermediates that meet the demand for biosynthetic precursors in activated or proliferating cells. Dimeric PKM2 can also translocate to the nucleus, where it can further promote aerobic glycolysis and regulate transcriptional activity, acting as a protein kinase that targets transcription factors and histones.
[0003] Cancer cells primarily utilize glycolysis to generate cellular energy and biosynthetic intermediates (termed the Warburg effect), and PKM2 plays a dominant role in glycolysis to achieve the nutritional demands of cancer cell growth (Chhipa et al., 2018). PKM2 is overexpressed in almost all cancers and has been shown to promote tumor cell proliferation and metastasis. In addition to controlling glycolytic flux, this non-metabolic role of PKM2 as a coactivator and protein kinase contributes to tumorigenesis (Dong et al., 2016). PKM2 directly binds to and phosphorylates histone H3, leading to the expression of c-Myc and Cyclin D1 and the proliferation of cancer cells. Activation of PKM2 tetramers by small molecules could be an attractive therapy to halt tumor growth by interfering with the non-metabolic functions of dimeric PKM2 in cancer.
[0004] Following activation or inflammatory stimuli, PKM2 is upregulated in many immune cells, including macrophages and T cells (Palsson-McDermott et al., 2020). A non-metabolic role of dimeric PKM2 has been shown to regulate immune responses; namely, PKM2 acts as a transcriptional coactivator of Hif-1α, b-catenin, and STAT3, leading to the expression of pro-inflammatory cytokines such as IL-1β and TNFα. Activating PKM2 by small molecules to prevent nuclear translocation may have therapeutic benefit in a range of inflammatory and autoimmune conditions, such as rheumatoid arthritis, inflammatory bowel disease, inflammatory skin conditions, coronary artery disease, and multiple sclerosis.
[0005] In diabetes, PKM2 regulates glucose-responsive pancreatic β-cell function and prevents metabolic stress (Abulizi et al., 2020; Lewandowski et al., 2020). Dimeric PKM2 plays a role in abnormal glycolysis by promoting HIF-1α accumulation, and in diabetic nephropathy, PKM2 has been implicated in a pathogenic role in glomerular injury and epithelial-mesenchymal transition leading to fibrosis (Liu et al., 2020). PKM2 activation has been shown to increase insulin release, improve insulin sensitivity, and prevent the progression of diabetic glomerular symptoms and renal fibrosis (Liu et al., 2020; Abulizi et al., 2020; Lewandowski et al., 2020; Qi et al., 2017).
[0006] Obesity is defined as abnormal or excessive adiposity that presents a risk to health and has been associated with increased incidence of type 2 diabetes and cardiovascular disease. This metabolic disorder is strongly associated with insulin resistance and detrimental effects on glucose metabolism and processing in obese subjects (Barazzoni et al., 2018). Studies on 3T3-L1 adipocytes exposed to different levels of insulin resulted in a significant increase in PKM2 mRNA levels independent of the level of glucose in the medium (Puckett et al., 2021). Studies on the effects of altered PKM2 phosphorylation status and the resulting reduced catalytic activity have confirmed that PKM2 is a likely contributor to insulin resistance in adipose tissue and linked it to metabolic conditions in humans (Bettaieb et al., 2013). Restoring PKM2 activity with small molecule allosteric activators has been shown to improve insulin sensitivity (Abulizi 2020; Lewandowski 2020), justifying further investigation as a novel target for pharmacological intervention in obesity.
[0007] Pyruvate kinase deficiency (PKD) is one of the most common enzyme defects in red blood cells, which manifests as hemolytic anemia, the accelerated destruction of red blood cells (Bianchi et al., 2020). Mature red blood cells are entirely dependent on glycolysis to maintain cellular integrity and function, and pyruvate kinase therefore plays a pivotal role in red blood cell metabolism and survival. Inherited mutations in the PKR enzyme lead to dysregulation of its catalytic activity, causing a deficiency of cellular energy within red blood cells, as evidenced by reduced pyruvate kinase enzyme activity, reduced ATP levels, and accumulation of upstream metabolites. Reduced PKR activity has also been associated with changes in red blood cell morphology and cell membrane surface, suggesting a broader involvement of this enzyme in the overall lifespan of this cell (Cancado et al., 2018). PK-deficient red blood cells are prematurely removed from the circulation through accelerated hemolysis by the spleen, resulting in the accumulation of iron. Increasing and / or restoring PKR activity to subbasal levels is believed to have the potential to treat PK deficiency-related complications. The current standard of care for PKD is supportive, including blood transfusions, splenectomy, chelation therapy to address iron overload, and / or other therapeutic and disease-related interventions for pathologies. There are no approved therapies to treat the underlying cause of PK deficiency. Activation of the PKR enzyme with a small molecule allosteric activator increased PK enzyme activity and enhanced glycolysis in red blood cells from patients with PK deficiency (Kung et al., 2017).
[0008] Pharmacological interventions using small molecule agonists such as TEPP-46 and DASA-58 have been widely utilized in in vitro and in vivo biological settings, showing some potential benefits offered by enhancing PK activity through allosteric modulation (Yi et al., 2021). Although these compounds have demonstrated good levels of in vitro activity, their ADME and pharmacokinetic / pharmacodynamic profiles have prevented them from being developed for the treatment of human disease. The structure of TEPP-46 is as follows: [ka] As stated above.
[0009] The most advanced PK activator that has been extensively tested in clinical practice is mitapivat (AG-348), a PKM2 and PKLR activator that is being investigated for the treatment of several blood disorders resulting from PK mutant forms that exhibit lower catalytic activity than the corresponding wild-type erythrocytes (Kung et al., 2017). The drug has shown a reasonable level of efficacy by increasing basal hemoglobin levels when administered to patients exhibiting PK deficiency. However, despite this promising result, the high dose regimen and BID (twice daily) dosing frequency required to achieve efficacy highlight the need to develop more effective compounds with more favorable pharmacokinetic and improved safety profiles (Grace et al., 2019). The structure of mitapivat is: [ka]
[0010] WO2020 / 167976A1 (Agios Pharmaceuticals) describes compounds for the treatment of cancer, obesity, and diabetes-related disorders that are said to modulate PK activity.
[0011] There remains a need to identify and develop novel disease-modifying PK modulators that meet several unmet medical needs associated with PK dysfunction, in particular to develop compounds that exhibit suitable activity while possessing favorable physical and chemical parameters. The compounds described herein as PK modulators, in particular PKM2 and / or PKLR modulators, in particular PKM2 and / or PKLR activators, address the above-mentioned unmet needs by exhibiting suitable affinity and functional activity for PK enzymes, in particular PKM2 and / or PKLR, while possessing better overall physical / chemical properties with improved ADME and PK profiles, making them suitable for the treatment of human diseases associated with functional alterations in the expression and / or activity of pyruvate kinase enzyme. Summary of the Invention
[0012] (Summary of the invention) The present invention relates to a compound of formula (Ia): [ka] (In the formula, R A is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle; where R A can have one or more R on available atoms. 1A where each R 1A are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , C 1-6Alkyl-NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2A R 3A , C.H. 2 CONR 2A R 3A , C 3-6 selected from the group consisting of cycloalkyl, oxo, and 4-membered heterocycle, wherein said 4-membered heterocycle is optionally substituted with hydroxy; R 2A and R 3A are independently H and C 1-6 alkyl, or R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; Here, R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A selected from the group consisting of; Here, R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10AR 11A and optionally substituted with one or more groups selected from Here, R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; or Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; Here, R 5A is H or C 1-3 is alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A selected from the group consisting of; Here, R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A and optionally substituted with one or more groups selected from Here, R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15Aare bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Z 1 and Z 2 is independently selected from N and CH, where Z 1 and Z 2 at least one of is CH; R B is phenyl, a phenyl fused to a 5- to 7-membered heterocycle, a 5- to 10-membered heteroaryl, a 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, a 5- to 7-membered heterocyclyl, or C 3-6 cycloalkyl; where R B can have one or more R on available atoms. 1B where each R 1B are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B , C 1-6 Alkyl-NR 2B R 3B , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 selected from the group consisting of cycloalkyl, oxo, and 4-membered heterocycle, wherein said 4-membered heterocycle is optionally substituted with hydroxy; R 2B and R3B are independently H and C 1-6 alkyl, or R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; R C H, Fluoro, C 1-3 Alkyl, C 1-2 Hydroxyalkyl or C 1-2 is methoxyalkyl; R D is H or fluoro; m is 0 or 1; X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -C(R E )(R F )O- or CH 2 NH-; and R E and R F is H or R E and R F is integrated into C 3-5 forming a heterocycloalkyl ring) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0013] The compounds of formula (Ia) are useful in therapy, particularly in the treatment of PK-mediated diseases, disorders, and conditions. The compounds of formula (Ia) may be activators of the PK protein family, particularly activators of PKM2 and / or PKLR.
[0014] The present invention provides a pharmaceutical composition comprising a compound of formula (Ia), or a pharma- ceutically acceptable salt and / or solvate thereof.
[0015] The present invention provides a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof for use as a medicament.
[0016] The present invention provides a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof for use in the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR.
[0017] The present invention provides a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof for use in the treatment or prevention of an inflammatory disease, a disease associated with an unwanted immune response, cancer, obesity, a diabetic disease, or a blood disorder.
[0018] The present invention provides the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for the treatment or prevention of an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a blood disorder.
[0019] The present invention provides a method for treating or preventing an inflammatory disease, a disease associated with an unwanted immune response, cancer, obesity, a diabetic disease, or a blood disorder comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0020] Also provided are intermediate compounds useful in the preparation of compounds of formula (Ia). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] Detailed Description of the Invention (Compound of formula (Ia)) In one embodiment, the compound of formula (Ia) has the formula (I): [ka] (In the formula, R Ais phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle; where R A has one or more R on an available carbon atom. 1A where R 1A are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , C 1-6 Alkyl-NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2A R 3A , C.H. 2 CONR 2A R 3A , C 3-6 cycloalkyl, and oxo; R 2A and R 3A are independently H and C 1-6 alkyl, or R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y3 At least two of the 4A and; Here, R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A selected from the group consisting of; Here, R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10A R 11A and optionally substituted with one or more groups selected from Here, R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; or Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; Here, R 5A is H or C 1-3 is alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A, halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A selected from the group consisting of; Here, R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A and optionally substituted with one or more groups selected from Here, R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Z 1 and Z 2 is independently selected from N and CH, where Z 1 and Z 2 at least one of is CH; R B is phenyl, a phenyl fused to a 5- to 7-membered heterocycle, a 5- to 10-membered heteroaryl, a 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, a 5- to 7-membered heterocyclyl, or C 3-6 cycloalkyl; where R B has one or more R on an available carbon atom. 1B where R 1B are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B , C 1-6 Alkyl-NR 2B R 3B , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 cycloalkyl, and oxo; R 2B and R 3B are independently H and C 1-6 alkyl, or R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; R C H, Fluoro, C 1-3 Alkyl, C 1-2 Hydroxyalkyl or C 1-2 is methoxyalkyl; R D is H or fluoro; m is 0 or 1; X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -CH 2 O- or CH 2 NH-) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0022] In one embodiment, the compound of formula (Ia) has the formula (Ib): [ka] (In the formula, R A is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle; where R A has one or more R on an available carbon or nitrogen atom. 1A where each R 1A are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , C 1-6 Alkyl-NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2A R 3A , C.H. 2 CONR 2A R 3A , C 3-6 cycloalkyl, and oxo; R 2A and R 3A are independently H and C 1-6 alkyl, or R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; Here, R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A selected from the group consisting of; Here, R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10A R 11A and optionally substituted with one or more groups selected from Here, R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; or Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; Here, R 5A is H or C1-3 is alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A selected from the group consisting of; Here, R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A and optionally substituted with one or more groups selected from Here, R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Z 1 and Z 2 is independently selected from N and CH, where Z 1 and Z 2 at least one of is CH; R B is phenyl, a phenyl fused to a 5- to 7-membered heterocycle, a 5- to 10-membered heteroaryl, a 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, a 5- to 7-membered heterocyclyl, or C 3-6 cycloalkyl; where R B has one or more R on an available carbon or nitrogen atom. 1B where each R 1B are independent, halo, C 1-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B , C 1-6 Alkyl-NR 2B R 3B , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 cycloalkyl, and oxo; R 2B and R 3B are independently H and C 1-6 alkyl, or R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4-7 membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; R C H, Fluoro, C 1-3 Alkyl, C 1-2 Hydroxyalkyl or C 1-2 is methoxyalkyl; R D is H or fluoro; m is 0 or 1; X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -CH 2O- or CH 2 NH-) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0023] The embodiments and preferences described herein for compounds of formula (Ia) apply equally to the pharmaceutical compositions, compounds for use, uses, methods and process aspects of the invention.
[0024] "C 1-6 The term "alkyl" means a straight-chain or branched, fully saturated hydrocarbon group having from 1 to 6 carbon atoms. This term includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, and n-hexyl. 1-5 Alkyl, C 1-4 Alkyl, C 1-3 Alkyl, C 1-2 Alkyl, C 2-6 Alkyl, C 2-5 Alkyl, C 2-4 Alkyl, C 2-3 Alkyl, C 3-6 Alkyl, C 3-5 Alkyl, C 3-4 Alkyl, C 4-6 Alkyl, C 4-5 Alkyl, and C 5-6 Alkyl is as defined above, but with a different number of carbon atoms. 1-6 The term "alkyl" refers to a difunctional linear or branched, fully saturated hydrocarbon group having 1 to 6 carbon atoms. 1-6 "Alkylene" is also included. 1-6 Examples of "alkylene" groups include methylene, ethylene, n-propylene, n-butylene, n-pentylene, and n-hexylene.
[0025] "C 2-6 The term "alkenyl" means a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. This term includes CH=CH 2, C.H. 2 CH=CH 2 , CH=CHCH 3 , C.H. 2 CH 2 CH=CH 2 , CH=CHCH 2 CH 3 , C.H. 2 CH=CHCH 3 , C.H. 2 CH 2 CH 2 CH=CH 2 , CH=CHCH 2 CH 2 CH 3 , C.H. 2 CH=CHCH 2 CH 3 , C.H. 2 CH 2 CH=CHCH 3 , CH=CHCH=CHCH 3 , and C.H. 2 CH=CHCH=CH 2 Includes CH(CH 3 )CH=CH 2 and CH=C(CH 3 ) 2 Other alkenyl groups, such as C 2-5 Alkenyl, C 2-4 Alkenyl, C 2-3 Alkenyl, C 3-6 Alkenyl, C 3-5 Alkenyl, C 3-4 Alkenyl, C 4-6 Alkenyl, C 4-5 Alkenyl, and C 5-6 Alkenyl is as defined above, but with a different number of carbon atoms. 2-6 The term "alkenyl" refers to a difunctional linear or branched hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. 2-6 "Alkenylene" is included. 2-6 Examples of "alkenylene" groups include ethenylene, n-propenylene, n-butenylene, n-heptenylene, and n-hexenylene.
[0026] "C 2-6 The term "alkynyl" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon triple bond. This term includes C≡CH, CH 2 C≡CH, C≡CCH 3 , C.H. 2 CH 2 C≡CH, C≡CCH 2 CH 3 , C.H. 2 C≡CCH 3 , C.H. 2 CH 2 CH 2 C≡CH, C≡CCH 2 CH 2 CH 3 , C.H. 2 C≡CCH 2 CH 3 , C.H. 2 CH 2 C≡CCH 3 , C≡CC≡CCH 3 , and C.H. 2 C≡CC≡CH. CH(CH 3 Branched variants such as )C≡CH are also included. Other alkynyl groups, e.g., C 2-5 Alkynyl, C 2-4 Alkynyl, C 2-3 Alkynyl, C 3-6 Alkynyl, C 3-5 Alkynyl, C 3-4 Alkynyl, C 4-6 Alkynyl, C 4-5 Alkynyl, and C 5-6 Alkynyl is as defined above, but with a different number of carbon atoms. 2-6 The term "alkynyl" refers to a difunctional linear or branched hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon triple bond. 2-6 "Alkynylene" is also included. 2-6 Examples of "alkynylene" groups include ethynylene, n-propynylene, n-butynylene, n-heptynylene, and n-hexynylene.
[0027] "C 1-6haloalkyl" (e.g., C 1-5 Haloalkyl, C 1-4 Haloalkyl, C 1-3 Haloalkyl, C 1-2 Haloalkyl, or C 1 The term haloalkyl) refers to a linear or branched fully saturated hydrocarbon group containing the specified number of carbon atoms and at least one halogen atom, such as fluoro or chloro, especially fluoro. An example of a haloalkyl is CF 3 Further examples of haloalkyl include CHF 2 and C.H. 2 CF 3 It is.
[0028] "C 3-6 Cycloalkyl" (e.g., C 3-4 Cycloalkyl, C 3-5 Cycloalkyl, C 4-5 Cycloalkyl, C 4-6 Cycloalkyl and C 5-6 The term cycloalkyl (and the like) means a fully saturated cyclic hydrocarbon group having from 3 to 6 carbon atoms. This term includes cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0029] The term "5-7 membered heterocycle" refers to a non-aromatic cyclic group having 5-7 ring atoms, at least one of which is a heteroatom selected from N, O, S, and B. The term "heterocycle" is interchangeable with "heterocyclyl". This term includes pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl. Other heterocyclyl groups, such as 6-7 membered heterocyclyl, 5-6 membered heterocyclyl, 5 membered heterocyclyl, 6 membered heterocyclyl, and 7 membered heterocyclyl, are as defined above but have a different number of ring atoms. Also included are the following: [ka] Also included are bicyclic heterocyclic compounds such as:
[0030] The term "four-membered heterocycle" refers to a non-aromatic cyclic group having four ring atoms, at least one of which is a heteroatom selected from N, O, and S. This term encompasses oxetane and azetidine, which, in one embodiment, are optionally substituted by hydroxy.
[0031] In some cases, the heterocycle may be substituted on one or more ring carbon atoms by oxo. Examples of this type of ring include pyridone and pyridazinone. However, although pyridone and pyridazinone are defined herein as "heterocycles", [ka] It should be noted that any aromatic tautomers of pyridones and pyridazinones, such as those shown in
[0032] The term "5-10 membered heteroaryl" refers to an aromatic cyclic group having 5-10 ring atoms, at least one of which is a heteroatom independently selected from N, O, and S. The term includes pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, and pyrazinyl. Also included are bicyclic heteroaryl compounds such as furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,2-a]pyridinyl. When a heteroaryl group has more than one ring, not all rings must contain heteroatoms and not all rings must be aromatic in nature. Other heteroaryl groups, such as 5-9 membered heteroaryl, 5-8 membered heteroaryl, 5-7 membered heteroaryl, 5-6 membered heteroaryl, 6-10 membered heteroaryl, 6-9 membered heteroaryl, 6-8 membered heteroaryl, 6-7 membered heteroaryl, 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl, and 10 membered heteroaryl, are as defined above but have a different number of ring atoms. Further examples of heteroaryl include indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, and quinazolinyl.
[0033] The term "hydroxy" (which may also be referred to as "hydroxyl") refers to an --OH group.
[0034] "C 1-6 Hydroxyalkyl" (e.g., C 1-5 Hydroxyalkyl, C 1-4 Hydroxyalkyl, C 1-3 Hydroxyalkyl, C 1-2 Hydroxyalkyl or C 1The term hydroxyalkyl) refers to a linear or branched, fully saturated hydrocarbon group containing the specified number of carbon atoms and at least one -OH group. Examples include -CH 2 C(H)OH-, -C(H)OHCH 3 , -C(H)OH-, -CH 2 OH and -CH 2 CH 2 OH is an example.
[0035] "C 1-6 Methoxyalkyl" (e.g., C 1-5 Methoxyalkyl, C 1-4 Methoxyalkyl, C 1-3 Methoxyalkyl, C 1-2 Methoxyalkyl, or C 1 The term methoxyalkyl (OCH) refers to a group having the specified number of carbon atoms and at least one methoxy (OCH 3 ) groups, e.g., linear or branched fully saturated hydrocarbon groups, e.g., -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , or C(H)(OCH 3 )CH 3 means...
[0036] The term "oxo" refers to an oxygen atom that is substituted with either carbon (e.g., C=O) or another element (e.g., S=O, S(=O) 2 ) means a =O substituent that is doubly bonded to a carbon atom or other element. The carbon or other element is preferably an atom of an alkyl, cycloalkyl, or heterocyclyl group.
[0037] The term "halo" means fluorine, chlorine, bromine, or iodine. Particular examples of halo are fluorine and bromine, especially fluorine.
[0038] C 1-6 In the case of alkyl-NR'R'' type substituents, the NR'R'' group is 1-6 It can be located at any feasible position on the group, for example, -CH 2 -NR'R'', -CH2 CH 2 -NR'R'', and -CH(NR'R'')-CH 3 Examples include:
[0039] When a substituent is shown to be optionally substituted on an available carbon atom in formula (Ia) in the embodiments and options set forth below, the optional substituent is attached to an available carbon atom, meaning a carbon atom attached to a hydrogen atom, i.e., a CH group, which optional substituent replaces a hydrogen atom attached to the carbon atom.
[0040] In some embodiments, R A has one or more R on an available carbon atom. 1A is phenyl optionally substituted by
[0041] In some embodiments, R A is a phenyl fused to a 5- to 7-membered heterocycle and has one or more R 1A Optionally substituted by R A is a phenyl fused to a 5- to 6-membered heterocycle, e.g., R A is selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine; in particular, 2,3-dihydrobenzofuranyl, benzo-1,4-dioxanyl, or 3,4-dihydro-2H-1,4-benzoxazine.
[0042] In some embodiments, R A is a 5-10 membered heteroaryl and has one or more R 1A Optionally substituted by R Ais selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, and quinazolinyl, in particular pyrazolyl. A is R 1A and pyrazolyl substituted by R 1Aは、 It is methyl.
[0043] In some embodiments, R A is a 5-6 membered heteroaryl fused to a 5-7 membered heterocycle and has one or more R 1A Optionally substituted by R A is 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl, or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl.
[0044] In some embodiments, R Ais phenyl, a phenyl fused to a 5-6 membered heterocycle (e.g., selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine), a 5-6 membered heteroaryl (e.g., pyrrolyl, pyrazolyl, pyrimidinyl, or pyridyl), or a 5-6 membered heteroaryl (e.g., pyrrolyl, pyrazolyl, pyrimidinyl, or pyridyl). 5-6 membered heteroaryl fused to a 5-6 membered heterocycle (e.g., 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl, or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl, etc.); in particular, phenyl; and one or more R 1A is optionally replaced by
[0045] In some embodiments, R A is unsubstituted. In another embodiment, R A is one or more (e.g., one, two, or three, e.g., one) R 1A Preferably, each R 1A are independent, halo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, CONR. 2A R 3A , C 3-6 and each R is selected from the group consisting of cycloalkyl, oxo, and a 4-membered heterocycle, wherein the 4-membered heterocycle is optionally substituted with hydroxy; 1A are independent, halo, C 1-6Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 is selected from alkyl, oxo, and oxetane or azetidine, both of which are optionally substituted by hydroxy; 1-6 Alkyl or OC 1-6 In one embodiment, R 1A is OCH 3 It is.
[0046] In some embodiments, R 2A and R 3A are independently H and C 1-6 alkyl, for example, C 1-4 Preferably, R 2A and R 3A is independently selected from the group consisting of H, methyl, and ethyl. In one embodiment, R 2A and R 3A are both H. In one embodiment, R 2A and R 3A and R are both methyl. 2A and R 3A One of is H and the other is methyl.
[0047] In some embodiments, R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 4- to 7-membered heterocycle (particularly a 5- to 7-membered heterocycle) optionally substituted with one or more groups selected from alkyl and oxo. 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 4-membered heterocyclic ring, optionally substituted with one or more groups selected from alkyl and oxo. 2A and R 3Aare bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 5-membered heterocycle, optionally substituted with one or more groups selected from alkyl and oxo. 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 7-membered heterocycle, optionally substituted with one or more groups selected from alkyl and oxo. 2A and R 3A are joined together with the N atom to which they are attached to form pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-thiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl, 1,4-piperazin-1-yl, or N-methyl-1,4-piperazin-1-yl. 2A and R 3A are joined together with the N atom to which they are attached to form pyrrolidin-1-yl or piperidin-1-yl. In some embodiments, R 2A and R 3A are joined together with the N atom to which they are attached to form pyrrolidin-1-yl. 2A and R 3A join together with the N atom to which they are attached to form piperidin-1-yl.
[0048] In some embodiments, R B has one or more R on an available carbon atom. 1B is phenyl optionally substituted by
[0049] In some embodiments, RB is a phenyl fused to a 5- to 7-membered heterocycle and has one or more R 1B Optionally substituted by R B is a phenyl fused to a 5- to 6-membered heterocycle, e.g., R B are 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine; in particular, are 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, or 1,3-benzodiazole.
[0050] In some embodiments, R B is a 5-10 membered heteroaryl and has one or more R 1B Optionally substituted by R B is selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl and quinazolinyl, in particular selected from the group consisting of furanyl, thienyl, pyrazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl and indazolyl. In one embodiment, R B is pyrazolyl.
[0051] In some embodiments, R Bis a 5-6 membered heteroaryl fused to a 5-7 membered heterocycle and has one or more R 1B Optionally substituted by R B is 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl, or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl.
[0052] In some embodiments, R B is a 5- to 7-membered heterocyclyl (e.g., a 5- to 6-membered heterocyclyl, etc.) and has one or more R on an available atom (e.g., a carbon or nitrogen atom); 1B Optionally substituted by R B is selected from the group consisting of pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridone, and pyridazinone; for example, pyridone or pyridazinone, in particular pyridone.
[0053] In some embodiments, R B is C 3-6 Cycloalkyl and has one or more R 1B is optionally replaced by
[0054] In some embodiments, R Bis phenyl, a phenyl fused to a 5- to 7-membered heterocycle (e.g., selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine), pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, quinazolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridone, and pyridazinone; and one or more R on an available atom (e.g., a carbon or nitrogen atom). 1B is optionally replaced by
[0055] In some embodiments, R B is unsubstituted. In another embodiment, R B is one or more (e.g., one, two, or three, e.g., one) R 1B Preferably, each R 1B are independent, halo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B ,CONR 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6cycloalkyl, oxo; and 4-membered heterocycle, wherein the 4-membered heterocycle is optionally substituted with hydroxy; in particular, each R 1B are independently fluoro, chloro, methyl, ethyl, CH 2 OH, CH 2 CH 2 OH, CHF 2 , Hydroxy, OCH 3 , O.C.H. 2 CH 2 OH,OCHF 2 , Cyano, N.H. 2 ,CONH 2 ,CONHCH 3 , C.H. 2 CONH 2 , cyclopropyl, oxo, and oxetane or azetidine, both of which are optionally substituted with hydroxy.
[0056] In some embodiments, R 2B and R 3B are independently H and C 1-6 alkyl, for example, C 1-4 Preferably, R 2B and R 3B is independently selected from the group consisting of H, methyl, and ethyl. In one embodiment, R 2B and R 3B are both H. In one embodiment, R 2B and R 3B and R are both methyl. 2B and R 3B One of is H and the other is methyl.
[0057] In some embodiments, R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 4- to 7-membered heterocycle (particularly a 5- to 7-membered heterocycle) optionally substituted with one or more groups selected from alkyl and oxo. 2Band R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 4-membered heterocyclic ring, optionally substituted with one or more groups selected from alkyl and oxo. 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 5-membered heterocycle, optionally substituted with one or more groups selected from alkyl and oxo. 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 In some embodiments, R forms a 7-membered heterocycle, optionally substituted with one or more groups selected from alkyl and oxo. 2B and R 3B are joined together with the N atom to which they are attached to form pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-thiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl, 1,4-piperazin-1-yl, or N-methyl-1,4-piperazin-1-yl. 2B and R 3B are joined together with the N atom to which they are attached to form pyrrolidin-1-yl or piperidin-1-yl. In some embodiments, R 2B and R 3B are joined together with the N atom to which they are attached to form pyrrolidin-1-yl. 2B and R 3B join together with the N atom to which they are attached to form piperidin-1-yl.
[0058] In some embodiments, Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A where R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A wherein R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10A R 11A wherein R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 Forms a 4- to 7-membered heterocyclic ring optionally substituted with one or more groups selected from alkyl and oxo; preferably, Y 1 , Y 2 , and Y 3 All are CR 4A where preferably R 4A is H.
[0059] In some embodiments, Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR5A And the remaining Y 1 Or Y 3 is N or CR 6A where R 5A is H or C 1-3 alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A wherein R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A wherein R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 Forms a 4- to 7-membered heterocyclic ring optionally substituted with one or more groups selected from alkyl and oxo. 5A is H and R 6A is H.
[0060] In some embodiments, Z 1 is N and Z 2 is CH. In some embodiments, Z 1 is CH and Z 2 is N. In some embodiments, Z 1 is CH and Z 2 is CH. Preferably, Z 1 is N and Z 2is CH.
[0061] In some embodiments, R C H, fluoro, CH 3 , C.H. 2 OH or CH 2 OCH 3 Preferably, R C is H.
[0062] In some embodiments, R D is H. In some embodiments, R D is fluoro. Preferably, R D is H.
[0063] In some embodiments, R C is fluoro and R D is fluoro. Preferably, R C is H and R D is H.
[0064] In some embodiments, m is 0. In some embodiments, m is 1. Suitably, m is 0.
[0065] In some embodiments, X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -CH 2 O- or CH 2 It is NH-.
[0066] In some embodiments, X is S(=O) 1-2 or S(=O)(=NH). Preferably, X is S(=O) 1-2 , especially S(=O) 2 It is.
[0067] X is -CH 2 -S(=O)1-2 -, -S(=O) 2 NH-, -NH-S(=O) 2 -, -CH 2 O- or CH 2 If NH-, then -CH 2 -S(=O) 2 - Regarding the following: [ka] As shown in the figure, the group on the left is the group R A It should be noted that the group on the right hand side as drawn and attached directly to is intended to be attached directly to the bicyclic core structure.
[0068] In some embodiments, R E and R F is H. In another embodiment, R E and R F are integrated to form C rings such as oxetanyl rings. 3-5 It forms a heterocycloalkyl ring, for example 3-oxetanyl.
[0069] In one embodiment, the compound of formula (Ia) has the formula (IIa) as follows: [ka] (In the formula, Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; R A , R B , R C , R D , m, X, Z 1 , Z 2 and R 4A are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0070] In one embodiment, the compound of formula (Ia) has the formula (IIaA) as follows: [ka] (In the formula, Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; R A , R B , R C , R D , X and R 4A are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0071] In one embodiment, the compound of formula (Ia) has the formula (IIaB) as follows: [ka] (In the formula, R A , R B , R C , R D and X is as previously defined herein. or a pharma- ceutically acceptable salt and / or solvate thereof.
[0072] In one embodiment, the compound of formula (Ia) has the formula (IIaC) as follows: [ka] (In the formula, R A , R B and X is as previously defined herein. or a pharma- ceutically acceptable salt and / or solvate thereof.
[0073] In one embodiment, the compound of formula (Ia) has the formula (IIaD) as follows: [ka] (In the formula, R A and R B are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0074] In one embodiment, the compound of formula (Ia) has the formula (IIIa) as follows: [ka] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , R C , R D , m, X, Z 1 , Z 2 , R 5A , and R 6A are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0075] In one embodiment, the compound of formula (Ia) has the formula (IIIaA) as follows: [ka] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , R C , R D , X, R 5A , and R 6A are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0076] In one embodiment, the compound of formula (Ia) has the formula (IIIaB) as follows: [ka] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , X, R 5A , and R 6A are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0077] In one embodiment, the compound of formula (Ia) has the formula (IIIaC) as follows: [ka] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , R 5A , and R 6A are as previously defined herein) or a pharma- ceutically acceptable salt and / or solvate thereof.
[0078] In one embodiment: 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(indolin-4-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-(2-hydroxyethyl)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((5-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-methoxy-1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-ethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiophene-2-carboxamide; 6-Methoxy-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carboxamide; 2-((1-(2-hydroxyethyl)-4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((6-((4-methoxyphenyl)sulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)-N-methylfuran-2-carboxamide; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carbonitrile; 2-(2-hydroxy-1-phenylethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-(hydroxymethyl)benzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-(2-hydroxyethoxy)pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-(hydroxymethyl)thiophen-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazine-2(1H)-yl)methyl)thiophene-2-carbonitrile; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((5-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((4-(hydroxymethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methylthiazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-fluorobenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-fluoro-5-methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(imidazo[1,2-a]pyridin-5-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-indazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-aminopyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-indazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(3-(difluoromethoxy)benzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-(pyridin-3-ylmethyl)phthalazin-1(2H)-one; 2-(2-aminobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-phenethylphthalazin-1(2H)-one; 2-(Isoxazol-5-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(4-chloro-2-fluorobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrobenzofuran-5-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-indazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(4-Methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-Benzyl-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-(2-fluoro-3-methoxybenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(2,6-difluoro-4-methoxybenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(benzo[d][1,3]dioxol-5-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1H-indazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methoxypyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)phenyl)acetamide; 2-((6-(difluoromethoxy)pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-(2-hydroxyethyl)benzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methyl-2,3-dihydrobenzofuran-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-(phenylsulfonyl)-2-(pyridin-3-ylmethyl)phthalazin-1(2H)-one; 2-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 2-(2-Methoxy-1-phenylethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-(phenylsulfonyl)-2-(1-(pyridin-3-yl)ethyl)phthalazin-1(2H)-one; 2-((1,3-dimethyl-1H-pyrazol-4-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-Benzyl-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-methylpyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methylthiazol-4-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(difluoro(pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-Methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methylisoxazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(3-Methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-Methoxy-1-phenylethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((1-ethyl-1H-pyrazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)furan-2-carboxamide; 5-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)furan-2-carboxamide; 2-((5-methoxypyrazin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1,4-dimethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-Chloro-6-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 2-Methoxy-6-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 4-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiazole-2-carboxamide; 5-Methyl-4-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)isoxazole-3-carboxamide; 2-((1-isopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((3-methylisothiazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxy-6-methylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxy-4-methylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((5-fluoro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxy-5-isopropylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((4-fluoro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((4-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((3-hydroxypyridin-4-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 5-Methoxy-2-((6-(4-methoxyphenylsulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)benzamide; 2-((4-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 6-(Phenylsulfonyl)-2-(pyrazolo[1,5-a]pyridin-2-ylmethyl)phthalazin-1(2H)-one; 2-((2-hydroxy-6-methoxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((4-fluoro-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-fluoro-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-(4-Methoxyphenylsulfonyl)-2-((3-(trifluoromethyl)isoxazol-5-yl)methyl)phthalazin-1(2H)-one; 2-((3-hydroxypyridin-2-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(quinolin-8-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(5-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(3-methoxyphenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 3-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)thiophene-2-carboxamide; 4-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)thiophene-2-carboxamide; 2-(3-aminobenzyl)-6-(phenylsulfinyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(pyridin-3-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-1-oxo-N-phenyl-1,2-dihydrophthalazine-6-sulfonamide; 6-((1H-indazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((6-(difluoromethoxy)pyridin-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 3-((6-methoxypyridin-3-yl)methyl)-7-((3-phenyloxetan-3-yl)oxy)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; R)-2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; (S)-2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; 6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((phenyl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(pyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((5-methylthiophen-2-yl)sulfonyl)phthalazin-1(2H)-one; 6-((4-fluorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(3-methylisothiazol-5-ylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-tosylphthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(benzo[d][1,3]dioxol-5-ylsulfonyl)phthalazin-1(2H)-one; 6-(4-(difluoromethoxy)phenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((3-chlorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((4-chlorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((3-fluorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(4-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(6-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 3-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)benzamide; 6-(2-fluorophenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2-chlorophenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2-Methoxyphenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(4-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(6-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(3-(difluoromethoxy)phenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(5-methylthiophen-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(5-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2-(difluoromethyl)thiazol-5-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(2-methylthiazol-4-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(6-methoxypyridin-3-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(2-methylbenzo[d]thiazol-4-ylsulfonyl)phthalazin-1(2H)-one; 6-(5-methoxypyrazin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(imidazo[1,2-a]pyridin-5-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1-(difluoromethyl)-1H-pyrazol-3-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydrofuro[2,3-b]pyridin-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(imidazo[1,2-a]pyridin-7-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1,2-dimethyl-1H-imidazol-4-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1,5-dimethyl-1H-pyrazol-4-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1-cyclopropyl-1H-pyrazol-4-ylsulfonyl)-2-((2-hydroxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1-cyclopropyl-1H-pyrazol-4-ylsulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(benzofuran-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-(3-(difluoromethoxy)benzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-(2-fluoro-5-methoxybenzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((4-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-(1-methyl-1H-pyrazol-3-ylsulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)benzamide; 2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-((4-(difluoromethoxy)phenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((4-ethoxyphenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; (R)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((4-(trifluoromethoxy)phenyl)sulfonyl)phthalazin-1(2H)-one; (S)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((3-methylbenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(benzofuran-6-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(furo[3,2-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-methylbenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(furo[2,3-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one; 6-((1H-indol-5-yl)sulfonyl)-2-((1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(benzo[b]thiophen-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-indol-5-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-3-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-(1-(2-hydroxyethyl)-1H-pyrazol-3-ylsulfonyl)-2-((2-hydroxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 7-Fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 5-Fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 7-((2-hydroxyethyl)amino)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 8-Fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 7-((2-hydroxyethyl)amino)-2-((2-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 5-((2-hydroxyethyl)amino)-2-((2-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-methyl-1H-pyrazol-3-yl)methyl)-7-(phenylsulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one; 3-((1-methyl-1H-pyrazol-3-yl)methyl)-7-(phenylsulfinyl)pyrido[3,4-d]pyridazin-4(3H)-one; 7-((1-methyl-1H-pyrazol-3-yl)methyl)-3-(phenylsulfonyl)pyrido[2,3-d]pyridazin-8(7H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-(1H-pyrazol-4-ylsulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-4-ylsulfonyl)phthalazin-1(2H)-one; 2-((2,4-dihydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(furo[3,2-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((5-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrofuro[2,3-c]pyridin-5-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(pyrazin-2-ylsulfonyl)phthalazin-1(2H)-one; 2-(imidazo[1,2-a]pyridin-3-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1H-pyrazol-3-yl)methyl)-7-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one; 7-((1H-pyrazol-3-yl)methyl)-3-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[2,3-d]pyridazin-8(7H)-one; 2-((1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methylpyridin-2-yl)methyl)-6-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-(oxetan-3-yl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-cyclopropylpyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-(azetidin-3-yl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1-(2-aminoethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; (S)-2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; (R)-2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((6-(3-hydroxyoxetan-3-yl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-cyclopropylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methylpyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((5-methylpyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methylpyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-(1H-pyrazol-4-ylsulfonyl)-2-((5-methoxy-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((5-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 6-(1H-pyrazol-4-ylsulfonyl)-2-((2,3-dihydrofuro[2,3-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; and (S)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; or a pharma- ceutically acceptable salt and / or solvate thereof.
[0079] In another embodiment: 6-((1H-pyrazol-4-yl)sulfonyl)-2-(furo[3,2-b]pyridin-5-ylmethyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 7-((1H-pyrazol-4-yl)sulfonyl)-3-((5-methyl-1H-pyrazol-3-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((3-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((6-cyclopropylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((5-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-cyclopropylpyridin-2-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((4-fluoro-1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((5-chloro-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((3-chloro-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((4-chloro-1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-5,6-dimethylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((5-fluoro-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((3-fluoro-6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 3-((5-methyl-1H-pyrazol-3-yl)methyl)-7-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-(furo[3,2-b]pyridin-5-ylmethyl)phthalazin-1(2H)-one; 2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-1,5-dimethyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3,5-difluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 7-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-3-((5-methyl-1H-pyrazol-3-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2-methylfuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-cyclopropylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 7-((1H-pyrazol-4-yl)sulfonyl)-3-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one; 2-((4,5-dimethyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((3-fluoro-5,6-dimethylpyridin-2-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl)phthalazin-1(2H)-one; 6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-2-((7-methyl-2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((5-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-[(7-methyl-2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl]-6-(1H-pyrazol-4-ylsulfonyl)phthalazin-1-one; (R)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; and (S)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; or a pharma- ceutically acceptable salt and / or solvate thereof.
[0080] In one embodiment: 6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-Bromo-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-mercapto-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; tert-Butyl (3-((6-bromo-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate; tert-Butyl (3-((6-mercapto-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate; 2-((2-chloropyridin-3-yl)methyl)-6-mercaptophthalazin-1(2H)-one; 6-mercapto-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-mercapto-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-mercaptophthalazin-1(2H)-one; 6-Bromo-2-((4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-Bromo-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-Mercaptophthalazin-1(2H)-one; 6-Mercapto-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 5-Fluoro-6-(phenylthio)phthalazin-1(2H)-one; 7-Fluoro-6-(phenylthio)phthalazin-1(2H)-one; and 6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one; or a salt thereof.
[0081] Compounds of formula (Ia) may be synthesized as shown in the scheme below and as shown in the Examples section. Scheme 1 - Synthesis of Compounds of Formula (Ia) [ka] (In the formula, R A , R B , RC , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , X, and m are defined elsewhere herein, and LG 2 is a leaving group such as halo (e.g., chloro, bromo, or iodo), OMs, or OTs). 2 CO 3 , K 2 CO 3 or in the presence of a base such as NaH to provide a compound of formula (Ia).
[0082] Scheme 2 - Synthesis of Compounds of Formula (Va) [ka] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 (wherein is defined elsewhere herein). In certain compounds of formula (Va), such compounds can be prepared by reacting a compound of formula (IVa) in which LG is a leaving group such as halo, OMs, or OTs with HS-R A (In the formula, R A (as defined elsewhere herein). The S atom in the compound of formula (Va) can be converted to S=O or SO under standard oxidation conditions such as Oxone in DMF at 60° C. 2 The oxidation may be carried out immediately after the synthesis of the compound of formula (Va) or as a later step, for example after coupling of the compound of formula (Va) with a compound of formula (IIIa-S) as shown in Scheme 1.
[0083] Those skilled in the art will recognize that protecting groups can be used throughout the synthetic schemes described herein to obtain protected derivatives of any of the above compounds or general formulas. Protecting groups and procedures for their removal are described in "Protective Groups in Organic Synthesis" by Theodora W. Greene and Peter GM Wuts, published by John Wiley & Sons, Inc., 4th Revised Edition, 2006, ISBN-10: 0471697540. Examples of nitrogen protecting groups include trityl (Tr), tert-butyloxycarbonyl (Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl (Ac), benzyl (Bn), and para-methoxybenzyl (PMB). Examples of oxygen protecting groups include acetyl (Ac), methoxymethyl (MOM), para-methoxybenzyl (PMB), benzyl, tert-butyl, methyl, ethyl, tetrahydropyranyl (THP), and silyl ethers and esters, such as trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tri-isopropylsilyloxymethyl (TOM), and triisopropylsilyl (TIPS) ethers and esters. Specific examples of carboxylic acid protecting groups include alkyl esters (C 1-6 Alkyl, e.g., C 1-4 alkyl esters), benzyl esters, and silyl esters.
[0084] In one embodiment, the compound of formula (IIa-S): [ka] or a salt thereof; Formula (IIIa-S): [ka] Compound (In the formula, R A , R B , R C , R D , Y1 , Y 2 , Y 3 , Z 1 , Z 2 , X, and m are defined elsewhere herein, and LG 2 is a leaving group such as halo (e.g., chloro, bromo, or iodo), OMs, or OTs);
[0033] There is provided a process for preparing a compound of formula (Ia) or a salt, such as a pharma- ceutically acceptable salt, thereof, which comprises reacting
[0085] In one embodiment, the compound of formula (IIa-S): [ka] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 and X are defined elsewhere herein. or a salt thereof.
[0086] In one embodiment, a compound of formula (IVa): [ka] (In the formula, Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined elsewhere herein and LG is a leaving group such as halo, OMs, or OTs. or a salt thereof.
[0087] In one embodiment, a compound of formula (Va): [ka] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , and Z2 are defined elsewhere in this specification) or a salt thereof.
[0088] In one embodiment, the compound of formula (VIa): [ka] (In the formula, R B , R C , R D , m, Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined elsewhere herein and LG 1 is a leaving group such as halo (e.g., chloro, bromo, or iodo), OMs, or OTs). or a salt thereof.
[0089] In one embodiment, Formula (VIIa): [ka] (In the formula, R A , R B , R C , R D , m, Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 are defined elsewhere in this specification) or a salt thereof.
[0090] It will be appreciated that for use in therapy, the salts of the compounds of formula (Ia) should be pharma- ceutically acceptable. Suitable pharma-ceutically acceptable salts will be apparent to those skilled in the art. Pharmaceutically acceptable salts include acid addition salts, preferably salts of the compounds of the invention containing a basic group, such as an amino group, formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, or phosphoric acid. Also included are salts formed with organic acids, such as succinic acid, maleic acid, acetic acid, fumaric acid, citric acid, tartaric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, and 1,5-naphthalenedisulfonic acid. Other salts, such as oxalates or formates, may be used, for example, in the isolation of the compounds of formula (Ia), and are also included within the scope of the present invention, as are basic addition salts, such as sodium, potassium, calcium, aluminum, zinc, magnesium, and other metal salts.
[0091] Pharmaceutically acceptable salts can also be formed with organic bases such as basic amines, for example, ammonia, meglumine, tromethamine, piperazine, arginine, choline, diethylamine, benzathine, or lysine.Thus, in one embodiment, the compound of formula (Ia) is provided in the form of a pharma-ceutically acceptable salt.Alternatively, the compound of formula (Ia) is provided in the form of a free acid.When a compound contains a basic group and a free acid, it can be a zwitterion.
[0092] Suitably the compound of formula (Ia) is not a salt, for example not a pharma- ceutical acceptable salt.
[0093] Suitably, the compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof is a pharma- ceutically acceptable salt of the compound of formula (Ia).
[0094] Alternatively, the compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof is a compound of formula (Ia).
[0095] Suitably, when the compound of formula (Ia) is in the form of a salt, the pharma- ceutical acceptable salt will be an acid addition salt, such as an ammonium salt (formed, for example, with an inorganic acid, such as HCl).
[0096] The compounds of formula (Ia) may be prepared in crystalline or non-crystalline form and, if crystalline, may optionally be solvated, for example as a hydrate. The present invention includes within its scope stoichiometric solvates (e.g., hydrates) and compounds containing variable amounts of solvent (e.g., water). Suitably, the compounds of formula (Ia) are not solvates.
[0097] The present invention extends to pharma- ceutically acceptable derivatives of compounds of formula (Ia), such as pharma- ceutically acceptable prodrugs thereof. Exemplary prodrugs of compounds of formula (Ia) that contain a carboxylic acid include esters thereof, e.g. 1-6 Alkyl, e.g., C 1-4 Alkyl ester) derivatives. Thus, in one embodiment, the compound of formula (Ia) is provided as a pharma- ceutically acceptable prodrug. In another embodiment, the compound of formula (Ia) is not provided as a pharma-ceutically acceptable prodrug.
[0098] It should be understood that the present invention encompasses all isomers of the compounds of formula (Ia), including all geometric, tautomeric and optical forms, as well as mixtures thereof (e.g., racemic mixtures). In particular, the present invention extends to all tautomeric forms of the compounds of formula (Ia). When additional chiral centers are present in the compounds of formula (Ia), the present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
[0099] The present invention also includes all isotopic forms of the compounds provided herein, whether (i) all atoms of a given atomic number have a mass number (or mixture of mass numbers) that is predominant in nature (referred to herein as "natural isotopic forms"), or (ii) one or more atoms are replaced by an atom having the same atomic number but a mass number different from the mass number of the atom that is predominant in nature (referred to herein as "non-natural variant isotopic forms"). It is understood that atoms may naturally occur as a mixture of mass numbers. The term "non-natural variant isotopic forms" also includes embodiments in which the proportion of atoms of a given atomic number that have mass numbers that are less commonly found in nature (referred to herein as "rare isotopes") is increased compared to that occurring in nature, for example, to a level of >20%, >50%, >75%, >90%, >95%, or >99% of the number of atoms of that atomic number (the latter embodiment is referred to as "isotopically enriched variant forms"). The term "non-natural variant isotopic form" also includes embodiments in which the ratio of rare isotopes is reduced compared to that occurring in nature. Isotopic forms can include radioactive forms (i.e., which incorporate a radioactive isotope) and non-radioactive forms. The radioactive form will usually be an isotopically enriched variant form.
[0100] Thus, non-natural variant isotopic forms of a compound may contain deuterium ( 2 H or D), carbon-11 ( 11 C), carbon-13( 13 C), carbon-14( 14 C), nitrogen-13( 13 N), nitrogen-15( 15 N), oxygen-15( 15 O), oxygen-17( 17 O), oxygen-18( 18 O), phosphorus-32( 32 P), sulfur-35( 35 S), Chlorine-36( 36 Cl), Chlorine-37( 37 Cl), Fluorine-18( 18 F), iodine-123( 123I), iodine-125( 125 I), or may contain an increased proportion of said isotopes at one or more atoms compared to the proportion predominant in nature.
[0101] Non-natural variant isotopic forms containing radioactive isotopes may be used, for example, in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e. 3 H, and carbon-14, i.e. 14 C are particularly useful for this purpose given their ease of incorporation and ready means of detection. Deuterium, i.e. 2 Non-natural variant isotopic forms incorporating H or D may offer certain therapeutic advantages due to greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in certain circumstances. Additionally, 11 C. 18 F, 15 O, and 13 Non-natural variant isotopic forms can be prepared that incorporate positron emitting isotopes, such as N, which may be useful for positron emission tissue distribution (PET) studies to examine substrate receptor occupancy.
[0102] In one embodiment, the compound of formula (Ia) is provided in natural isotopic form. In one embodiment, the compound of formula (Ia) is provided in non-natural variant isotopic form. In a specific embodiment, the non-natural variant isotopic form is a form in which one or more atoms of the compound of formula (Ia) have deuterium (i.e., 2 In one embodiment, the atom of the compound of formula (Ia) is in a non-radioactive isotopic form. In one embodiment, one or more atoms of the compound of formula (Ia) are in a radioactive isotopic form. Preferably, the radioisotope is a stable isotope. Preferably, the non-natural variant isotopic form is a medicamentously acceptable form.
[0103] In one embodiment, compounds of formula (Ia) are provided in which a single atom of the compound is present in a non-natural variant isotopic form. In another embodiment, compounds of formula (Ia) are provided in which two or more atoms are present in a non-natural variant isotopic form.
[0104] Non-natural isotopically variant forms can generally be prepared by conventional techniques known to those skilled in the art or by methods described herein, for example, methods similar to those described in the accompanying examples for preparing natural isotopically variant forms. Thus, non-natural isotopically variant forms can be prepared by substituting appropriate isotopically variant (or labeling) reagents for the conventional reagents employed in the examples. It will be readily understood that since the compounds of formula (Ia) are intended for use in pharmaceutical compositions, they are each preferably provided in substantially pure form, for example at least 60% pure, more preferably at least 75% pure, and preferably at least 85%, especially at least 98% pure (percentages are on a weight-to-weight basis). Impure preparations of the compounds may be used to prepare the purer forms used in pharmaceutical compositions.
[0105] (Therapeutic efficacy) The compounds of formula (Ia) are useful in therapy, in particular for treating or preventing inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or blood disorders. As shown in Biological Example 1 below, the tested example compounds of formula (Ia) showed improved PKM2 modulator activity compared to mitapivat. As shown in Biological Example 2 below, the tested example compounds of formula (Ia) also showed improved PKLR modulator activity, again using mitapivat as a control drug. As shown in Biological Example 3 below, the tested example compounds of formula (Ia) also showed in vitro antiproliferative activity. Therefore, it is expected that the compounds of formula (Ia) are suitable for treating diseases associated with PK, in particular PKM2 and PKLR activity.
[0106] Thus, in a first aspect, the present invention provides a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use as a medicament. Also provided is a pharmaceutical composition comprising a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof. Such a pharmaceutical composition comprises a compound of formula (Ia) and one or more pharma- ceutically acceptable diluents or carriers. Suitably, the present invention provides a pharmaceutical composition as defined above for use as a medicament. The following alternatives to the use of a compound of formula (Ia) apply equally to a pharmaceutical composition as defined herein comprising a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0107] In a further aspect, the present invention provides a compound of formula (Ia) as defined herein, or a pharma- ceutically acceptable salt and / or solvate thereof, for use in the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR. In a further aspect, the present invention provides the use of a compound of formula (Ia) as defined herein, or a pharma- ceutically acceptable salt and / or solvate thereof, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR. In a further aspect, the present invention provides a method for the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR, comprising administering a compound of formula (Ia) as defined herein, or a pharma- ceutically acceptable salt and / or solvate thereof.
[0108] In a further aspect, the present invention provides a compound of formula (Ia) as defined herein, or a pharma- ceutically acceptable salt and / or solvate thereof, for use in the treatment or prevention of symptoms associated with a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR. In a further aspect, the present invention provides the use of a compound of formula (Ia) as defined herein, or a pharma- ceutically acceptable salt and / or solvate thereof, in the manufacture of a medicament for the treatment or prevention of symptoms associated with a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR. In a further aspect, the present invention provides a method for the treatment or prevention of symptoms associated with a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR, comprising administering a compound of formula (Ia) as defined herein, or a pharma- ceutically acceptable salt and / or solvate thereof.
[0109] In one embodiment, the compound of formula (Ia) is a modulator of PKM2. In another embodiment, the compound of formula (Ia) is an activator of PKM2. In one embodiment, the compound of formula (Ia) is a modulator of PKLR. In another embodiment, the compound of formula (Ia) is an activator of PKLR. A compound is an "activator" of PK (e.g., PKM2 and / or PKLR) if it increases the activity of the enzyme, which can be quantified, for example, by determining the concentration of ATP generated in a suitable assay (such as Biological Example 1 for PKM2 and Biological Example 2 for PKLR).
[0110] In a further aspect, the present invention provides a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in the treatment or prevention of an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a blood disorder. In a further aspect, the present invention provides the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for treating or preventing an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a blood disorder. In a further aspect, the present invention provides a method for treating or preventing an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a blood disorder comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0111] In a further aspect, the present invention provides a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in the treatment or prevention of an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a condition associated with a blood disorder. In a further aspect, the present invention provides the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for the treatment or prevention of an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a condition associated with a blood disorder. In a further aspect, the present invention provides a method for the treatment or prevention of an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a condition associated with a blood disorder comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0112] For all aspects of the invention, preferably the compound is administered to a subject in need thereof, which is preferably a human subject.
[0113] In one embodiment, there is provided a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in the treatment of inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or blood disorders.In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for treating inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or blood disorders.In one embodiment of the present invention, there is provided a method for treating inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or blood disorders, comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0114] In one embodiment, there is provided a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in the treatment of inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or conditions associated with blood disorders.In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for treating inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or conditions associated with blood disorders.In one embodiment of the present invention, there is provided a method for treating inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or conditions associated with blood disorders, comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0115] In one embodiment, there is provided a compound of formula (Ia) or its pharma- ceutically acceptable salt and / or solvate as defined herein for use in the prophylaxis of inflammatory disease, disease associated with undesired immune response, cancer, obesity, diabetic disease, or blood disorder.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) or its pharma-ceutically acceptable salt and / or solvate as defined herein in the manufacture of a medicament for the prophylaxis of inflammatory disease, disease associated with undesired immune response, cancer, obesity, diabetic disease, or blood disorder.In one embodiment of the present invention, there is provided a method for the prophylaxis of inflammatory disease, disease associated with undesired immune response, cancer, obesity, diabetic disease, or blood disorder, comprising administering a compound of formula (Ia) or its pharma-ceutically acceptable salt and / or solvate as defined herein.
[0116] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in the prophylaxis of inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or conditions associated with blood disorders.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma-ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for the prophylaxis of inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or conditions associated with blood disorders.In one embodiment of the present invention, there is provided a method for the prophylaxis of inflammatory diseases, diseases associated with undesired immune responses, cancer, obesity, diabetic diseases, or conditions associated with blood disorders, comprising administering a compound of formula (Ia) as defined herein or a pharma-ceutically acceptable salt and / or solvate thereof.
[0117] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing inflammatory disease.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing inflammatory disease.In one embodiment of the present invention, there is provided a method for treating or preventing inflammatory disease, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0118] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing symptoms associated with inflammatory disease.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing symptoms associated with inflammatory disease.In one embodiment of the present invention, there is provided a method for treating or preventing symptoms associated with inflammatory disease, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0119] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing inflammation associated with inflammatory disease.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing inflammation associated with inflammatory disease.In one embodiment of the present invention, there is provided a method for treating or preventing inflammation associated with inflammatory disease, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0120] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in the treatment or prevention of a disease associated with an undesired immune response.In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for the treatment or prevention of a disease associated with an undesired immune response.In one embodiment of the present invention, there is provided a method for the treatment or prevention of a disease associated with an undesired immune response, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0121] In one embodiment, there is provided a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in the treatment or prevention of a condition associated with a disease associated with an undesired immune response.In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for the treatment or prevention of a condition associated with a disease associated with an undesired immune response.In one embodiment of the present invention, there is provided a method for the treatment or prevention of a condition associated with a disease associated with an undesired immune response, comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0122] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing inflammation associated with a disease associated with an undesired immune response.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing inflammation associated with a disease associated with an undesired immune response.In one embodiment of the present invention, there is provided a method for treating or preventing inflammation associated with a disease associated with an undesired immune response, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0123] In one embodiment, there is provided a compound of formula (Ia) as defined herein or its pharma- ceutically acceptable salt and / or solvate for use in treating or preventing cancer.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or its pharma- ceutically acceptable salt and / or solvate in the manufacture of a medicament for treating or preventing cancer.In one embodiment of the present invention, there is provided a method for treating or preventing cancer, comprising administering a compound of formula (Ia) as defined herein or its pharma- ceutically acceptable salt and / or solvate.
[0124] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing symptoms associated with cancer.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing symptoms associated with cancer.In one embodiment of the present invention, there is provided a method for treating or preventing symptoms associated with cancer, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0125] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing obesity.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing obesity.In one embodiment of the present invention, there is provided a method for treating or preventing obesity, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0126] In one embodiment, there is provided a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in treating or preventing symptoms associated with obesity.In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for treating or preventing symptoms associated with obesity.In one embodiment of the present invention, there is provided a method for treating or preventing symptoms associated with obesity, comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0127] In one embodiment, there is provided a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in treating or preventing diabetic disease. In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for treating or preventing diabetic disease. In one embodiment of the present invention, there is provided a method for treating or preventing diabetic disease comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0128] In one embodiment, there is provided a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein for use in treating or preventing symptoms associated with diabetic disease.In one embodiment of the present invention, there is provided the use of a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein in the manufacture of a medicament for treating or preventing symptoms associated with diabetic disease.In one embodiment of the present invention, there is provided a method for treating or preventing symptoms associated with diabetic disease comprising administering a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof as defined herein.
[0129] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing blood disorders.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing blood disorders.In one embodiment of the present invention, there is provided a method for treating or preventing blood disorders, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0130] In one embodiment, there is provided a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof for use in treating or preventing a condition associated with a blood disorder.In one embodiment of the present invention, there is provided a use of a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof in the manufacture of a medicament for treating or preventing a condition associated with a blood disorder.In one embodiment of the present invention, there is provided a method for treating or preventing a condition associated with a blood disorder, comprising administering a compound of formula (Ia) as defined herein or a pharma- ceutically acceptable salt and / or solvate thereof.
[0131] An unwanted immune response will typically be one that gives rise to a pathology, i.e., it is a pathological immune response or reaction.
[0132] In one embodiment, said inflammatory disease or disease associated with an unwanted immune response is an autoimmune disease.
[0133] In one embodiment, the inflammatory disease or disease associated with an unwanted immune response is: psoriasis (including chronic plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis, and nail psoriasis), asthma, chronic obstructive pulmonary disease (including COPD, chronic bronchitis, and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and / or atherothrombosis related disorders (including peripheral vascular disease and ischemic stroke), mitochondrial and neurodegenerative diseases (e.g. for example, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplant rejection (including antibody-mediated and T-cell mediated forms), multiple sclerosis, transverse myelitis, ischemia-reperfusion injury (e.g., during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, treatment of acute ST-segment elevation myocardial infarction or ischemic stroke), , organ transplant, or acute compartment syndrome), AGE-induced genomic damage, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, nonalcoholic fatty liver disease (nonalcoholic steatohepatitis), rheumatoid, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, Dressler syndrome, giant cell myocarditis, postpericardiotomy syndrome, drug-induced hypersensitivity syndrome (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritis (including peripheral spondyloarthritis associated with psoriasis, inflammatory bowel disease, reactive arthritis, or juvenile-onset forms of spondyloarthritis), antiphospholipid syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (bullous pemphigoid, mucous membrane pemphigoid,cicatricial pemphigoid, herpes gestationis or pemphigoid of gestationis, ophthalmic cicatricial pemphigoid), linear IgA disease, Behçet's disease, celiac disease, Chagas disease, dermatomyositis, type I diabetes mellitus, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome and its subtypes (acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMS) AN), pharyngeal-cervical-brachial, Miller-Fisher, and Bickerstaff brainstem encephalitis), progressive inflammatory neuropathies, Hashimoto's thyroiditis, hidradenitis suppurativa, inclusion body myositis, necrotizing myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schönlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (Mu (including SK antibody positive and seronegative types), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, relapsing rheumatoid arthritis, schizophrenia, autoimmune (meningo)encephalitis syndrome, scleroderma, Sjogren's syndrome, stiff-body syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu's arteritis, polyarteritis nodosa, Kawasaki disease, polyangiitis Granulomatosis (GPA; formerly Wegener's granulomatosis), Eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome), Microscopic polyarteritis / polyangiitis, Hypocomplementemic urticarial vasculitis, Hypersensitivity vasculitis, Cryoglobulinemia, Thromboangiitis obliterans (Buerger's disease), Vasculitis, Leukocytoclastic vasculitis, Vitiligo, Acute disseminated encephalomyelitis, Adrenoleukodystrophy, Alexander disease, Alper's disease disease), Barrow concentric sclerosis or Marburg disease, idiopathic organizing pneumonia (formerly bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitis syndromes, Charcot-Marie-Tooth disease, ataxia of childhood with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms and intestinal GVHD), hepatitis C (HCV) infection or complications,Herpes simplex virus infection or complications, human immunodeficiency virus (HIV) infection or complications, lichen planus, Hirayama disease, fibrosis, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), pulmonary sarcoidosis, idiopathic pulmonary fibrosis, renal fibrosis, childhood asthma, atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular edema, diabetic macular edema, central retinal vein occlusion (CRVO), macular degeneration (dry and / or wet age-related macular degeneration, including AMD), post-cataract surgery inflammation, uveitis (including posterior, anterior, intermediate and panuveitis), iridocyclitis, scleritis, corneal transplant and limbal cell graft rejection, gluten-sensitive enteropathy (celiac disease), dermatitis herpetiformis, eosinophilic esophagitis, esophageal obstruction, autoimmune autonomic neuropathy, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behçet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, systemic juvenile idiopathic Juvenile idiopathic arthritis including Still's disease, adult-onset Still's disease, lignified conjunctivitis, Mooren's ulcer, pityriasis lichenoides varioliformis (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), childhood acute-onset neuropsychiatric syndromes (PANS) including pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), paraneoplastic syndromes including paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus-myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, thymoma-associated multisystem autoimmunity ), perivenous encephalomyelitis, reflex sympathetic dystrophy, relapsing polychondritis, sperm and testicular autoimmunity, Susac syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada disease, antisynthetase syndrome, autoimmune enteropathy, X-linked immunodysregulation-polyendocrinopathy enteropathy (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Schulman syndrome),Progesterone hypersensitivity (including progesterone dermatitis), Familial Mediterranean Fever (FMF), Tumor necrosis factor (TNF) receptor-associated periodic fever syndrome (TRAPS), Hyperglobulinemia with Periodic Fever Syndrome (HIDS), PAPA (Septic arthritis, pyoderma gangrenosum, severe cystic acne) syndrome, Interleukin-1 receptor antagonist deficiency (DIRA), Interleukin-36-receptor antagonist deficiency (DITRA), Cryopyrin-associated periodic fever Syndromes (CAPS) (including familial cold autoinflammatory syndrome [FCAS], Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease [NOMID]), NLRP12-associated autoinflammatory disorder (NLRP12AD), periodic fever aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and hyperthermia (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatous disease), macrophage activation syndrome, chronic relapsing multifocal Osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spinal intrachondrodysplasia, infantile-onset STING [stimulator of interferon genes]-associated vasculopathy, proteasome-associated autoinflammatory syndrome, familial lupus pernio, hereditary symmetrical pigmentary dysplasia), Schnitzler syndrome; familial cylindromatosis, congenital The disease is or is associated with a disease selected from the group consisting of B-cell lymphocytosis, OTULIN-associated autoinflammatory syndrome, type 2 diabetes, insulin resistance and metabolic syndrome (including obesity-associated inflammation), atherosclerotic disorders (e.g., myocardial infarction, angina pectoris, ischemic heart failure, ischemic renal damage, ischemic stroke, peripheral vascular disease, aortic aneurysm), and renal inflammatory disorders (e.g., diabetic nephropathy, membranous nephropathy, minimal change disease, crescentic glomerulonephritis, acute kidney injury, kidney transplantation).
[0134] In one embodiment, the inflammatory disease or disease associated with an unwanted immune response is selected from the following autoinflammatory diseases: Familial Mediterranean Fever (FMF), Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Fever Syndrome (TRAPS), Hyperglobulinemia with Periodic Fever Syndrome (HIDS), PAPA (Septic Arthritis, Pyoderma Gangrenosum, and Severe Cystic Acne) Syndrome, Interleukin-1 Receptor Antagonist Deficiency (DIRA), Interleukin-36-Receptor Antagonist Deficiency (DITRA), Cryopyrin-Associated Periodic Syndromes (CAPS) (including Familial Cold Autoinflammatory Syndrome [FCAS], Muckle-Wells Syndrome, and Neonatal-Onset Multisystem Inflammatory Disease [NOMID]), NLRP12-Associated Autoinflammatory Disorder (NLRP12AD), being or associated with a disease selected from periodic fever with aphthous stomatitis (PFAPA), chronic atypical neutrophilic dermatosis with lipodystrophy and hyperpyrexia (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), macrophage activation syndrome, chronic relapsing multifocal osteomyelitis (CRMO), familial cold autoinflammatory syndrome, mutant adenosine deaminase 2 and monogenic interferonopathies (including Aicardi-Goutières syndrome, retinal vasculopathy with cerebral leukodystrophy, spinal enchondrodysplasia, infantile-onset STING [stimulator of interferon genes]-associated vasculopathy, proteasome-associated autoinflammatory syndrome, familial lupus pernio, hereditary symmetrical pigmentary dysplasia), and Schnitzler syndrome.
[0135] In one embodiment, the inflammatory disease or disease associated with an undesired immune response is mediated by excess NF-κB or gain of function in the NF-κB signaling pathway or has a significant contribution to abnormal pathogenesis from them (including non-canonical NF-κB signaling): familial cylindromatosis, congenital B-cell lymphocytosis, OTULIN-associated autoinflammatory syndrome, type 2 diabetes, insulin resistance, and metabolic syndrome (obesity). In one embodiment, the present invention relates to a disease selected from or associated with a disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), chronic obstructive pulmonary disease (COPD), chronic pulmonary disease (COPD), chronic pulmonary arthritis (COPD), chronic pulmonary disease (CPD), chronic obstructive pulmonary disease ...
[0136] In one embodiment, the disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), atopic dermatitis, fibrosis, uveitis, cryopyrin-associated periodic syndrome, Muckle-Wells syndrome, juvenile idiopathic arthritis, chronic obstructive pulmonary disease, and asthma.
[0137] In one embodiment, the disease is multiple sclerosis.
[0138] In one embodiment, the disease is psoriasis.
[0139] In one embodiment, the disease is asthma.
[0140] In one embodiment, the disease is chronic obstructive pulmonary disease.
[0141] In one embodiment, the disease is systemic lupus erythematosus.
[0142] In one embodiment, the disease is rheumatoid arthritis.
[0143] In one embodiment, the disease is inflammatory bowel disease (including ulcerative colitis and Crohn's disease).
[0144] In one embodiment, the disease is atopic dermatitis.
[0145] In one embodiment, the disease is fibrosis.
[0146] In one embodiment, the cancer is acute lymphoblastic leukemia, adult; acute lymphoblastic leukemia, pediatric; acute myeloid leukemia, adult; adrenocortical carcinoma; adrenocortical carcinoma, pediatric; AIDS-related lymphoma; AIDS-related malignancies; anal cancer; astrocytoma, pediatric cerebellum; astrocytoma, pediatric cerebral; Barrett's esophagus (precancerous syndrome); cholangiocarcinoma, extrahepatic; bladder cancer; bladder cancer, pediatric; bone cancer, osteosarcoma / malignant fibrous histiocytoma; brain stem glioma, pediatric; brain tumor, adult; brain tumor, brain stem glioma, pediatric; brain tumor, cerebellar astrocytoma, pediatric; brain tumor, cerebral astrocytoma / malignant glioma, pediatric; brain tumor, ependymoma, pediatric; brain tumor. tumor, medulloblastoma, children;brain tumor, supratentorial primitive neuroectodermal tumor, children;brain tumor, optic tract and hypothalamic glioma, children;brain tumor, children (other);breast cancer;breast cancer and pregnancy;breast cancer, children;breast cancer, male;bronchial adenoma / carcinoid, children;carcinoid tumor, children;carcinoid tumor, gastrointestinal;cancer, adrenal cortex;cancer, islet cell;cancer of unknown primary;central nervous system lymphoma, primary;cerebellar astrocytoma, children;cerebral astrocytoma / malignant glioma, children;cervical cancer;childhood cancer;chronic lymphocytic leukemia;chronic myeloid leukemia;chronic myeloproliferative disorder;clear cell sarcoma of tendon sheath;colon cancer;colon Rectal cancer;Colorectal cancer, children;Cutaneous T-cell lymphoma;Endometrial cancer;Ependymoma, children;Epithelial carcinoma, ovarian;Esophageal cancer;Esophageal cancer, children;Ewing family tumors;Extracranial germ cell tumors, children;Extragonadal germ cell tumors;Extrahepatic bile duct carcinoma;Eye cancer, intraocular melanoma;Eye cancer, retinoblastoma;Gallbladder cancer;Gastric cancer;Gastric cancer, children;Gastrointestinal carcinoid tumors;Germ cell tumors, extracranial, children;Germ cell tumors, extragonadal;Germ cell tumors, ovarian;Gestational trophoblastic tumors;Glioma, children's brain stem;Glioma, children's visual pathway and hypothalamus;Hairy cell leukemia;Head and neck cancer;Hepatocellular (liver) cancer;Hepatocellular (liver) cancer ) cancer, adult (primary);hepatocellular (liver) cancer, childhood (primary);cancer of the esophagus;Hodgkin's lymphoma;Hodgkin's lymphoma, adult;Hodgkin's lymphoma, childhood;Hodgkin's lymphoma, pregnancy;hypopharyngeal cancer;hypothalamic and optic tract glioma, childhood;intraocular melanoma;islet cell carcinoma (endocrine pancreas);cancer of the endocrine system (e.g., cancer of the thyroid, pancreas, parathyroid, or adrenal gland);Kaposi's sarcoma;kidney cancer;laryngeal cancer;laryngeal cancer, childhood;leukemia, acute lymphoblastic, adult;leukemia, acute lymphoblastic, childhood;leukemia, acute myeloid, adult;leukemia, acute myeloid, childhood;leukemia, chronic lymphocytic;Leukemia, chronic myeloid;Leukemia, hairy cell;Lymphocytic lymphoma;Lip and oral cavity cancer;Liver cancer, adult (primary);Liver cancer, childhood (primary);Lung cancer;Lung cancer, non-small cell;Lung cancer, small cell;Lymphoblastic leukemia, adult acute;Lymphoblastic leukemia, childhood acute;Lymphocytic leukemia, chronic;Lymphoma, AIDS-related;Lymphoma, central nervous system (primary);Lymphoma, cutaneous T-cell;Lymphoma, Hodgkin, adult;Lymphoma, Hodgkin, childhood;Lymphoma, Hodgkin, pregnancy;Lymphoma, non-Hodgkin, adult;Lymphoma, non-Hodgkin, childhood;Lymphoma, non-Hodgkin , pregnancy;Lymphoma, primary central nervous system;Macroglobulinemia, Waldenström;Male breast cancer;Malignant mesothelioma, adult;Malignant mesothelioma, childhood;Malignant thymoma;Medulloblastoma, childhood;Melanoma;Melanoma, intraocular;Merkel cell carcinoma;Mesothelioma, malignant;Metastatic squamous neck cancer of unknown primary;Multiple endocrine neoplasia syndrome, childhood;Multiple myeloma / plasma cell neoplasm;Mycosis fungoides;Myelodysplastic syndrome;Myeloid leukemia, chronic;Myeloid leukemia, acute, childhood;Myeloma, multiple;Myeloproliferative disorder, chronic;Nasal cavity and paranasal sinus cancer;Nasopharyngeal carcinoma;Nasopharyngeal carcinoma, childhood;Neuroblastoma;Non-homologous skin disease Hodgkin's lymphoma, adult;Non-Hodgkin's lymphoma, childhood;Non-Hodgkin's lymphoma, pregnancy;Non-small cell lung cancer;Neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumor, medulloblastoma, brain stem glioma, or pituitary adenoma);Oat cell carcinoma;Oral cavity cancer, childhood;Cancer of the oral cavity and lip;Oropharyngeal cancer;Osteosarcoma / malignant fibrous histiocytoma of bone;Ovarian cancer;Ovarian cancer, childhood;Ovarian epithelial cancer;Ovarian germ cell tumor;Ovarian low malignant potential tumor;Childhood malignant tumors;Pancreatic cancer;Pancreatic cancer, childhood;Pancreatic islet cell cancer;Sino-nasal and nasal cancer;Parathyroid cancer;Penile cancer;Pheochromocytoma;Pineal and tentorial cancer Superior primitive neuroectodermal tumors, children;Pituitary tumors;Plasma cell neoplasms / multiple myeloma;Pleuropulmonary blastoma;Pregnancy and breast cancer;Pregnancy and Hodgkin's lymphoma;Pregnancy and non-Hodgkin's lymphoma;Primary central nervous system lymphoma;Primary liver cancer, adults;Primary liver cancer, children;Prostate cancer (especially hormone refractory);Chronic or acute leukemia;Solid tumors of childhood;Hypereosinophilia;Rectal cancer;Renal cell (kidney) cancer;Renal cell carcinoma, children;Renal pelvis and ureter, transitional cell carcinoma;Retinoblastoma;Rhabdomyosarcoma, children;Salivary gland cancer;Salivary gland cancer, children;Sarcoma, Ewing family tumors;Sarcoma, Kaposi;Sarcoma (osteosarcoma) / malignant fibrous histiocytoma of bone;Sarcoma, rhabdomyosarcoma, childhood;Sarcoma of soft tissue;Sarcoma, soft tissue, adult;Sarcoma, soft tissue, childhood;Sezary syndrome;Skin cancer;Skin cancer, childhood;Skin cancer (melanoma);Skin cancer, Merkel cell;Small cell lung cancer;Dermatofibrosarcoma protuberans;Small intestine cancer;Soft tissue sarcoma, adult;Soft tissue sarcoma, childhood;Head and neck cancer;Squamous cell neck carcinoma of unknown primary, metastatic;Gastric cancer;Gastric cancer, childhood;Supratentorial primitive neuroectodermal tumor, childhood;T-cell lymphoma, skin;Testicular cancer;Thymoma, small The tumor is selected from the group consisting of: pediatric; thymoma, malignant; thyroid cancer; thyroid cancer, pediatric; transitional cell carcinoma of the renal pelvis and ureter; trophoblastic tumor, gestational; cancer of unknown primary site, pediatric; rare cancers of childhood; ureter and renal pelvis, transitional cell carcinoma; urethral cancer; cancer of the ureter (e.g., renal cell carcinoma, renal pelvis cancer); cancer of the penis; gynecological tumors; uterine cancer; uterine sarcoma; cancer of the fallopian tube; cancer of the endometrium; vaginal cancer; cancer of the vagina; cancer of the vulva; optic tract and hypothalamic glioma, pediatric; vulvar cancer; Waldenstrom's macroglobulinemia; and Wilms' tumor.
[0147] In one embodiment, the cancer is selected from the group consisting of lung cancer; NSCLC (non-small cell lung cancer); oat cell carcinoma; bone cancer; pancreatic cancer; skin cancer; dermatofibrosarcoma protuberans; cancer of the head and neck; cutaneous or intraocular melanoma; uterine cancer; ovarian cancer; colorectal cancer; anal cancer; gastric cancer; colon cancer; breast cancer; gynecological tumors (e.g., uterine sarcoma, cancer of the fallopian tubes, cancer of the endometrium, cancer of the cervix, cancer of the vagina, or cancer of the vulva); Hodgkin's disease; hepatocellular carcinoma; cancer of the esophagus; small intestine cancer; cancer of the endocrine system (e.g., thyroid, pancreatic, parathyroid, gland, adrenal, or adrenal gland cancer); soft tissue sarcoma; urethral cancer; penile cancer; prostate cancer (especially hormone refractory); chronic or acute leukemia; childhood solid tumors; hypereosinophilia; lymphocytic lymphoma; bladder cancer; kidney cancer; ureteral cancer (e.g., renal cell carcinoma, renal pelvis carcinoma); childhood malignancies; central nervous system neoplasms (e.g., primary CNS lymphoma, spinal axis tumor, medulloblastoma, brain stem glioma, or pituitary adenoma); Barrett's esophagus (precancerous syndrome), and neoplastic skin diseases.
[0148] "Obesity" means the condition in which a subject has a body mass index of greater than or equal to 30. Body mass index (BMI) is according to the NIH Clinical Guidelines on the Identification and Evaluation, and Treatment of Overweight and Obesity in Adults (1998).
[0149] In one embodiment, administering the compound of formula (Ia) to the subject reduces the BMI of the subject to less than 30, for example, less than 29, less than 28, less than 27, less than 26, or less than 25. In one embodiment, the compound of formula (Ia) is used to treat or prevent abnormal or inappropriate weight gain, metabolic rate, or fat accumulation, for example, to treat anorexia, bulimia, obesity, diabetes, or hyperlipidemia (e.g., high triglyceride levels and / or high cholesterol levels), and disorders of fat or lipid metabolism. In one embodiment, the compound of formula (Ia) is used to treat or prevent metabolic syndrome.
[0150] In one embodiment, the compounds of formula (Ia) are used to treat obesity associated with Prader-Willi syndrome (PWS). In one embodiment, the compounds of formula (Ia) are used to reduce body fat, prevent body fat gain, reduce cholesterol (e.g., total cholesterol and / or the ratio of total cholesterol to HDL cholesterol), and / or reduce appetite, and / or reduce comorbidities such as diabetes, cardiovascular disease, and stroke in individuals with PWS-associated obesity.
[0151] "Diabetic disease" means diabetes mellitus ("diabetes") or diabetic complications. The two main types of diabetes are (i) type 1 diabetes, which results from the pancreas not producing insulin and the usual treatment is insulin replacement therapy, and (ii) type 2 diabetes, in which patients either produce insufficient insulin or are insulin resistant. Diabetic complications include microvascular and macrovascular complications, including coronary artery disease, peripheral artery disease, stroke, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic kidney disease, and NASH.
[0152] In one embodiment, the "blood disorder" is selected from the group consisting of thalassemia (e.g., β-thalassemia), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemia (e.g., enzymopathies)), and anemia of chronic disease.
[0153] (Administration) References in this section to a compound of formula (Ia) will be understood to include a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof, preferably a compound of formula (Ia).
[0154] Typically, the compound of formula (Ia) is administered as a pharmaceutical composition. Thus, in one embodiment, there is provided a pharmaceutical composition comprising a compound of formula (Ia) and one or more pharma- ceutically acceptable diluents or carriers.
[0155] The compounds of formula (Ia) may be administered by any convenient way, for example, oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, the pharmaceutical composition being adapted accordingly.
[0156] The compounds of formula (Ia) may be administered locally to a target organ, for example to the eye, lung, nose, or skin.Thus, the present invention provides pharmaceutical compositions comprising a compound of formula (Ia), optionally in combination with one or more topically acceptable diluents or carriers.
[0157] Compounds of formula (Ia) that are active when given orally can be formulated as liquids or solids, for example, as syrups, suspensions, emulsions, tablets, capsules, or lozenges.
[0158] Liquid formulations generally consist of a suspension or solution of the compound of formula (Ia) in a suitable liquid carrier(s).Preferably, the carrier is non-aqueous, for example, polyethylene glycol or oil.The formulation may also contain a suspending agent, a preservative, a flavoring agent, and / or a coloring agent.
[0159] A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) normally used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose, and cellulose.
[0160] A composition in the form of a capsule may be prepared using commonly used encapsulation procedures, for example, pellets containing the active ingredient may be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension may be prepared using any suitable pharmaceutical carrier(s), for example, aqueous gums, celluloses, silicates, or oils, and the dispersion or suspension may then be filled into a soft gelatin capsule.
[0161] A typical parenteral composition will consist of a solution or suspension of the compound of formula (Ia) in a sterile aqueous carrier or parenterally acceptable oil, such as polyethylene glycol, polyvinylpyrrolidone, lecithin, peanut oil, or sesame oil. Alternatively, the solution can be lyophilized and then reconstituted with a suitable solvent just prior to administration.
[0162] Conveniently, compositions for nasal administration can be formulated as aerosols, drops, gels, and powders. Aerosol formulations usually contain a solution or fine suspension of the compound of formula (Ia) in a medicamentously acceptable aqueous or non-aqueous solvent, and are usually provided in a sterile form in a sealed container in single or multiple doses, and can take the form of cartridges or refills for use with a nebulizer. Alternatively, the sealed container can be a disposable dispensing device, such as a single-dose nasal inhaler or an aerosol dispenser with a metering valve. When the dosage form includes an aerosol dispenser, it will contain a propellant, which can be a compressed gas, e.g., air, or an organic propellant, such as a chlorofluorocarbon (CFC) or a hydrofluorocarbon (HFC). The aerosol dosage form can also take the form of a pump-action atomizer.
[0163] Topical administration to the lung can be achieved by means of an aerosol formulation, which typically contains the active ingredient suspended or dissolved in a suitable aerosol propellant, such as a chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC).
[0164] Topical administration to the lung may also be achieved using non-pressurized formulations, such as aqueous solutions or suspensions, which may be administered by a nebulizer, for example a hand-held or home or hospital (i.e., non-portable) nebulizer. Such formulations may include excipients such as water, buffers, osmolality adjusters, pH adjusters, surfactants, and co-solvents.
[0165] Topical administration to the lung may also be achieved using a dry powder formulation, which will normally contain a locally acceptable diluent such as lactose, glucose or mannitol, preferably lactose.
[0166] The compounds of the present invention can also be administered rectally in the form of suppositories or enemas, including, for example, aqueous or oily solutions, as well as suspensions and emulsions and foams. Such compositions are prepared according to standard procedures well known to those skilled in the art. For example, suppositories can be prepared by mixing the active ingredient with a conventional suppository base, such as cocoa butter or other glycerides. In this case, the drug is mixed with a suitable non-irritating excipient that is solid at normal temperature but liquid at rectal temperature, and therefore melts in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycol.
[0167] Generally, for compositions intended to be administered topically to the eye in the form of eye drops or eye ointment, the total amount of the compounds of the invention will be from about 0.0001% (w / w) to less than 4.0% (w / w).
[0168] Preferably, for topical administration to the eye, the compositions administered according to the present invention will be formulated as solutions, suspensions, emulsions, and other dosage forms.
[0169] The compositions administered according to the present invention may also include various other ingredients, including, but not limited to, tonicity agents, buffers, surfactants, stabilizing polymers, preservatives, cosolvents, and viscosity enhancing agents. A suitable pharmaceutical composition of the present invention includes a compound of the present invention formulated with a tonicity agent and a buffer. In addition, the pharmaceutical composition of the present invention may optionally include a surfactant and / or a emollient and / or a stabilizing polymer.
[0170] In the ophthalmic composition, various tonicity agents may be employed to adjust the osmolality of the composition, preferably to that of natural tears. For example, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, monosaccharides such as glucose, fructose, galactose, and / or polyols such as simple sugar alcohols mannitol, sorbitol, xylitol, lactitol, isomaltitol, maltitol, and hydrogenated starch hydrolysates may be added to the composition to approximate physiological osmolality. The amount of such tonicity agents will vary depending on the particular agent added. Generally, however, the composition will contain a sufficient amount of tonicity agent to provide the final composition with an ophthalmologically acceptable osmolality (generally about 150-450 mOsm, preferably 250-350 mOsm, and most preferably about 290 mOsm). Generally, the tonicity agents of the present invention will be present in the range of 2-4% w / w. Suitable tonicity agents of the present invention include the above-mentioned monosaccharides or sugar alcohols, such as D-mannitol.
[0171] A suitable buffer system (e.g., sodium phosphate, sodium acetate, sodium citrate, sodium borate, or boric acid) may be added to the composition to prevent pH drift under storage conditions. The specific concentration will vary depending on the agent employed. However, preferably, the buffer will be selected to maintain a target pH in the range of pH 5-8, more preferably a target pH of pH 5-7.
[0172] Surfactants may optionally be employed to deliver higher concentrations of the compounds of the present invention. Surfactants serve to solubilize the compounds and stabilize colloidal dispersions such as micellar solutions, microemulsions, emulsions, and suspensions. Examples of surfactants that may be optionally used include polysorbates, poloxamers, polyosyl 40 stearate, polyoxyl castor oil, tyloxapol, Triton, and sorbitan monolaurate. Suitable surfactants to be employed in the present invention have a hydrophilic lipophilic balance "HLB" in the range of 12.4 to 13.2, such as Triton X114 and tyloxapol, and are acceptable for ophthalmic use.
[0173] An additional agent that may be added to the ophthalmic composition of the compounds of the present invention is a demulcent, which acts as a stabilizing polymer. The stabilizing polymer should be an ionic / charged example preferred for topical ocular use, more specifically a polymer that has a negative charge on its surface capable of exhibiting a zeta potential of (-)10-50 mV for physical stability, and that is capable of forming a dispersion in water (i.e., is water-soluble). A suitable stabilizing polymer of the present invention would be a polyelectrolyte (singular) or polyelectrolyte (s) of the family of crosslinked polyacrylates, such as Carbomer and Pemulen®, specifically Carbomer 974p (polyacrylic acid), at 0.1-0.5% w / w.
[0174] Other compounds may also be added to the ophthalmic compositions of the compounds of the present invention to increase the viscosity of the carrier. Examples of viscosity enhancing agents include, but are not limited to: hyaluronic acid and its salts, chondroitin sulfate and its salts, polysaccharides such as dextran, various polymers of the cellulose family; vinyl polymers; and acrylic acid polymers.
[0175] Topical ophthalmic products are usually packaged in multi-dose form. Thus, preservatives are required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, chlorobutanol, benzododecinium bromide, methylparaben, propylparaben, phenylethyl alcohol, disodium edetate, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are usually employed at a level of 0.001-1.0% w / v. The unit dose compositions of the present invention are sterile but usually not preserved. Thus, such compositions generally do not contain preservatives.
[0176] Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles wherein the compound of formula (Ia) is formulated with carriers such as sugar and acacia, tragacanth, or gelatin and glycerin.
[0177] Compositions suitable for transdermal administration include ointments, gels, and patches.
[0178] The composition may contain 0.1% to 100% by weight, for example 10 to 60% by weight, of the compound of formula (Ia) depending on the method of administration. The composition may contain 0% to 99.9% by weight, for example 40% to 90% by weight, of the carrier depending on the method of administration. The composition may contain 0.05 mg to 1000 mg, for example 1.0 mg to 500 mg, 1.0 mg to 50 mg, for example about 10 mg of the compound of formula (Ia) depending on the method of administration. The composition may contain 50 mg to 1000 mg, for example 100 mg to 400 mg of the carrier depending on the method of administration. The dose of the compound used in the treatment of the above-mentioned disorders will vary in the usual manner with the severity of the disorder, the weight of the patient, and other similar factors. However, as a general guideline, a suitable unit dose may be from 0.05 to 1000 mg, more preferably from 1.0 to 500 mg, for example from 1.0 mg to 50 mg, for example about 10 mg, and such unit doses may be administered more than once a day, for example two or three times a day. Such therapy may extend for a period of several weeks or months.
[0179] In one embodiment of the present invention, the compound of formula (Ia) is used in combination with additional therapeutic agent(s).When the compound of formula (Ia) is used in combination with other therapeutic agents, the compounds can be administered either sequentially or simultaneously by any convenient route.Alternatively, the compounds can be administered separately.
[0180] When the compounds of formula (Ia) are used to treat or prevent inflammatory diseases or diseases associated with an undesired immune response, therapeutic agents which may be used in combination with the compounds of formula (Ia) include corticosteroids (glucocorticoids), retinoids (e.g., acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogues (e.g., cacitriol, calcipotriol), calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g., psoralen ultraviolet irradiation, PUVA) or other forms of ultraviolet light radiation therapy, cyclosporine, thiopurines (e.g., azathioprine, 6-mercaptopurine), Methotrexate, anti-TNFα agents (e.g., infliximab, etanercept, adalimumab, certolizumab, golimumab, and biosimilars), phosphodiesterase-4 (PDE4) inhibitors (e.g., apremilast, crisaborole), anti-IL-17 agents (e.g., brodalumab, ixekizumab, secukinumab), anti-IL12 / IL-23 agents (e.g., ustekinumab, briakinumab), anti-IL-23 agents (e.g., guselkumab, tildrakizumab), JAK (Janus kinase) inhibitors (e.g., tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasma exchange, intravenous immunoglobulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agents (e.g., rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogues (e.g., mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulators or sphingosine analogues (e.g., fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparations (interferon beta 1b / 1a), glatiramer, anti-CD3 therapy (e.g., OKT3), anti-CD52 targeted agents (e.g., alemtuzumab), leflunomide, teriflunomide, gold compounds, laquinimod, potassium channel blockers (e.g., dalfampridine / 4-aminopyridine), mycophenolic acid, mycophenolate mofetil, purine analogs (e.g., pentostatin), mTOR (target of rapamycin) pathway inhibitors (e.g., sirolimus, everolimus),Antithymocyte globulin (ATG), IL-2 receptor (CD25) inhibitors (e.g., basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agents (e.g., tocilizumab, siltuximab), Bruton's tyrosine kinase (BTK) inhibitors (e.g., ibrutinib), tyrosine kinase inhibitors (e.g., imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B-cell activating factor (BAFF, also known as BlyS, B-lymphocyte stimulating factor) inhibitors (e.g., belimumab, blissibimod), APRIL (proliferative ligand), and Other B cell targeted therapies, including fusion proteins targeting both BlyS and BlyS (e.g., atacicept), PI3K inhibitors, including pan inhibitors or those targeting p110δ and / or p110γ containing isoforms (e.g., idelalisib, copanlisib, duvelisib), interferon alpha receptor inhibitors (e.g., anifrolumab, sifalimumab), T cell costimulation blockers (e.g., abatacept, belatacept), thalidomide and its derivatives (e.g., lenalidomide), dapsone, clofazimine, leukotriene antagonists (e.g., montelukast), theophylline, anti-IgE therapy (e.g., omalizumab), anti-IL-5 agents (e.g., mepolizumab, reslizumab), long-acting muscarinic drugs (e.g., tiotropium, aclidinium, umeclidinium), PDE4 inhibitors (e.g., roflumilast), riluzole, free radical scavengers (e.g., edaravone), proteasome inhibitors (e.g., bortezomib), complement cascade inhibitors including those against C5 (e.g., eculizumab), immunoadsorbents, antithymocyte globulin, 5-aminosalicylates, and derivatives thereof (e.g., sulfasalazine, balsalazide, mesalamine), anti-integrin agents including those targeting α4β1 and / or α4β7 integrins (e.g., natalizumab, vedolizumab), anti-CD11-α agents (e.g., efalizumab), nonsteroidal anti-inflammatory drugs (NSAIDs) including salicylates (e.g., aspirin), propionic acids (e.g., ibuprofen, naproxen), acetates (e.g., indomethacin, diclofenac, etodolac), oxicams (e.g., meloxicam) and fenamates (e.g., mefenamic acid),Selective or relatively selective COX-2 inhibitors (e.g., celecoxib, etroxicoxib, valdecoxib and etodolac, meloxicam, nabumetone), colchicine, IL-4 receptor inhibitors (e.g., dupilumab), topical / contact immunotherapy (e.g., diphenylcyclopropenone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g., anakinra), IL-1β inhibitors (e.g., canakinumab), IL-1 neutralizing therapy (e.g., rilonacept), chlorambucil, immunomodulatory properties and / or NRF2 modulating These include certain antibiotics with the ability to inhibit IL-19 (e.g., minocycline, tetracyclines including clindamycin, macrolide antibiotics), antiandrogen therapy (e.g., cyproterone, spironolactone, finasteride), pentoxifylline, ursodeoxycholic acid, obeticholic acid, fibrates, cystic fibrosis transmembrane conductance regulator (CFTR) modulators, VEGF (vascular endothelial growth factor) inhibitors (e.g., bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone, and mizoribine.
[0181] When the compound of formula (Ia) is used to treat or prevent cancer, the therapeutic agent that may be used in combination with the compound of formula (Ia) includes active agents used in combination with cancer therapy, such as agents used as palliative treatment to improve undesired side effects.Thus, in one embodiment, the additional therapeutic agent is an agent used as palliative treatment, such as those selected from the group consisting of: antiemetics, drugs intended to relieve pain, such as opioids, drugs used to reduce high blood uric acid levels, such as allopurinol or rasburicase, antidepressants, sedatives, anticonvulsants, laxatives, antidiarrheals, and / or antacids.
[0182] In another embodiment, the additional therapeutic agent is an additional cancer treatment, such as chemotherapy, targeted therapy, immunotherapy, and hormonal therapy.
[0183] Examples of chemotherapeutic agents include antimetabolites (e.g., folic acid, purine, and pyrimidine derivatives) and alkylating agents (e.g., nitrogen mustards, nitrosoureas, platinum, alkylsulfonates, hydrazines, triazenes, aziridines, spindle poisons, cytotoxic agents, toposimerase inhibitors, and others). In one embodiment, the additional therapeutic agent is a chemotherapeutic agent, such as aclarubicin, actinomycin, alitretinone, altretamine, aminopterin, aminolevulinic acid, amrubicin, amsacrine, anagrelide, arsenic trioxide, asparaginase, atrasentan, belotecan, bexarotene, endamustine, bleomycin, bortezomib, busulfan, camptothecin, capecitabine, carbo Platinum, Carboquone, Carmofur, Carmustine, Celecoxib, Chlorambucil, Chlormethine, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Demecolcine, Docetaxel, Doxorubicin, Efaproxiral, Elesclomol, Elsamitrucin, Enocitabine, Epirubicin, Estramustine, Etoglucide, Etoposide, Floxuridine, fludarabine, fluorouracil (5FU), fotemustine, gemcitabine, gliadel implant, hydroxycarbamide, hydroxyurea, idarubicin, ifosfamide, irinotecan, irofulven, ixabepilone, larotaxel, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lonidamine, lomustine, lucantone, mannosulfan, masoprocol, melphalan, mercaptopurine, mesna, meth Trexate, methyl aminolevulinate, mitobronitol, mitoguazone, mitotane, mitomycin, mitoxantrone, nedaplatin, nimustine, oblimersen, omacetaxine, ortataxel, oxaliplatin, paclitaxel, pegaspargase, pemetrexed, pentostatin, pirarubicin, pixantrone, plicamycin, porfimer sodium, prednimustine, procarbazine, raltitrexed, ranimustine, rubitecan,The agent is selected from the group consisting of sapacitabine, semustine, sitimagene seradenovec, satraplatin, streptozocin, talaporfin, tegafur-uracil, temoporfin, temozolomide, teniposide, tesetaxel, testolactone, tetranitrate, thiotepa, tiazofurin, thioguanine, tipifarnib, topotecan, trabectedin, triazicon, triethylenemelamine, triplatin, tretinoin, treosulfan, trofosfamide, uramustine, valrubicin, verteporfin, vinblastine, vincristine, vindesine, vinfhmine, vinorelbine, vorinostat, and zorubicin.
[0184] Examples of targeted therapy include tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, monoclonal antibodies, and fusion proteins.In one embodiment, the additional therapeutic agent is selected from the group consisting of axitinib, bosutinib, cediranib, dasatinib, erlotinib, imatinib, gefitinib, lapatinib, lestaurtinib, nilotinib, semaxanib, sorafenib, sunitinib, vandetanib, alvocidib, seliciclib, herceptin, rituximab, tositumomab, cetuximab, panitumumab, trastuzumab, alemtuzumab, bevacizumab, edrecolomab, gemtuzumab, aflibercept, denileukin diftitox, and bexar.
[0185] When a compound of formula (Ia) is used to treat or prevent obesity, therapeutic agents that may be used in combination with a compound of formula (Ia) include gastric or pancreatic lipase inhibitors (such as orlistat); lipid lowering agents (such as statins, fibrates, niacin or its derivatives (such as acipimox), lecithin, bile acid sequestrants, ezetimibe, lomitapide, phytosterols, omega-3 supplements, PCSK9 inhibitors); CB-1 antagonists; lipoxygenase inhibitors; somostatin. somostatin analogues; insulin compounds or insulin analogues (e.g., human insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec); insulin sensitizers such as PPAR-gamma agonists, PPAR-alpha agonists, or mixed PPAR-gamma / alpha agonists (e.g., metformin, pioglitazone, or rosiglitazone); insulin secretagogues (e.g., nateglinide or repa glinides, or sulfonylureas such as gliclazide, glimeperide, limepiride, or glyburide; SGLT2 inhibitors (such as dapagliflozin, canagliflozin, or empagliflozin); amylin analogs (such as pramlintide); DPPIV inhibitors (such as sitagliptin, saxagliptin, linagliptin, alogliptin, or vildagliptin); GLP-1 agonists (albiglutide, dulaglutide) , exenatide, liraglutide, semaglutide, or lixisenatide); alpha-glucosidase inhibitors (such as acarbose, miglitol, or voglibose); phosphodiesterase inhibitors (such as pentoxifylline); glycogen phosphorylase inhibitors; MCH-1 antagonists; glucokinase activators; glucagon antagonists; insulin signaling agonists; PTP1B inhibitors; gluconeogenesis inhibitors; GSK inhibitors or galanin receptor agonists.
[0186] When the compounds of formula (Ia) are used to treat or prevent diabetic diseases, therapeutic agents that may be used in combination with the compounds of formula (Ia) include gastric or pancreatic lipase inhibitors (such as orlistat); lipid lowering agents (such as statins, fibrates, niacin or its derivatives (such as acipimox), lecithin, bile acid sequestrants, ezetimibe, lomitapide, phytosterols, omega-3 supplements, PCSK9 inhibitors); CB-1 antagonists; lipoxygenase inhibitors; somostat. somostatin analogs; insulin compounds or insulin analogs (e.g., human insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec); insulin sensitizers such as PPAR-gamma agonists, PPAR-alpha agonists, or mixed PPAR-gamma / alpha agonists (e.g., metformin, pioglitazone, or rosiglitazone); insulin secretagogues (e.g., nateglinide or levoglitinide); paglinide, or sulfonylureas such as gliclazide, glimeperide, limepiride, or glyburide; SGLT2 inhibitors (such as dapagliflozin, canagliflozin, or empagliflozin); amylin analogs (such as pramlintide); DPPIV inhibitors (such as sitagliptin, saxagliptin, linagliptin, alogliptin, or vildagliptin); GLP-1 agonists (albiglutide, dulaglutide) , exenatide, liraglutide, semaglutide, or lixisenatide); alpha-glucosidase inhibitors (such as acarbose, miglitol, or voglibose); phosphodiesterase inhibitors (such as pentoxifylline); glycogen phosphorylase inhibitors; MCH-1 antagonists; glucokinase activators; glucagon antagonists; insulin signaling agonists; PTP1B inhibitors; gluconeogenesis inhibitors; GSK inhibitors or galanin receptor agonists.
[0187] Compounds of formula (Ia) have the following desirable properties: Low EC for PKM2 activation 50 Value and / or high Emax value; Low EC for PKLR activation 50 Value and / or high E max value; Low EC for activation of PKM2 and PKLR 50 Value and / or high E max value; Low IC for reduced cell proliferation 50 value; Reduced dose and dosing frequency due to improved pharmacokinetics; ·Improved oral systemic bioavailability; Decreased plasma clearance after intravenous administration; Enhanced cell permeability; Low toxicity at appropriate therapeutic doses may indicate one or more of:
[0188] (abbreviation) [Table 1] TIFF2024543028000029.tif247170TIFF2024543028000030.tif189170 EXAMPLES
[0189] (Example) (Analysis equipment) NMR spectra were recorded using a Bruker 400MHz Avance III spectrometer fitted with a BBFO 5mm probe or a Bruker 500MHz Avance III HD spectrometer fitted with a Bruker 5mm SmartProbe™. Spectra were measured at 298K and referenced to the solvent resonance unless otherwise indicated. Chemical shifts are reported in parts per million. Data were acquired using Bruker TopSpin software.
[0190] UPLC / MS analysis was performed on a Waters Acquity UPLC system using either a Waters Acquity CSH C18 or BEH C18 column (2.1 × 30 mm) maintained at a temperature of 40 °C and eluted at a constant flow rate of 0.77 mL / min for 3 or 10 min with a linear acetonitrile gradient appropriate for the lipophilicity of the compound. The aqueous portion of the mobile phase was either 0.1% formic acid (CSH C18 column) or 10 mM ammonium bicarbonate (BEH C18 column). LC-UV chromatograms were recorded between 210 and 400 nm using a Waters Acquity PDA detector. Mass spectra were recorded using a Waters Acquity Qda detector with electrospray ionization switched between positive and negative ion modes. Sample concentrations were adjusted to obtain an appropriate UV response.
[0191] LCMS analysis was performed on an Agilent LCMS system using either a Waters Acquity CSH C18 (4.6 x 30 mm) or BEH C18 column (4.6 x 30 mm) maintained at a temperature of 40 °C and eluted at a constant flow rate of 2.5 mL / min for 4 or 15 min with a linear acetonitrile gradient appropriate for the lipophilicity of the compound. The aqueous portion of the mobile phase was either 0.1% formic acid (CSH C18 column) or 10 mM ammonium bicarbonate (BEH C18 column). LC-UV chromatograms were recorded at 254 nm using an Agilent VWD or DAD detector. Mass spectra were recorded using an Agilent MSD detector with electrospray ionization switched between positive and negative ion modes. Sample concentrations were adjusted to obtain an appropriate UV response.
[0192] (Preparative HPLC purification method) (Acidic method (A)) The product was dissolved in DMSO (mL), filtered and purified by reversed-phase preparative HPLC (Waters 2767 Sample Manager, Waters 2545 Binary Gradient Module, Waters Systems Fluidics Organiser, Waters 515 ACD pump, Waters 515 Makeup pump, Waters 2998 Photodiode Array Detector, Waters Qda) using a Waters X-SELECT CSH C18 ODB preparative column, 130 Å, 5 μm, 30 mm×100 mm, flow rate 40 mL / min, eluting with a 0.1% formic acid-MeCN gradient in water over 12.5. At-column dilution pump outputs 2 mL / min of MeCN throughout the process, which is included in the MeCN percentages below. Gradient information: 0.0-0.5 min, lp % MeCN; 0.5-10.5 min, ramp from lp % MeCN to fp % MeCN; 10.5-10.6 min, ramp from fp % MeCN to 100% MeCN; 10.6-12.5 min, hold at 100% MeCN. Clean fractions were evaporated using a Genevac.
[0193] (Basic Method (B)) The product was dissolved in DMSO (0.5 mL), filtered, and purified by reversed-phase preparative HPLC on a Waters X-Bridge BEH C18 ODB preparative column, 130 Å, 5 μm, 30 mm×100 mm, flow rate 40 mL / min, eluting with a 0.3% ammonia in water-MeCN gradient over 12.5 min with full wavelength UV detection on the PDA and QDA and ELS detectors. The at-column dilution pump delivered 2 mL / min of MeCN throughout the method, which included the following MeCN percentages: Gradient information: 0.0-0.5 min, 20% MeCN; 0.5-10.5 min, ramp from 20% MeCN to 50% MeCN; 10.5-10.6 min, ramp from 50% MeCN to 100% MeCN; 10.6-12.5 min, hold at 100% MeCN. Clean fractions were evaporated in a Genevac.
[0194] Alternatively, the following analytical LCMS equipment and methods were used: [Table 2]
[0195] (Commercially available materials) All starting materials and solvents were either obtained from commercial suppliers or prepared according to the cited literature.
[0196] (General method) All reactions were stirred unless otherwise noted. Organic solutions were dried over anhydrous magnesium sulfate using standard methods. Hydrogenations were carried out in a Thales H-cube flow reactor under conditions as described or in a gas autoclave under pressure.
[0197] General Route 1 - Synthesis of Compounds of Formula (Ia) Wherein X is S(=O) [ka] (In the formula, R A , R B , RC , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , and m are defined elsewhere herein, and LG 1 and L.G. 2 are independently leaving groups such as halo (eg, chloro, bromo, or iodo), OMs, or OTs).
[0198] General Route 1a - Synthesis of Compounds of Formula (Ia) Wherein X is S(=O) [ka] (In the formula, R A , R B , R C , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , and m are defined elsewhere herein, and LG 1 is a leaving group such as halo (e.g., chloro, bromo, or iodo), OMs, or OTs). Coupling conditions are as described herein, for example, in Example 119, and are known to those skilled in the art. Oxidation conditions in step 2 are as used in Example 119, i.e., NaIO at 40° C. 4 , H 2 O, DCM, and MeOH. Other suitable oxidation conditions are known to those skilled in the art.
[0199] (General Route 2 - X is S(=O) 2 Synthesis of a compound of formula (Ia) [ka] (In the formula, R A , R B , R C , R D , Y 1 , Y 2 , Y 3 , Z1 , Z 2 , and m are defined elsewhere herein, and LG 1 and L.G. 2 are independently leaving groups such as halo (eg, chloro, bromo, or iodo), OMs, or OTs).
[0200] (General Route 3 - X is S(=O) 2 Synthesis of a compound of formula (Ia) [ka] (In the formula, R A , R B , R C , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , and m are defined elsewhere herein, and LG 1 and L.G. 2 are independently leaving groups such as halo (eg, chloro, bromo, or iodo), OMs, or OTs).
[0201] (General Route 4 - X is S(=O) 2 Synthesis of a compound of formula (Ia) [ka] (In the formula, R A , R B , R C , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , and m are defined elsewhere herein, and LG 1 and L.G. 2 are independently leaving groups such as halo (eg, chloro, bromo, or iodo), OMs, or OTs).
[0202] (General Route 5 - X is S(=O) 2Synthesis of a compound of formula (Ia) [ka] (In the formula, R A , R B , R C , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , and m are defined elsewhere herein, and LG 1 and L.G. 2 are independently leaving groups such as halo (eg, chloro, bromo, or iodo), OMs, or OTs).
[0203] (General Procedure 1 - R 1B Synthesis of compounds where is hydroxyl [ka] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined elsewhere herein, and a moiety containing multiple Q groups represents phenyl, phenyl fused to a 5-7 membered heterocycle, a 5-10 membered heteroaryl, or a 5-6 membered heteroaryl fused to a 5-7 membered heterocycle).
[0204] tBuXPhos (0.2 equivalents) and Pd 2 dba 3(0.1 eq.) was added to a stirred solution of the appropriate chloro-heterocyclic sulfone (1 eq.) in dry 1,4-dioxane (3 mL) under nitrogen atmosphere. A 2N solution of sodium hydroxide (10 eq.) was then added dropwise and the reaction mixture was stirred at 100° C. under nitrogen for 2 h. The reaction was cooled to room temperature and 1N HCl (3 mL) was added and then extracted with DCM (2×5 mL). The organic phase was collected, dried (phase separator) and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give the desired hydroxyheterocyclic compound.
[0205] (General Procedure 2 - R 1B Synthesis of Compounds Wherein is an Amine Substituent [ka] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined elsewhere herein, and a moiety containing multiple Q groups represents phenyl, phenyl fused to a 5-7 membered heterocycle, a 5-10 membered heteroaryl, or a 5-6 membered heteroaryl fused to a 5-7 membered heterocycle).
[0206] A stirred solution of the desired Boc-protected aminoheterocycle (1 equiv., 1.18 mmol) in DCM (10 mL) was treated dropwise with TFA (1.48 g, 1.00 mL, 11.0 equiv., 13.0 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was washed with 2M NaOH(aq.) (10 mL) and the organic layer was collected. The aqueous layer was extracted with DCM (2×10 mL) and the combined organic extracts were dried (phase separator) and concentrated in vacuo to give the crude product. The crude product was purified by chromatography on silica gel to give the desired aminoheterocycle.
[0207] (General Procedure 3 - THP Deprotection) [ka] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined elsewhere herein, and a moiety containing multiple Q groups represents a 5-10 membered heteroaryl or a 5-6 membered heteroaryl fused to a 5-7 membered heterocycle, where the moiety contains an NH.
[0208] HCl (4N in dioxane) (4 molar, 15 equiv.) was added to a solution of the appropriate THP-protected N-heterocycle (1 equiv.) in MeOH (0.5 mL) or alternatively in DCM (0.5 mL), and the mixture was stirred for 1 h and then concentrated in vacuo. 3 and DCM were added and the layers were separated through a phase separator. The organic layer was washed with brine and then absorbed onto silica. The crude product was purified by chromatography on silica gel to give the desired NH-heterocycle.
[0209] (Intermediate 1 - 6-((4-Methoxyphenyl)sulfonyl)phthalazin-1(2H)-one) [ka] (Process 1) Nitrogen was bubbled through a mixture of 6-bromophthalazin-1(2H)-one (1.6 g, 1 equiv, 7.1 mmol), 4-methoxybenzenethiol (1.0 g, 0.87 mL, 1 equiv, 7.1 mmol), and DIPEA (1.8 g, 2.5 mL, 2 equiv, 14 mmol) in DMF (12 mL) and the mixture was stirred for 5 min. tBuBrettPhos Pd G3 (0.30 g, 0.05 equiv, 0.36 mmol) was added and the mixture was stirred at 100° C. under nitrogen overnight and then allowed to cool to room temperature. The mixture was poured onto ice and the resulting precipitate was washed with water, then DCM and MTBE to give crude 6-((4-methoxyphenyl)thio)phthalazin-1(2H)-one (1.632 g, 91% purity) as an orange solid. MS (ES) +):285(M+H) +
[0210] (Process 2) Oxone® (10.59 g, 3 equiv., 17.22 mmol) was added to a solution of 6-((4-methoxyphenyl)thio)phthalazin-1(2H)-one (1.632 g, 1 equiv., 5.740 mmol) in DMF (55 mL) and the reaction mixture was left stirring at room temperature for 3 h. The reaction was diluted with water (100 mL) and the resulting precipitate was filtered and washed with water then MTBE to give the title compound (1.031 g) as an off-white solid. MS (ES + ):317(M+H) +
[0211] (Intermediate 2 - 6-(phenylsulfonyl)phthalazin-1(2H)-one) [ka]
[0212] (Process 1) A suspension of 6-bromophthalazin-1(2H)-one (2.00 g, 98 wt%, 1 equiv, 8.71 mmol) and cesium carbonate (4.54 g, 1.6 equiv, 13.9 mmol) in DMF (20 mL) was added to a 20 mL flask containing 100 mL of N 2 The mixture was aerated for 5 minutes with Pd 2 (dba) 3 (399 mg, 0.05 equiv, 435 μmol), xantphos (504 mg, 0.1 equiv, 871 μmol), and thiophenol (1.44 g, 1.35 mL, 1.50 equiv, 13.1 mmol) were added sequentially. The reaction mixture was heated at 100 °C under N 2 The mixture was stirred at room temperature for 18 h, allowed to cool to room temperature, and then poured into water (100 mL). The precipitate was collected by filtration, washed with water, and dried under vacuum to give 6-(phenylthio)phthalazin-1(2H)-one (3.084 g, 90% purity) as a red solid. This product was used in the next step without further purification. MS (ES) + ):255(M+H) +
[0213] (Process 2) A stirred suspension of 6-(phenylthio)phthalazin-1(2H)-one (3.084 g, 90 wt%, 1 equiv, 10.91 mmol) in DMF (60 mL) was treated with Oxone® (15.677 g, 2.337 equiv, 25.502 mmol) in portions. The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was concentrated in vacuo and the residue was treated with water (150 mL). The precipitate was collected by filtration, washed with water and then dried under vacuum to give 6-(phenylsulfonyl)phthalazin-1(2H)-one as a pale yellow solid. The crude product was purified by chromatography on silica gel to give the title compound (2.448 g). MS (ES + ):287(M+H) +
[0214] (Intermediate 3 - 5-(chloromethyl)-2-methoxypyridine hydrochloride) [ka] A stirred solution of (6-methoxypyridin-3-yl)methanol (2.00 g, 1.73 mL, 1 equiv, 14.4 mmol) in toluene (10 mL) was treated dropwise with thionyl chloride (1.88 g, 1.15 mL, 1.1 equiv, 15.8 mmol). The resulting suspension was stirred at room temperature for 18 h. The reaction mixture was concentrated in vacuo to give the title compound (2.806 g, 13 mmol, 91%) as a sticky yellow gum. [ka] In DMSO, one proton was not observed.
[0215] (Intermediate 4 - tert-Butyl 4-(chloromethyl)indoline-1-carboxylate) [ka] (Process 1) Boc-anhydride (402 mg, 423 μL, 1.1 equiv, 1.84 mmol) was added to a stirred solution of indolin-4-ylmethanol (250 mg, 1 equiv, 1.68 mmol) and DIPEA (238 mg, 321 μL, 1.1 equiv, 1.84 mmol) in dry DCM (8 mL). The reaction mixture was stirred for 18 h at room temperature. 1N HCl (10 mL) and DCM (5 mL) were added and the layers were separated through a phase separation cartridge. The organic layer was washed with water (10 mL), brine (10 mL) and dried (MgSO 4 ) and concentrated in vacuo to give crude tert-butyl 4-(hydroxymethyl)indoline-1-carboxylate (0.41 g, 1.6 mmol, 93%) as an off-white solid. MS (ES + ):272(M+Na) + .
[0216] (Process 2) A mixture of tert-butyl 4-(hydroxymethyl)indoline-1-carboxylate (100 mg, 95 wt%, 1 equiv, 381 μmol), triethylamine (38.6 mg, 53.1 μL, 1 equiv, 381 μmol), and mesyl-Cl (43.6 mg, 29.7 μL, 1 equiv, 381 μmol) in DCM (6.0 mL) was stirred at room temperature for 3 days. The reaction mixture was evaporated under reduced pressure and purified by chromatography on silica gel to give the title compound (0.11 g) as a clear, colorless oil. MS (ES) + ):212 / 214(M-tBu+H) + .
[0217] (Intermediate 5 - 3-(chloromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole) [ka] A suspension of 3-(chloromethyl)-1H-pyrazole, HCl (500 mg, 96 wt%, 1 eq, 3.14 mmol) in DCM was treated dropwise with 3,4-dihydro-2H-pyran (286 mg, 310 μL, 97 wt%, 1.05 eq, 3.29 mmol). The reaction mixture was stirred at room temperature for 24 h. DCM (10 mL) and saturated NaHCO 3 Water (10 mL) was added and the phases mixed. The mixture was passed through a phase separator and the aqueous layer was extracted with DCM (2 x 10 mL). The combined organic extracts were dried (phase separator) and concentrated in vacuo to give the title compound (501 mg) as a pale yellow oil. The product was used in the next step without further purification. MS (ES + ):435 223(M+Na) + .
[0218] (Intermediate 6 - 3-(chloromethyl)-1-cyclopropyl-1H-pyrazole hydrochloride) [ka] SOCl 2 (206 μL, 2.82 mmol, 3.00 equiv) was added dropwise to a stirred solution of (1-cyclopropyl-1H-pyrazol-3-yl)methanol (130 mg, 941 μmol, 1 equiv) in DCM (5 mL) at 0° C. The resulting mixture was stirred for 20 h at room temperature and then evaporated under reduced pressure. The residue was co-evaporated three times with toluene to give the title compound (0.16 g) as a dark orange oil. MS (ES + ):157 / 159(M+H) + .
[0219] (Intermediate 7 - 2-Chloro-3-(chloromethyl)-6-methoxypyridine) [ka] DIPEA (0.11 g, 0.15 mL, 1.5 equiv, 0.86 mmol) was added to a stirred solution of (2-chloro-6-methoxypyridin-3-yl)methanol (0.10 g, 1 equiv, 0.58 mmol) and methanesulfonyl chloride (73 mg, 49 μL, 1.1 equiv, 0.63 mmol) in dry DCM (6 mL) at 0° C. under nitrogen atmosphere. The reaction mixture was stirred for 2 h at 0° C., then allowed to warm to room temperature and stirred for 20 h. The reaction mixture was evaporated under reduced pressure and the crude was used in the next step without further purification. MS (ES) + ):192 / 194(M+H) + .
[0220] (Intermediate 8 - Ethyl 3-(chloromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxyl) [ka] A stirred solution of ethyl 3-(chloromethyl)-1H-pyrazole-4-carboxylate (250 mg, 1 equiv, 1.33 mmol) and 4-methylbenzenesulfonic acid hydrate (30 mg, 0.12 equiv, 0.16 mmol) in DCM (5 mL) was treated with 3,4-dihydro-2H-pyran (138 mg, 150 μL, 97 wt%, 1.20 equiv, 1.59 mmol). The reaction mixture was stirred at room temperature for 22 h. The reaction mixture was diluted with saturated NaHCO 3 It was washed with water (10 mL). The organic layer was collected and the aqueous layer was extracted with DCM (2×5 mL). The combined organic extracts were dried (phase separator) and concentrated in vacuo to give the title compound (356 mg) as an orange oil. [ka]
[0221] (Intermediate 9 - 3-(chloromethyl)-1,4-dimethyl-1H-pyrazole hydrochloride) [ka] (Process 1) LiAlH4 (56.4 mg, 372 μL, 4.0 molar, 1.0 equiv, 1.49 mmol) was added dropwise to a stirred solution of ethyl 1,4-dimethyl-1H-pyrazole-3-carboxylate (0.250 g, 1 equiv, 1.49 mmol) in THF (4.0 mL) at −78° C., and the resulting mixture was stirred at that temperature for 1 h, then warmed to 0° C. and stirring was continued for an additional 1 h. The reaction was then carefully quenched by the addition of saturated aqueous Rochelle's salt (15 mL). The solution was allowed to warm to room temperature and stirred vigorously until the two phases were clear. The phases were separated and the aqueous phase was extracted with EtOAC (3×30 mL). The combined organic phase was dried (MgSO 4 ) and then concentrated under reduced pressure. The crude product was purified by chromatography on silica gel to give (1,4-dimethyl-1H-pyrazol-3-yl)methanol (0.160 g) as a clear oil. MS (ES + ):127(M+H) + .
[0222] (Process 2) Thionyl chloride (166 mg, 102 μL, 1.1 equiv, 1.40 mmol) was added dropwise to a stirred solution of (1,4-dimethyl-1H-pyrazol-3-yl)methanol (0.160 g, 1 equiv, 1.27 mmol) in toluene (3.5 mL) and the resulting suspension was stirred at room temperature for 18 h. The reaction mixture was concentrated in vacuo to give the title compound (0.205 g) as a white solid. [ka]
[0223] (Intermediate 10 - 3-(chloromethyl)-4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole) [ka] (Process 1) SEM-Cl (0.39 g, 0.41 mL, 1.2 equiv, 2.3 mmol) was added dropwise to a suspension of ethyl 4-methyl-1H-pyrazole-3-carboxylate (0.30 g, 1 equiv, 1.9 mmol) and NaH (93 mg, 60 wt%, 1.2 equiv, 2.3 mmol) in THF (20 mL) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 1 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (30 mL) and extracted with DCM (2×20 mL). The organic phase was collected, dried (phase separator) and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give ethyl 4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (0.42 g) as a pale yellow oil. MS (ES + ):285(M+H) + .
[0224] (Process 2) Lithium borohydride (61 mg, 1.4 mL, 2.00 molar, 2 equiv, 2.8 mmol) was added dropwise to a stirred solution of ethyl 4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (0.40 g, 1 equiv, 1.4 mmol) in dry THF (10.0 mL). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with water (25 mL) and transferred to a separatory funnel. The layers were extracted with EtOAc (2×25 mL). The combined organic layers were collected and dried (MgSO 4 ), filtered and concentrated in vacuo. The crude product was purified by chromatography on silica gel to give (4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.35 g) as a clear yellow solid. MS (ES + ):243(M+H) + .
[0225] (Step 3) DIPEA (0.28 g, 0.38 mL, 1.5 equiv, 2.2 mmol) was added to a stirred solution of (4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (0.35 g, 1 equiv, 1.4 mmol) and methanesulfonyl chloride (0.18 g, 0.12 mL, 1.1 equiv, 1.6 mmol) in dry DCM (10 mL) at 0° C. under nitrogen atmosphere. The reaction mixture was stirred for 2 h at 0° C., then allowed to warm to room temperature and stirred overnight. The reaction mixture was evaporated under reduced pressure to give the title compound (0.35 g, 85% purity). MS (ES + ):261 / 263(M+H) + .
[0226] (Intermediate 11 - Methyl 2-bromo-2-(6-methoxypyridin-3-yl)acetate) [ka] (Process 1) To a stirred solution of 2-(6-methoxypyridin-3-yl)acetic acid (1.000 g, 1 equiv, 5.982 mmol) in acetone (25 mL) at room temperature was added potassium carbonate (1.240 g, 1.5 equiv, 8.973 mmol) followed by methyl iodide (2.547 g, 1.122 mL, 3.0 equiv, 17.95 mmol). The resulting mixture was heated to 60° C. and stirring was continued overnight. The reaction mixture was concentrated under reduced pressure, diluted in DCM (10 mL) and washed with water (2×10 mL). The organic layer was diluted with MgSO 4 The extract was dried at 4° C. and concentrated under reduced pressure to give the crude product, which was purified by chromatography on silica gel to give methyl 2-(6-methoxypyridin-3-yl)acetate (0.957 g) as a translucent oil. [ka]
[0227] (Process 2) DBU (458 μL, 1.1 equiv, 3.04 mmol) was added to a stirred solution of methyl 2-(6-methoxypyridin-3-yl)acetate (0.500 g, 1 equiv, 2.76 mmol) in dry THF (60 mL) at 0° C. The reaction mixture was allowed to warm to room temperature over 30 min and then cooled to −78° C. CBr 4 (1.01 g, 1.1 eq, 3.04 mmol) was added and stirring was continued at -78°C for 2 h and then at 0°C for 2 h. The reaction mixture was diluted with saturated NH 4 It was quenched with aqueous Cl (10 mL) and the phases were separated. The organic phase was washed (brine), dried (Na 2 SO 4 ), filtered and concentrated in vacuo. The crude product was purified by chromatography on silica gel (12 g cartridge, 0-50% EtOAc / DCM) to give the title compound (0.188 g) as a translucent oil. MS (ES + ):260 / 262(M+H) + .
[0228] (Intermediate 12 - 6-(bromomethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole) [ka] A yellow suspension of 6-(bromomethyl)-1H-indazole hydrobromide (0.12 g, 0.4 mmol) and 3,4-dihydro-2H-pyran (0.1 mL, 1.0 mmol) in THF (10.0 mL) was heated at reflux for 2 h. After cooling to room temperature, the reaction mixture was rinsed with N 2 The reaction mixture was diluted with methylene chloride (25 mL) and saturated NaHCO 3 Washed with water (10 mL), water (10 mL), and brine (10 mL). Dried (MgSO 4 ) After evaporation, the solvent was removed under reduced pressure to give the title compound (0.15 g) as a brown oil. MS(ES) + :295 / 297(M+H) + .
[0229] (Intermediate 13 - 3-(chloromethyl)-4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole) [ka] (Process 1) A stirred solution of methyl 4-fluoro-1H-pyrazole-3-carboxylate (120 mg, 1 equiv, 833 μmol) and p-toluenesulfonic acid monohydrate (79.2 mg, 0.5 equiv, 416 μmol) in DCM (12 mL). was treated with 3,4-dihydro-2H-pyran (108 mg, 117 μL, 97 wt%, 1.50 equiv, 1.25 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with saturated NaHCO 3 Washed with water (10 mL). Collected organic layer and extracted aqueous layer with DCM (2 x 5 mL). Combined organic extracts were dried (phase separator) and concentrated in vacuo to give 4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carboxylate (0.20 g) as an orange oil. [ka]
[0230] (Process 2) Lithium borohydride (38.2 mg, 876 μL, 2.00 molar, 2 equiv, 1.75 mmol) was added dropwise to a stirred solution of methyl 4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carboxylate (200 mg, 1 equiv, 876 μmol) in dry THF (3.0 mL) and the mixture was stirred at room temperature for 18 hours. The reaction was monitored by HCl distillation with NH 4 It was quenched with Cl (10 mL) and extracted with DCM (2×10 mL). The organic phases were collected, dried (phase separator) and evaporated under reduced pressure to give (4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methanol (0.20 g) as a clear yellow oil. [ka]
[0231] (Step 3) DIPEA (0.15 g, 0.21 mL, 1.5 equiv, 1.2 mmol) was added to a stirred solution of (4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methanol (0.20 g, 80 wt%, 1 equiv, 0.80 mmol) and methanesulfonyl chloride (0.10 g, 68 μL, 1.1 equiv, 0.88 mmol) in dry DCM (6 mL) at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with DCM (10 mL) and diluted with NaHCO 3 (20mL); the organic phase was collected, dried (phase separator) and evaporated under reduced pressure to give the title compound (0.11g, 90% purity) as a dark brown oil. [ka]
[0232] (Intermediate 14 - 3-(chloromethyl)-5-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole) [ka] (Process 1) A stirred solution of methyl 4-fluoro-1H-pyrazole-3-carboxylate (120 mg, 1 equiv, 833 μmol) and p-toluenesulfonic acid monohydrate (79.2 mg, 0.5 equiv, 416 μmol) in DCM (12 mL) was treated with 3,4-dihydro-2H-pyran (108 mg, 117 μL, 97 wt%, 1.50 equiv, 1.25 mmol) and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with saturated NaHCO 3 It was washed with water (10 mL). The organic layer was collected and the aqueous layer was extracted with DCM (2×5 mL). The combined organic extracts were dried (phase separator) and concentrated in vacuo to give methyl 4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carboxylate (0.20 g) as an orange oil. [ka]
[0233] (Process 2) Lithium borohydride (38.2 mg, 876 μL, 2.00 molar, 2 equiv, 1.75 mmol) was added dropwise to a stirred solution of methyl 4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-carboxylate (200 mg, 1 equiv, 876 μmol) in dry THF (3.0 mL) and the mixture was stirred for 18 hours at room temperature. The reaction was monitored by HCl distillation with NH 4 Quenched with Cl (10 mL) and extracted with DCM (2 x 10 mL). The organic phase was collected, dried (phase separator) and evaporated under reduced pressure to give (4-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methanol (0.20 g) as a clear yellow oil. This product was used in the next step without further purification. [ka]
[0234] (Step 3) DIPEA (48 mg, 65 μL, 1.5 equiv, 0.37 mmol) was added to a stirred solution of (5-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methanol (0.10 g, 50 wt%, 1 equiv, 0.25 mmol) and methanesulfonyl chloride (31 mg, 21 μL, 1.1 equiv, 0.27 mmol) in dry DCM (3 mL) at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with DCM (10 mL) and diluted with NaHCO 3 (20mL); the organic phase was collected, dried (phase separator) and evaporated under reduced pressure to give the title compound (55mg) as a dark brown oil. [ka]
[0235] (Intermediate 15 - 5-(1-chloroethyl)-2-methoxypyridine hydrochloride) [ka] Thionyl chloride (188 mg, 115 μL, 1.1 equiv, 1.58 mmol) was added to a solution of 1-(6-methoxypyridin-3-yl)ethan-1-ol (220 mg, 1 equiv, 1.44 mmol) in toluene (5 mL) and the mixture was stirred for 1.5 h and then concentrated in vacuo. The residue was triturated with MTBE and the resulting mixture was concentrated in vacuo to give the crude title compound as a colorless semi-solid. The product was used in the next step without purification. Quantitative yield was assumed.
[0236] (Intermediate 16 - Methyl 3-(bromomethyl)picolinate) [ka] CCl 4 A solution of methyl 3-methylpicolinate (1.51 g, 10.0 mmol), N-bromosuccinimide (1.6 g, 9.0 mmol), and AIBN (164 mg, 1.0 mmol) in 10 mL of ethyl acetate was stirred at 75° C. for 12 h. The mixture was diluted with saturated NaHCO 3 The mixture was diluted with ethyl acetate, extracted with DCM and washed with brine (10 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give the title compound (1.0 g, 44%) as a yellow oil. [ka]
[0237] (Intermediate 17 - Methyl 3-(bromomethyl)thiophene-2-carboxylate) [ka] CCl 4To a solution of methyl 3-methylthiophene-2-carboxylate (500 mg, 3.20 mmol) in (10 mL) was added NBS (456 mg, 2.56 mmol) and AIBN (53 mg, 0.32 mmol) and the mixture was stirred at 75 °C for 12 h. The mixture was diluted with saturated NaHCO 3 The mixture was diluted with ethyl acetate, extracted with DCM and washed with brine (10 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give the title compound (300 mg) as a yellow oil. MS (ES + ):235.0(M+H) + .
[0238] (Intermediate 18 - Methyl 3-(bromomethyl)furan-2-carboxylate) [ka] A solution of methyl 3-methylfuran-2-carboxylate (500 mg, 3.57 mmol) was added to CCl 4 NBS (509 mg, 2.86 mmol), AIBN (60 mg, 0.36 mmol) in (10 mL) were added. The mixture was then stirred at 75° C. for 12 h. The mixture was diluted with saturated NaHCO 3 It was diluted with water, extracted with DCM and washed with brine (10 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give the title compound (300 mg, 39%) as a yellow oil. MS (ES + ):219.0(M+H) + .
[0239] (Intermediate 19 - Methyl 3-(bromomethyl)-6-methoxypicolinate) [ka] (Process 1) A solution of methyl 6-chloro-3-methylpicolinate (900 mg, 4.86 mmol) in MeOH (2 mL), MeONa (2 M in MeOH) (5 mL) was then stirred at room temperature for 12 h. The mixture was then diluted with saturated NH 4 The mixture was diluted with Cl, extracted with DCM and washed with brine (5 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give methyl 6-methoxy-3-methylpicolinate (200 mg, 23%) as a yellow oil. MS (ES + ):182.3(M+H) + .
[0240] (Process 2) CCl 4 A solution of methyl 6-methoxy-3-methylpicolinate (200 mg, 1.10 mmol), NBS (157 mg, 0.88 mmol), AIBN (18 mg, 0.11 mmol) in (5 mL). The mixture was stirred at 75 °C for 12 h. The mixture was diluted with saturated NaHCO 3 The mixture was diluted with ethyl acetate, extracted with DCM and washed with brine (5 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give the title compound (200 mg) as a yellow oil. MS (ES + ):260.0(M+H) + .
[0241] (Intermediate 20 - Methyl 5-(bromomethyl)furan-2-carboxylate) [ka] CCl 4 A solution of methyl 5-methylfuran-2-carboxylate (500 mg, 3.57 mmol), NBS (509 mg, 2.86 mmol), AIBN (59 mg, 0.36 mmol) in (10 mL). The mixture was then stirred at 75° C. for 12 h. The mixture was diluted with saturated NaHCO 3The mixture was diluted with ethyl acetate, extracted with DCM and washed with brine (10 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give the title compound (300 mg) as a yellow oil. MS (ES + ):219.0(M+H) + .
[0242] (Intermediate 21 - 2-(chloromethyl)-5-methoxypyrazine) [ka] (Process 1) To a solution of methyl 5-chloropyrazine-2-carboxylate (1 g, 5.8 mmol) in MeOH (30 mL) was added MeONa (344 mg, 6.4 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the reaction mixture was extracted with EtOAc (2×50 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 After drying at 40° C., filtration, and concentration under reduced pressure at 30° C., the residue was purified by flash column chromatography to give methyl 5-methoxypyrazine-2-carboxylate (400 mg) as a yellow oil. MS (ES + ):169.2(M+H) + .
[0243] (Process 2) To a solution of methyl 5-methoxypyrazine-2-carboxylate (400 mg, 2.4 mmol) in MeOH (12 mL), NaBH 4 (880 mg, 24 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 1 h. After LCMS showed the reaction was complete, the reaction mixture was quenched with ice water (10 mL), adjusted to pH=5 with 0.5 N aqueous HCl, and extracted with EtOAc (2×50 mL). The organic layer was washed with brine and diluted with Na 2 SO 4The mixture was dried at 40° C., filtered, concentrated under reduced pressure at 30° C., and the residue was purified by flash column chromatography to give (5-methoxypyrazin-2-yl)methanol (300 mg) as a yellow oil. MS (ES + ):141.3(M+H) + .
[0244] (Step 3) To a solution of (5-methoxypyrazin-2-yl)methanol (300 mg, 2.1 mmol) in DCM (8 mL), SOCl 2 (1.25 g, 10.5 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100 ml of DCM (2×10 mL) and the organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (250 mg) as a yellow oil which was used directly in the next step. MS (ES + ):159.2(M+H) + .
[0245] (Intermediate 22 - Methyl 2-(bromomethyl)-6-chlorobenzoate) [ka] (Process 1) Ethyl 2-chloro-6-methylbenzoate (1.5 g, 8.8 mmol) and CH 3 A solution of I (1.3 g, 9 mmol) was added to K 2 CO 3 (2.4 mg, 17 mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 4 h. After LCMS showed the reaction was complete, the reaction mixture was extracted with EtOAc (2×50 mL). The organic layer was washed with brine and diluted with Na 2 SO4 After drying at 40° C., filtering and concentrating under reduced pressure at 30° C., the residue was purified by flash column chromatography to give methyl 2-chloro-6-methylbenzoate (1.5 g) as a yellow oil. [ka]
[0246] (Process 2) CCl 4 To a solution of methyl 2-chloro-6-methylbenzoate (1.5 g, 8 mmol) and NBS (1.56 g, 8.8 mmol) in (50 mL) was added AIBN (263 mg, 1.6 mmol) at room temperature and the reaction mixture was stirred at 90° C. for 4 h. After LCMS showed the reaction was complete, the reaction mixture was extracted with EtOAc (2×50 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, concentrated under reduced pressure at 30° C., and the residue was purified by flash column chromatography to give the title compound (1.1 g) as a yellow oil. MS (ES + ):263.0(M+H) + .
[0247] (Intermediate 23 - Ethyl 2-(bromomethyl)-6-methoxybenzoate) [ka] CCl 4 To a solution of ethyl 2-methoxy-6-methylbenzoate (2 g, 10 mmol) and NBS (1.95 g, 11 mmol) in (50 mL) was added AIBN (328 mg, 2 mmol) at room temperature and the reaction mixture was stirred at 90° C. for 4 h. After LCMS showed the reaction was complete, the reaction mixture was extracted with EtOAc (2×50 mL). The organic layer was washed with brine and diluted with Na 2 SO 4The mixture was dried at 40° C., filtered, concentrated under reduced pressure at 30° C., and the residue was purified by flash column chromatography to give the title compound (1.8 g) as a yellow oil. MS (ES + ):273.0(M+H) + .
[0248] (Intermediate 24 - Methyl 4-(bromomethyl)thiazole-2-carboxylate) [ka] CCl 4 To a solution of methyl 4-methylthiazole-2-carboxylate (900 mg, 5.73 mmol) in (10 mL) was added NBS (815 mg, 4.58 mmol) and AIBN (94 mg, 0.57 mmol), and the mixture was then stirred at 75° C. for 12 h. The mixture was diluted with saturated NaHCO 3 It was diluted with water, extracted with DCM and washed with brine (10 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give the title compound (300 mg) as a yellow oil. MS (ES + ):236.0(M+H) + .
[0249] (Intermediate 25 - Methyl 4-(chloromethyl)-5-methylisoxazole-3-carboxylate) [ka] (Process 1) A mixture of ethyl 5-methylisoxazole-3-carboxylate (900 mg, 5.80 mmol), 1,3,5-trioxane (783 mg, 8.70 mmol), and aqueous HBr (62%, 10.0 mL) was stirred at 60 °C overnight in a sealed flask. After cooling, the mixture was poured into anhydrous MeOH (20 mL) and evaporated at 60-70 °C. The mixture was used crude in the next step without further manipulation.
[0250] (Process 2) The mixture was dissolved in MeOH (20 ml) and thionyl chloride (4 mL) was added; the mixture was then stirred at 60° C. for 30 min. The reaction mixture was dried and then evaporated to give the title compound (300 mg) as a yellow oil. MS (ES + ):190.2(M+H) + .
[0251] (Intermediate 26 - 2-Chloro-3-(chloromethyl)-6-methylpyridine) [ka] To a mixture of (2-chloro-6-methylpyridin-3-yl)methanol (400 mg, 2.5 mmol) in DCM (5 mL), SOCl 2 (1.1 g, 9.5 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100 ml of DCM (2×10 mL) and the organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (400 mg) as a yellow oil which was used directly in the next step. MS (ES + ):176.2(M+H) + .
[0252] (Intermediate 27 - 2-Chloro-3-(chloromethyl)-4-methylpyridine) [ka] To a mixture of (2-chloro-4-methylpyridin-3-yl)methanol (300 mg, 1.9 mmol) in DCM (5 mL), SOCl 2(1.1 g, 9.5 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100 ml of DCM (2×10 mL) and the organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (300 mg) as a yellow oil which was used directly in the next step. MS (ES + ):176.2(M+H) + .
[0253] (Intermediate 28 - 2-Chloro-3-(chloromethyl)-5-fluoropyridine) [ka] To a mixture of (2-chloro-5-fluoropyridin-3-yl)methanol (500 mg, 3.1 mmol) in DCM (5 mL), SOCl 2 (1.1 g, 9.5 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of DCM (10 mL x 2). The organic layer was washed with brine and added Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (400 mg) as a yellow oil which was used directly in the next step. [ka]
[0254] (Intermediate 29 - 2-Chloro-3-(chloromethyl)-5-isopropylpyridine) [ka] (Process 1) Tol / H 2 (5-Bromo-2-chloropyridin-3-yl)methanol (1.4 g, 6.3 mmol), Pd(Oac) in 2O (10 mL, 5:1) 2 (141mg, 0.63mmol), cataCXium A (443mg, 1.2mmol), K 2 CO 3 To a mixture of (1.7 g, 12 mmol), potassium isopropenyltrifluoroborate (962 mg, 6.5 mmol) was added at room temperature, and the reaction mixture was stirred at 90° C. overnight under nitrogen atmosphere. After LCMS showed the reaction was complete, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was diluted with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine and diluted with Na 2 SO 4 The mixture was dried at 45° C., filtered, and concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography to give (2-chloro-5-(prop-1-en-2-yl)pyridin-3-yl)methanol (1.1 g) as a yellow solid. MS (ES + ):184.2(M+H) + .
[0255] (Process 2) To a solution of (2-chloro-5-(prop-1-en-2-yl)pyridin-3-yl)methanol (1.1 g, 6 mmol) in EtOAc (10 mL) was added PtO 2 (1.4 g, 6.6 mmol) was added at room temperature and the reaction mixture was diluted with H 2 The mixture was stirred at room temperature for 2 h under reduced pressure. After LCMS showed the reaction was complete, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was diluted with water (10 mL) and extracted with EtOAc (3×15 mL). The combined organic layers were washed with brine and diluted with Na 2 SO 4The mixture was dried at 45° C., filtered, and concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography to give (2-chloro-5-isopropylpyridin-3-yl)methanol (1 g) as a yellow solid. MS (ES + ):186.2(M+H) + .
[0256] (Step 3) To a mixture of (2-chloro-5-isopropylpyridin-3-yl)methanol (1 g, 5.4 mmol) in DCM (15 mL), SOCl 2 (2.4 g, 20 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. and diluted with DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100% H 2 O and extracted with DCM (2×20 mL). The organic layer was washed with brine and 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 30° C. to give 2-chloro-3-(chloromethyl)-5-isopropylpyridine (800 mg) as a yellow oil, which was used without further purification. MS (ES + ):204.2(M+H) + .
[0257] (Intermediate 30 - 1-(2-(tert-butyldimethylsilyloxy)ethyl)-3-(chloromethyl)pyridin-2(1H)-one) [ka] (Process 1) 2-Hydroxynicotinaldehyde (200 mg, 1.6 mmol) in MeCN (15 mL), Cs 2 CO 3To a solution of (1.56 g, 4.8 mmol), (2-bromoethoxy)(tert-butyl)dimethylsilane (571 mg, 2.4 mmol) was added at 60° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was quenched with water (10 mL) and filtered. The cake was dissolved in ethyl acetate (10 mL), washed with brine, and concentrated with Na 2 SO 4 The filtrate was concentrated under reduced pressure at 30° C., and the residue was triturated with petroleum ether / ethyl acetate=1 / 1, filtered, and dried under reduced pressure at 30° C. to give 1-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxo-1,2-dihydropyridine-3-carbaldehyde (200 mg) as a white solid. MS (ES + ):282.2(M+H) + .
[0258] (Process 2) To a solution of 1-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxo-1,2-dihydropyridine-3-carbaldehyde (200 mg, 0.71 mmol) in MeOH (10 mL) was added NaBH 4 (54 mg, 1.42 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to remove DCM. The residue was quenched with ice water (10 mL) and extracted with DCM (2×10 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 30° C. to give 1-(2-(tert-butyldimethylsilyloxy)ethyl)-3-(hydroxymethyl)pyridin-2(1H)-one (120 mg) as a yellow oil. MS (ES + ):284.2(M+H) + .
[0259] (Step 3) 1-(2-(tert-butyldimethylsilyloxy)ethyl)-3-(hydroxymethyl)pyridin-2(1H)-one (120 mg, 0.4 mmol) in DCM (5 mL), Et3 To a solution of N (121 mg, 1.2 mmol) was added MsCl (68 mg, 0.6 mmol) at room temperature for 3 h. After LCMS showed the reaction was complete, the reaction mixture was quenched with water (10 mL) and filtered. The cake was dissolved in DCM (5 mL), washed with brine and added Na 2 SO 4 The mixture was dried at 40° C. and filtered. The filtrate was concentrated under reduced pressure at 30° C. to give 1-(2-(tert-butyldimethylsilyloxy)ethyl)-3-(chloromethyl)pyridin-2(1H)-one (80 mg) as a yellow oil. MS (ES + ):302.2(M+H) + .
[0260] (Intermediate 31 - 2,4-Dichloro-3-(chloromethyl)pyridine) [ka] (Process 1) A solution of 2,4-dichloronicotinaldehyde (1.0 g, 5.71 mmol) in MeOH (20 mL) was added to NaBH 4 (433 mg, 11.4 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 1 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to remove DCM. The residue was quenched with ice water (10 mL) and extracted with DCM (2×10 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 30° C. to give (2,4-dichloropyridin-3-yl)methanol (900 mg) as a yellow oil. MS (ES + ):178.2(M+H) + .
[0261] (Process 2) To a solution of (2,4-dichloropyridin-3-yl)methanol (900 mg, 5.1 mmol) in DCM (10 mL) was added SOCl 2(3 g, 25.5 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl. 2 The majority of the residue was removed. The residue was quenched with ice water (50 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100% H 2 O and extracted with DCM (2×40 mL). The organic layer was washed with brine and 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (800 mg) as a yellow oil. MS (ES + ):196.0(M+H) + .
[0262] (Intermediate 32 - 2-Chloro-3-(chloromethyl)-4-fluoropyridine) [ka] (Process 1) To a solution of 2-chloro-4-fluoronicotinaldehyde (908 mg, 5.71 mmol) in MeOH (20 mL) was added NaBH 4 (433 mg, 11.4 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 1 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to remove DCM. The residue was quenched with ice water (10 mL) and extracted with DCM (2×10 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 30° C. to give (2-chloro-4-fluoropyridin-3-yl)methanol (820 mg) as a yellow oil. MS (ES + ):162.2(M+H) + .
[0263] (Process 2) To a solution of (2-chloro-4-fluoropyridin-3-yl)methanol (820 mg, 5.1 mmol) in DCM (10 mL) was added SOCl 2(3 g, 25.5 mmol) was added dropwise at 0° C., and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. The residue was quenched with ice water (50 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100% H 2 O and extracted with DCM (2×40 mL). The organic layer was washed with brine and 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (700 mg) as a yellow oil. MS (ES + ):180.0(M+H) + .
[0264] (Intermediate 33 - 3-Bromo-4-(chloromethyl)pyridine) [ka] To a mixture of (3-bromopyridin-4-yl)methanol (300 mg, 1.6 mmol) in DCM (5 mL), SOCl 2 (1.1 g, 9.5 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100 ml of DCM (2×10 mL) and the organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (305 mg) as a yellow oil. MS (ES + ):206.0(M+H) + .
[0265] (Intermediate 34 - Methyl 2-(bromomethyl)-5-methoxybenzoate) [ka] (Process 1) To a solution of 5-methoxy-2-methylbenzoic acid (1.0 g, 6 mmol) in MeOH (20 mL), add SOCl 2 (1.4 mg, 12 mmol) was added at room temperature and the reaction mixture was stirred at 70° C. for 3 h. After LCMS showed the reaction was complete, the reaction mixture was extracted with EtOAc (2×20 mL). The organic layer was washed with brine and Na 2 SO 4 The mixture was dried at 40° C., filtered, concentrated under reduced pressure at 30° C., and the residue was purified by flash column chromatography to give methyl 5-methoxy-2-methylbenzoate (1.1 g) as a yellow oil. MS (ES + ):181.2(M+H) + .
[0266] (Process 2) CCl 4 To a solution of methyl 5-methoxy-2-methylbenzoate (1.1 g, 6 mmol) and NBS (1.17 g, 6.6 mmol) in (30 mL) was added AIBN (197 mg, 1.2 mmol) at room temperature and the reaction mixture was stirred at 100° C. for 3 h. After LCMS showed the reaction was complete, the reaction mixture was extracted with EtOAc (2×30 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 It was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. The residue was purified by flash column chromatography to give the title compound (700 mg) as a yellow oil. [ka]
[0267] (Intermediate 35 - 4-Chloro-3-(chloromethyl)pyridine) [ka] To a mixture of (4-chloropyridin-3-yl)methanol (500 mg, 3.5 mmol) in DCM (5 mL), SOCl 2(1.7 g, 14 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100 ml of DCM (2×10 mL) and the organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (490 mg) as a yellow oil. MS (ES + ):162.2(M+H) + .
[0268] (Intermediate 36 - 2-Chloro-3-(chloromethyl)-6-methoxypyridine) [ka] (Process 1) To a solution of methyl 2-chloro-6-methoxynicotinate (500 mg, 2.49 mmol) in MeOH (10 mL), NaBH 4 (189 mg, 4.98 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 1 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to remove DCM. The residue was quenched with ice water (10 mL) and extracted with DCM (2×10 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 30° C. to give (2-chloro-6-methoxypyridin-3-yl)methanol (400 mg) as a yellow oil. MS (ES + ):174.2(M+H) + .
[0269] (Process 2) To a solution of (2-chloro-6-methoxypyridin-3-yl)methanol (400 mg, 2.3 mmol) in DCM (10 mL), SOCl 2(1.4 g, 11.5 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (50 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 with aqueous solution of 100% H 2 O and extracted with DCM (2×40 mL). The organic layer was washed with brine and 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (380 mg) as a yellow oil. MS (ES + ):192.0(M+H) + .
[0270] (Intermediate 37 - 5-(chloromethyl)-3-(trifluoromethyl)isoxazole) [ka] (Process 1) To a 50 mL solution of 2.5 M n-BuLi (30 mL, 76.44 mmol) in hexanes was added dropwise tert-butyldimethyl(prop-2-ynyloxy)silane (10 g, 58.8 mmol) in glacial THF (50 mL). The mixture was stirred at 10° C. for 15 min. Ethyl 2,2,2-trifluoroacetate (11.7 g, 82.3 mmol) was added to the resulting slightly yellow solution while cooling with a dry ice acetone bath (−40° C.). The mixture was stirred at room temperature for 18 h. The reaction mixture was poured onto ice mixed with 10% aqueous citric acid. The phases were separated and the organic phase was washed with 10% aqueous sodium bicarbonate and brine, purified by filtration through approximately 120 g of silica gel, filtered and dried under reduced pressure at 30° C. to give 5-(tert-butyldimethylsilyloxy)-1,1,1-trifluoropent-3-yn-2-one (5.8 g) as a yellow oil which was used directly in the next step.
[0271] (Process 2) To a solution of hydroxylamine hydrochloride (1.5 g, 21.8 mmol) and sodium hydroxide (43.6 mg, 1.09 mmol) in 25 mL of methanol was added 5-(tert-butyldimethylsilyloxy)-1,1,1-trifluoropent-3-yn-2-one (5.8 g, 21.8 mmol) and the mixture was heated to reflux for 3 h. The reaction mixture was extracted with EtOAc and purified by chromatography on silica gel to give (3-(trifluoromethyl)isoxazol-5-yl)methanol (1.5 g) as a colorless oil. [ka]
[0272] (Step 3) A solution of (3-(trifluoromethyl)isoxazol-5-yl)methanol (200 mg, 1.20 mmol) in DCM (5 mL) was added with SOCl 2 (714 mg, 6.0 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 Most of the was removed to give the title compound (185 mg) as a yellow oil which was used in the next step without further characterization or purification.
[0273] (Intermediate 38 - 3-Bromo-2-(chloromethyl)pyridine) [ka] To a mixture of (3-bromopyridin-2-yl)methanol (500 mg, 2.7 mmol) in DCM (5 mL), SOCl 2 (1.7 g, 14 mmol) was added at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3The pH was adjusted to 9 with aqueous solution of DCM (10 mL x 2). The organic layer was washed with brine and added Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (490 mg) as a yellow oil which was used directly in the next step. MS (ES + ):206.0(M+H) +
[0274] (Intermediate 39 - 6-Bromo-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one) [ka] (Process 1) To a solution of (6-methoxypyridin-3-yl)methanol (22.8 g, 164 mmol) in DCM (80 mL) was added SOCl 2 (58.5 g, 492 mmol) was added at 0° C., and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. Ice water (50 mL) was added to the mixture. The reaction mixture was diluted with 2N K 2 CO 3 Quench with water to pH=9, separate, extract with DCM (40 mL x 2) and add Na 2 SO 4 The mixture was dried at 40° C. and filtered. The filtrate was concentrated under reduced pressure at 30° C. to give 5-(chloromethyl)-2-methoxypyridine (25 g, 97%) as a yellow oil. MS (ES + ):158.2(M+H) +
[0275] (Process 2) 5-(Chloromethyl)-2-methoxypyridine (25 g, 159 mmol) in DMF (80 mL), K 2 CO 3(33.8 g, 245 mmol) was added with 6-bromophthalazin-1(2H)-one (27.3 g, 122 mmol) at room temperature, and the reaction mixture was stirred at 90° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was quenched with water (300 mL) and filtered. The cake was dissolved in DCM (400 mL), washed with brine, and concentrated with Na 2 SO 4 The filtrate was concentrated under reduced pressure at 30° C., and the resulting residue was then triturated with hexane and MTBE (10 / 1), filtered, and dried under reduced pressure at 30° C. to give the title compound (52 g) as a yellow solid. MS (ES + ):346.0(M+H) +
[0276] (Intermediate 40 - 6-Mercapto-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one) [ka] (Process 1) 6-Bromo-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one (Intermediate 39, 52 g, 150 mmol) in DMF (80 mL), Pd 2 (dba) 3 (13.73 g, 15 mmol), Xantphos (17.34 g, 30 mmol), and DIPEA (58 g, 450 mmol) were mixed with 2-ethylhexyl 3-mercaptopropanoate (49 g, 225 mmol) in a solution of N 2 The mixture was added at room temperature under reduced pressure and the reaction mixture was stirred at 100° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was filtered. To the mixture was added EtOAc (80 mL) and the combined organic layers were washed with brine, separated and back extracted with additional EtOAc (50 mL×3). The organic phase was washed with Na 2 SO 4The residue was purified by flash column chromatography to give 6-bromo-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one (62 g, 86%) as a yellow solid. MS (ES) + ):484.0(M+H) +
[0277] (Process 2) To a solution of 6-bromo-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one (5 g, 10 mmol) in THF (50 mL) was added NaOEt (816 mg, 12 mmol) at room temperature. The reaction mixture was stirred at room temperature for 15 min. After LCMS showed the reaction was complete, the reaction mixture was quenched with 0.5N aqueous HCl to pH=5, separated and extracted with EtOAc (20 mL×2). The combined organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 40° C. to give the title compound (2.6 g) as a brown solid. MS (ES + ):300.0(M+H) +
[0278] (Intermediate 41 - tert-butyl (3-((6-bromo-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate) [ka] tert-Butyl (3-(bromomethyl)phenyl)carbamate (5.1 g, 1 equiv., 18 mmol) was added to a stirred suspension of 6-bromophthalazin-1(2H)-one (4.0 g, 1.0 equiv., 18 mmol) and cesium carbonate (12 g, 2.0 equiv., 36 mmol) in dry DMF (100 mL) under N 2 The mixture was added at 70° C. for 18 h. The reaction mixture was stirred for 18 h. The product was precipitated with water (500 mL) and filtered to give the title compound (6.1 g) as a light brown solid. MS (ES) + :452 / 454(M+Na) +
[0279] (Intermediate 42 - tert-butyl (3-((6-mercapto-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate) [ka] (Process 1) tert-Butyl (3-((6-bromo-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate (Intermediate 41, 1.000 g, 1 equiv, 2.324 mmol), 2-ethylhexyl 3-mercaptopropanoate (532.8 mg, 1.05 equiv, 2.440 mmol), DIPEA (600.7 mg, 810 μL, 2 equiv, 4.648 mmol), xantphos (134.5 mg, 0.1 equiv, 232.4 μmol), and Pd 2 (dba) 3 A degassed mixture of (106.4 mg, 0.05 equiv., 116.2 μmol) was diluted with N 2 The mixture was heated to 100° C. under reduced pressure for 2 h. After cooling to room temperature, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (10×5 mL). The organic phase was collected and dried (MgSO 4 ) and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give 2-ethylhexyl 3-((2-(3-((tert-butoxycarbonyl)amino)benzyl)-1-oxo-1,2-dihydrophthalazin-6-yl)thio)propanoate (0.925 g) as an orange oil. MS (ES + ):590.8(M+Na) +
[0280] (Process 2) Sodium ethoxide (2.360 g, 2.72 mL, 21 wt%, 2 equiv, 7.281 mmol) was added to a stirred solution of 2-ethylhexyl 3-((2-(3-((tert-butoxycarbonyl)amino)benzyl)-1-oxo-1,2-dihydrophthalazin-6-yl)thio)propanoate (2.067 g, 1 equiv, 3.641 mmol) in THF (12 mL) at 0° C. and the resulting solution was stirred for 1 h while warming to room temperature. The reaction was diluted with DCM (20 mL) and washed with saturated NH 4 The mixture was quenched with aqueous Cl (10 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc (2×20 mL). The combined organic phase was washed with MgSO 4 Drying at 40° C., filtration and removal of volatiles under reduced pressure gave the title compound (0.877 g). MS (ES + ): 406 (M+Na) +
[0281] (Intermediate 43 - 1-Methyl-1H-pyrazole-3-thiol) [ka] (Process 1) 3-Bromo-1-methyl-1H-pyrazole (0.500 g, 315 μL, 1 equiv, 3.11 mmol), 2-ethylhexyl 3-mercaptopropanoate (746 mg, 1.1 equiv, 3.42 mmol), DIPEA (803 mg, 1.08 mL, 2 equiv, 6.21 mmol), xantphos (180 mg, 0.1 equiv, 311 μmol), and Pd in 1,4-dioxane (10 mL). 2 (dba) 3 A degassed mixture of (142 mg, 0.05 equiv., 155 μmol) was heated to 100° C. for 20 h. After cooling to room temperature, the reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The organic phase was collected and dried (MgSO 4 ) and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give 2-ethylhexyl 3-((1-methyl-1H-pyrazol-3-yl)thio)propanoate (0.803 g) as an orange oil. MS (ES +):299(M+H) +
[0282] (Process 2) Sodium ethoxide (1.74 g, 2.01 mL, 21 wt%, 2 equiv, 5.38 mmol) was added to a stirred solution of 2-ethylhexyl 3-((1-methyl-1H-pyrazol-3-yl)thio)propanoate (0.803 g, 1 equiv, 2.69 mmol) in THF (9.0 mL) at 0 °C and the resulting solution was stirred for 1 h while warming to room temperature. The reaction was diluted with DCM (10 mL) and washed with saturated NH 4 The mixture was quenched with aqueous Cl (5 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc (2×10 mL). The combined organic phase was washed with MgSO 4 It was dried at 40° C., filtered and the volatiles were removed under reduced pressure. The aqueous layer was concentrated, diluted in MeOH and adsorbed onto silica gel. Purification by chromatography on silica gel afforded the title compound (0.125 g) as a pale orange oil. [ka] (No -SH signal could be observed).
[0283] (Intermediate 44 - Benzo[d][1,3]dioxole-5-thiol) [ka] (Process 1) 5-Bromobenzo[d][1,3]dioxole (0.850 g, 1 equiv., 4.23 mmol), 2-ethylhexyl 3-mercaptopropanoate (1.02 g, 1.1 equiv., 4.65 mmol), Xantphos (245 mg, 0.1 equiv., 423 μmol), Pd 2 (dba) 3A degassed mixture of (194 mg, 0.05 equiv., 211 μmol) and DIPEA (1.09 g, 1.47 mL, 2 equiv., 8.46 mmol) was heated to 100° C. for 20 h. After cooling to room temperature, the reaction mixture was filtered through a pad of Celite and evaporated to dryness. The crude product was purified by chromatography on silica gel to give 2-ethylhexyl 3-(benzo[d][1,3]dioxol-5-ylthio)propanoate (1.478 g) as an orange oil. MS (ES) + ):339(M+H) +
[0284] (Process 2) Sodium ethoxide (3.092 g, 3.56 mL, 21 wt%, 2.2 equiv, 9.542 mmol) was added to a stirred solution of 2-ethylhexyl 3-(benzo[d][1,3]dioxol-5-ylthio)propanoate (1.468 g, 1 equiv, 4.337 mmol) in THF (15 mL) at 0° C. and the resulting solution was stirred for 1 h while warming to room temperature. The reaction mixture was filtered through a pad of silica and then evaporated to dryness. The crude product was purified by chromatography on silica gel to give the title compound (0.379 g) as an orange oil. [ka] (No -SH signal could be observed). The product was analyzed by LCMS (Agilent, Cortecs C18+, 90 Å, 2.7 μm, 2.1 mm×30 mm, acidic (0.1% formic acid), 3 min, 5-100% MeCN / water): 3056-364 F9-16 (mislabelled), m / z 481 (M+H) + (ES + );1.84 min, 98% purity at 254 nm.
[0285] (Intermediate 45 - 2-Chloro-3-(chloromethyl)pyridine) [ka] To a solution of (2-chloropyridin-3-yl)methanol (1 g, 7 mmol) in DCM (10 mL), SOCl 2 (4.17 g, 35 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to remove DCM and residual SOCl. 2 The mixture was quenched with ice water (10 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 by adding aqueous solution of 1,000 ml of DCM and extracted with DCM (10 mL x 2). The organic layer was washed with brine and added with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give the title compound (1 g) as a yellow oil. MS (ES + ):162.2(M+H) +
[0286] (Intermediate 46 - 2-((2-chloropyridin-3-yl)methyl)-6-mercaptophthalazin-1(2H)-one) [ka] (Process 1) 6-Bromophthalazin-1(2H)-one (1.34 g, 6 mmol) and K in DMF (10 mL) 2 CO 3 To a solution of (1.66 g, 12 mmol) was added 2-chloro-3-(chloromethyl)pyridine (Intermediate 45, 1 g, 6 mmol) at room temperature and the reaction mixture was stirred at 90° C. overnight. LCMS analysis showed the reaction was complete, and the reaction mixture was diluted with water (20 mL) and filtered. The filtered solid was dissolved in DCM (20 mL), washed with water and brine, and added with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 30° C. The remaining solid was triturated with a mixture of n-hexane and MTBE (10 / 1); filtered, and dried under vacuum at 30° C. to give 6-bromo-2-((2-chloropyridin-3-yl)methyl)phthalazin-1(2H)-one (1.2 g) as a yellow solid. MS (ES) +):350.0(M+H) +
[0287] (Process 2) 6-Bromo-2-((2-chloropyridin-3-yl)methyl)phthalazin-1(2H)-one (1.2 g, 3.4 mmol) in DMF (20 mL), Pd 2 (dba) 3 (311 mg, 0.34 mmol), Xantphos (393 mg, 0.68 mmol), and DIPEA (1.3 g, 10.2 mmol) were dissolved in 2-ethylhexyl 3-mercaptopropanoate (1.1 g, 5 mmol) and N 2 The mixture was added at room temperature under reduced pressure and the reaction mixture was stirred at 100° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was diluted with water (30 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography to give 2-ethylhexyl 3-(2-((2-chloropyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylthio)propanoate (1.5 g) as a yellow solid. MS (ES + ):488.0(M+H) +
[0288] (Step 3) To a solution of 2-ethylhexyl 3-(2-((2-chloropyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylthio)propanoate (1.5 g, 3 mmol) in THF (20 mL) was added NaOEt (1.6 mL, 2.5 N in EtOH, 4 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 15 min. After LCMS showed the reaction was complete, the reaction mixture was quenched by dropwise addition of 0.5 N aqueous HCl, adjusted to pH=5, and extracted with EtOAc (20 mL×2). The combined organic layer was washed with brine and diluted with Na 2 SO 4The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 40° C. to give the title compound (900 mg) as a brown solid. MS (ES + ):304.0(M+H) +
[0289] (Intermediate 47 - 3-(chloromethyl)-1-methyl-1H-pyrazole) [ka] To a solution of (1-methyl-1H-pyrazol-3-yl)methanol (3 g, 27 mmol) in DCM (30 mL), SOCl 2 (16 g, 135 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 The majority of the residue was removed. The residue was quenched with ice water (30 mL) and diluted with 2N K 2 CO 3 The pH was adjusted to 9 by addition of aqueous solution of 1,2-dichloromethane and extracted with DCM (30 mL x 2). The organic layer was washed with brine and 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. to give (3 g) as a yellow oil. MS (ES + ):131.2(M+H) +
[0290] (Intermediate 48 - 6-Mercapto-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one) [ka] (Process 1) 6-Bromophthalazin-1(2H)-one (3.5 g, 15.6 mmol) and K in DMF (30 mL) 2 CO 3To a solution of (4.14 g, 30 mmol), 3-(chloromethyl)-1-methyl-1H-pyrazole (Intermediate 47, 2.1 g, 16 mmol) was added at room temperature, and the reaction mixture was stirred at 90° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was diluted with water (30 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 45° C., filtered, and concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography to give 6-bromo-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (3.1 g) as a yellow solid. MS (ES + ):319.0(M+H) +
[0291] (Process 2) 6-Bromo-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (3.1 g, 9.7 mmol) in DMF (20 mL), Pd 2 (dba) 3 (888 mg, 0.97 mmol), Xantphos (1.12 g, 1.94 mmol), and DIPEA (3.7 g, 29 mmol) were dissolved in 2-ethylhexyl 3-mercaptopropanoate (2.3 g, 9.7 mmol) and N 2 The mixture was added at room temperature under reduced pressure and the reaction mixture was stirred at 100° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was diluted with water (30 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, and concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography to give 2-ethylheptyl 2-(2-((1-methyl-1H-pyrazol-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylthio)acetate (4 g) as a yellow solid. MS (ES + ):457.0(M+H)+
[0292] (Step 3) To a solution of 2-ethylheptyl 2-(2-((1-methyl-1H-pyrazol-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylthio)acetate (4 g, 8.7 mmol) in THF (40 mL) was added NaOEt (3.52 mL, 2.5 N in EtOH, 8.8 mmol) at room temperature, and the reaction mixture was stirred at room temperature for 15 min. After LCMS showed the reaction was complete, the reaction mixture was quenched by dropwise addition of 0.5 N aqueous HCl, adjusted to pH=5, and extracted with EtOAc (20 mL×2). The combined organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 40° C. to give the title compound (2.1 g) as a brown solid. MS (ES + ):273.0(M+H) +
[0293] (Intermediate 49 - 6-Mercapto-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one) [ka] (Process 1) A suspension of 6-bromophthalazin-1(2H)-one (2.117 g, 98 wt%, 1 eq, 9.217 mmol) and cesium carbonate (6.006 g, 2.0 eq, 18.43 mmol) in DMF (40 mL) was stirred at 80° C. for 1 h and then allowed to cool to room temperature. A solution of 3-(chloromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (2.055 g, 9.217 mmol) in DMF (10 mL) was added and the reaction mixture was stirred at room temperature for 20 h. EtOAc (150 mL) was added and the reaction mixture was washed with water (100 mL). The organic layer was collected and the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic extracts were washed with 50% brine (2×100 mL), brine (100 mL) and concentrated in vacuo to give the crude product. The crude product was purified by chromatography on silica gel to give impure product. The crude product was purified by chromatography on silica gel to give 6-bromo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (Intermediate 49A, 2.192 g) as an off-white solid. MS (ES + ):389 / 391(M+H) +
[0294] (Process 2) A solution of 6-bromo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (1.47 g, 3.40 mmol) in DMF (30 mL) was diluted with N 2 The mixture was aerated with DIPEA (879 mg, 1.18 mL, 2.00 equiv., 6.80 mmol), Xantphos (197 mg, 340 μmol), Pd 2 (dba) 3(156 mg, 170 μmol), and 2-ethylhexyl 3-mercaptopropanoate (852 mg, 3.90 mmol) were added sequentially. The reaction mixture was stirred at 100° C. for 90 min. 2-Ethylhexyl 3-mercaptopropanoate (0.20 mL, 0.876 mmol) was added and stirred at 100° C. for 90 min. The reaction mixture was concentrated in vacuo and the residue was azeotroped with toluene (3 times) to give the crude product. The crude product was purified by chromatography on silica gel to give 2-ethylhexyl 3-((1-oxo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)-1,2-dihydrophthalazin-6-yl)thio)propanoate (1.648 g) as a thick yellow oil. MS (ES) + ):527(M+H) +
[0295] (Step 3) A stirred solution of 2-ethylhexyl 3-((1-oxo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)-1,2-dihydrophthalazin-6-yl)thio)propanoate (1.64 g, 2.77 mmol) in THF (25 mL) was treated dropwise with sodium ethoxide (2.13 g, 6.56 mmol). The reaction mixture was stirred at room temperature for 1 h and then diluted with DCM (100 mL) and saturated NH 4 Diluted with aqueous Cl (100 mL). Collected organic layer and extracted aqueous with DCM (2 x 50 mL). Combined organic extracts were washed with 50% brine (50 mL), dried (phase separator) and concentrated in vacuo to give crude product. Purified by chromatography on silica gel to give the title compound (715 mg) as a pale pink solid. [ka]
[0296] (Intermediate 50 - 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-mercaptophthalazin-1(2H)-one) [ka] (Process 1) A stirred suspension of 6-bromophthalazin-1(2H)-one (407 mg, 1 equiv, 1.81 mmol) and cesium carbonate (2.36 g, 4.0 equiv, 7.24 mmol) in DMF (10 mL) was heated to 85° C. for 2 h and then allowed to cool to room temperature. A solution of 3-(chloromethyl)-1-cyclopropyl-1H-pyrazole hydrochloride (Intermediate 6, 349 mg, 100 wt %, 1 equiv, 1.81 mmol) in DMF (2 mL) was added and the reaction mixture was stirred at room temperature for 18 h. Water (50 mL) was added and the resulting solid was collected by filtration and washed with water to give 6-bromo-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (500 mg) as a yellow solid. MS (ES) + ):345(M+H) +
[0297] (Process 2) A suspension of 6-bromo-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (500 mg, 79 wt%, 1 equiv, 1.14 mmol) in DMF (8 mL) was added to N 2 The mixture was aerated with DIPEA (223 mg, 300 μL, 1.51 equivalents, 1.72 mmol), Xantphos (84 mg, 0.13 equivalents, 0.15 mmol), Pd 2 (dba) 3 (66 mg, 0.063 equiv, 72 μmol), and 2-ethylhexyl 3-mercaptopropanoate (384 mg, 400 μL, 1.54 equiv, 1.76 mmol) were added sequentially. The reaction mixture was cooled to 5° C. for 1 hour and then cooled to 5° C. 2 The mixture was stirred at 120° C. for 1 h. The reaction mixture was allowed to cool to room temperature and then diluted with EtOAc (50 mL) and saturated NaHCO 3 Partitioned between water (50 mL). The organic layer was collected and the aqueous layer was extracted with EtOAc (50 mL). The combined organic extracts were washed with 50% brine (50 mL), brine (50 mL) and dried (MgSO 4) and concentrated in vacuo to give the crude product, which was purified by chromatography on silica gel to give 2-ethylhexyl 3-((2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-yl)thio)propanoate (630 mg) as a yellow oil. MS (ES + ):483(M+H) +
[0298] (Step 3) A solution of 2-ethylhexyl 3-((2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-yl)thio)propanoate (630 mg, 88 wt%, 1 equiv, 1.15 mmol) in THF (10 mL) was treated with sodium ethoxide (1.04 g, 1.20 mL, 21 wt%, 2.80 equiv, 3.21 mmol). The reaction mixture was stirred at room temperature for 15 min and then water (10 mL) was added. The mixture was acidified with 1 M HCl (aq.) and then extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (40 mL), dried (MgSO 4 ) and concentrated in vacuo to give the crude product as an orange solid. The crude product was purified by chromatography on silica gel to give the title compound (379 mg) as a pale yellow solid. MS (ES + ):299(M+H) +
[0299] (Intermediate 51 - 6-Bromo-2-((4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one) [ka] A stirred suspension of 6-bromophthalazin-1(2H)-one (120 mg, 1.55 equiv, 533 μmol) and cesium carbonate (224 mg, 2.0 equiv, 687 μmol) in DMF (2 mL) was heated to 85° C. for 90 min and then allowed to cool to room temperature. A solution of 3-(chloromethyl)-4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (Intermediate 10, 121 mg, 74 wt%, 1 equiv, 343 μmol) in DMF (2 mL) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was diluted with DCM (5 mL) and saturated NaHCO 3 Washed with water (5 mL). The organic layer was collected and the aqueous layer was extracted with DCM (2 x 5 mL). The combined organic extracts were dried (phase separator) and concentrated in vacuo to give the crude product. The crude product was purified by chromatography on silica gel to give the title compound (120 mg) as a clear yellow oil that solidified on standing. MS(ES + ):449 / 451(M+H) +
[0300] (Intermediate 52 - 6-Bromo-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one) [ka] A stirred suspension of 6-bromophthalazin-1(2H)-one (865 mg, 1.74 equiv, 3.84 mmol) and cesium carbonate (2.50 g, 3.48 equiv, 7.67 mmol) in DMF (25 mL) was heated to 85° C. for 90 min and then allowed to cool to room temperature. 3-(Chloromethyl)-5-methyl-1H-pyrazole, HCl (368 mg, 1 equiv, 2.20 mmol) was added in portions and the reaction mixture was stirred at room temperature for 18 h. Further cesium carbonate (2.50 g, 3.48 equiv, 7.67 mmol) was added and the mixture was heated to 50° C. for 4 h and then allowed to cool to room temperature. The reaction mixture was diluted with EtOAc (100 mL) and saturated NaHCO 3The organic layer was collected and the aqueous layer was extracted with EtOAc (2×50 mL). The combined organic extracts were washed with brine (100 mL) and dried (MgSO 4 ) and concentrated in vacuo to give the crude product. The crude product was purified by chromatography on silica gel to give a mixture of the title compound (370 mg, 0.58 mmol) and starting material (370 mg) as a pale yellow solid. MS (ES + ):319 / 321(M+H) +
[0301] (Intermediate 53 - 6-Mercaptophthalazin-1(2H)-one) [ka] 6-Bromophthalazin-1(2H)-one (0.60 g, 1 equiv, 2.7 mmol), 2-ethylhexyl 3-mercaptopropanoate (0.61 g, 0.64 mL, 1.05 equiv, 2.8 mmol), cesium carbonate (1.7 g, 2 equiv, 5.3 mmol), Xantphos (0.15 g, 0.1 equiv, 0.27 mmol), and Pd 2 (dba) 3 A mixture of (0.12 g, 0.05 equiv, 0.13 mmol) was heated to 100 °C for 12 h. After cooling to room temperature, the reaction mixture was diluted with water (50 mL) and then extracted with DCM (20 mL). The aqueous layer was acidified with 1 M HCl and then extracted with EtOAc (2 x 50 mL). The organic phase was collected, dried (MgSO 4 ) and evaporated under reduced pressure to give the title compound (0.33 g) as a sticky orange solid. MS (ES + ):179(M+H) +
[0302] Intermediate 54 - 3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole [ka] To a solution of 3-iodo-1H-pyrazole (4 g, 21 mmol) and 3,4-dihydro-2H-pyran (1.99 g, 23.1 mmol) in toluene (100 mL) was added TsOH (361.2 mg, 2.1 mmol) at room temperature, and the reaction mixture was stirred at 120° C. overnight. After LCMS showed that the reaction was complete, the reaction mixture was filtered through Celite and washed with EtOAc. The filtrate was diluted with water (50 mL) and extracted with EtOAc (40 mL×3). The combined organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 50° C. The residue was purified by flash column chromatography to give the title compound (4.4 g) as a yellow solid. MS (ES + ):278.9(M+H) +
[0303] (Intermediate 55 - 6-Mercapto-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one) [ka] (Process 1) A mixture of 6-bromophthalazin-1(2H)-one (2.00 g, 1 eq, 8.89 mmol) and cesium carbonate (5.79 g, 2 eq, 17.8 mmol) in DMF (45 mL) was stirred at 70° C. for 45 min. 2-(bromomethyl)-6-methylpyridine (1.74 g, 1.05 eq, 9.33 mmol) was added and the mixture was stirred at room temperature overnight and then poured into ice / water. The resulting precipitate was filtered, washed with water and then dried in a vacuum oven at 40° C. overnight to give 6-bromo-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one (2.43 g, 7.3 mmol). MS (ES) + )330 / 332(M+H) +
[0304] (Process 2) A solution of 6-bromo-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one (1.424 g, 99 wt%, 1 equiv, 4.270 mmol) in DMF (38.0 mL) was diluted with N 2 The mixture was aerated with 0.05% CO for 5 min. DIPEA (1.104 g, 1.49 mL, 2.00 equiv., 8.539 mmol), Xantphos (247.0 mg, 0.10 equiv., 427.0 μmol), Pd 2 (dba) 3 (195.5 mg, 0.05 equiv, 213.5 μmol), and 2-ethylhexyl 3-mercaptopropanoate (1.119 g, 1.17 mL, 1.20 equiv, 5.123 mmol) were added sequentially. The reaction mixture was stirred at 100 °C for 2 h. The reaction was cooled to room temperature, concentrated in vacuo, and azeotroped with PhMe. The residue was partitioned between EtOAc (50 mL) and water (50 mL). The aqueous layer was extracted with EtOAc (70 mL x 3) and the combined organic layers were washed with a 1:1 mixture of brine and water (100 mL x 3), dried (MgSO 4 ), filtered and concentrated under reduced pressure to give a crude dark orange oil (2.92 g). The crude was dissolved in DCM (50 mL), concentrated onto silica and purified by chromatography to give 2-ethylhexyl 3-((2-((6-methylpyridin-2-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-yl)thio)propanoate (2.02 g, 4.2 mmol) as a thick orange oil. [ka]
[0305] (Step 3) A solution of 2-ethylhexyl 3-((2-((6-methylpyridin-2-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-yl)thio)propanoate (2.02 g, 1 equiv, 4.32 mmol) in THF (50.0 mL) at 0° C. was treated with sodium ethoxide (3.50 g, 4.03 mL, 21 wt%, 2.5 equiv, 10.8 mmol). The reaction mixture was stirred at 0° C. for 1.5 h before water (50 mL) was added. The mixture was acidified with 1 M HCl (aq.) (ca. 6-8 mL; to reach pH 4), then allowed to warm to room temperature and extracted with EtOAc (3×40 mL). The combined organic layers were washed with brine (60 mL×2) followed by water (60 mL). The resulting suspension was concentrated under reduced pressure to give a light brown solid (3.79 g). The crude was dissolved in DCM (20 mL), concentrated onto silica and purified by chromatography to give the title compound (894.2 mg, 3.1 mmol) as a pale orange solid. [ka]
[0306] Intermediates 56 and 57 - 5-Fluoro-6-(phenylthio)phthalazin-1(2H)-one and 7-Fluoro-6-(phenylthio)phthalazin-1(2H)-one. [ka] (Process 1) A stirred suspension of methyl 2-bromo-4,5-difluorobenzoate (2.019 g, 99 wt%, 1 equiv, 7.962 mmol) and cesium carbonate (3.144 g, 1.212 equiv, 9.649 mmol) in DMF (20 mL) was treated dropwise with benzenethiol (885.2 mg, 825.0 μL, 1.009 equiv, 8.035 mmol). The reaction mixture was stirred at room temperature for 3 h, then diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was collected and the aqueous layer was extracted with EtOAc (3×25 mL). The combined organic extracts were washed with 50% brine (50 mL), brine (50 mL), dried (MgSO 4) and concentrated in vacuo to give the crude product as a pale yellow oil. The crude product was purified by chromatography to give methyl 2-bromo-5-fluoro-4-(phenylthio)benzoate (2.64 g) as a colorless oil. MS (ES + ):341 / 343(M+H) +
[0307] (Process 2) A solution of methyl 2-bromo-5-fluoro-4-(phenylthio)benzoate (2.209 g, 99 wt%, 1 eq, 6.410 mmol) and NaOH (0.54 g, 6.730 mL, 2.00 molar, 2.1 eq, 13.46 mmol) in THF (20 mL) was stirred at room temperature for 18 h. The mixture was acidified with 1 M HCl (aq.) (ca. 20 mL) and then extracted with DCM (2×50 mL). The combined organic extracts were dried (phase separator) and concentrated in vacuo to give 2-bromo-5-fluoro-4-(phenylthio)benzoic acid (2.136 g) as a white solid. MS (ES) + ):327 / 329(M+H) +
[0308] (Step 3) n-Butyllithium (1.9 M in hexanes) (864 mg, 7.10 mL, 1.90 molar, 2.13 equiv, 13.5 mmol) was dissolved in THF (7 mL) and 2 The mixture was added at −78° C. under reduced pressure. A solution of 2-bromo-5-fluoro-4-(phenylthio)benzoic acid (2.136 g, 97 wt%, 1 eq, 6.333 mmol) in THF (10 mL) was added at −78° C. and the reaction mixture was stirred at −78° C. for 30 min. DMF (2.5 mL) was added and the reaction mixture was stirred at −78° C. for 30 min, then allowed to warm to room temperature and stirred for 1 h. The reaction mixture was carefully quenched with 1M HCl (aq.) (50 mL) and then extracted with EtOAc (2×100 mL). The combined organic extracts were washed with brine (50 mL), dried (MgSO 4) and concentrated in vacuo to give the crude product, which was purified by chromatography to give an inseparable mixture of 5-fluoro-2-formyl-4-(phenylthio)benzoic acid (1.732 g) and 3-fluoro-2-formyl-4-(phenylthio)benzoic acid (1.732 g) as a yellow oil. MS (ES + ):277(M+H) +
[0309] (Step 4) A solution of 5-fluoro-2-formyl-4-(phenylthio)benzoic acid (1.430 g, 65 wt%, 1 eq, 3.364 mmol) in EtOH (15 mL) was treated with hydrazine hydrate (327 mg, 320 μL, 35 wt%, 1.06 eq, 3.57 mmol) and the resulting suspension was stirred at 80° C. for 4 h, then allowed to cool to room temperature and stirred for 18 h. Additional hydrazine hydrate (327 mg, 320 μL, 35 wt%, 1.06 eq, 3.57 mmol) was added and the reaction mixture was heated to 85° C. for 21 h. The crude product (1.2 g) was purified by chromatography to give an inseparable 2:1 mixture of 7-fluoro-6-(phenylthio)phthalazin-1(2H)-one and 5-fluoro-6-(phenylthio)phthalazin-1(2H)-one (1.033 g, 1.176 mmol) as a yellow solid. A 50 mg portion of the crude mixture was purified by chromatography on RP Flash C18 (4 g cartridge, 10-50% MeCN / 0.1% formic acid in water) to give a 4:1 mixture (12 mg) of 5-fluoro-6-(phenylthio)phthalazin-1(2H)-one (Intermediate 56) and 7-fluoro-6-(phenylthio)phthalazin-1(2H)-one (Intermediate 57). MS (ES) + ):273(M+H) +
[0310] (Intermediate 58 - 6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one) [ka] 6-Mercaptophthalazin-1(2H)-one (1.26 g, 80 wt%, 1 equiv, 5.66 mmol), 4-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (1.82 g, 95 wt%, 1.1 equiv, 6.22 mmol), K 2 CO 3 A suspension of 1.56 g (2.0 equiv., 11.3 mmol) and 1,10-phenanthroline (408 mg, 0.4 equiv., 2.26 mmol) was added to N 2 The reaction mixture was purged with 500 mL of ethyl acetate for 10-15 min, followed by the addition of copper(I) iodide (215 mg, 0.2 equiv., 1.13 mmol). 2 The mixture was purged with 500 mL of ethyl acetate for 10 min and then heated at 100 °C overnight. The reaction was cooled to room temperature and poured into a mixture of ice and water, forming a precipitate which was filtered and washed with water (50 mL). The resulting dark brown gummy solid was dissolved in DCM (250 mL) and washed with half-strength brine (200 mL). The organic layer was dried (MgSO 4 ), filtered and concentrated under reduced pressure to give a solid (1.87 g). The crude was combined with a crude mixture from a separate experiment (1.63 g), dissolved in DCM (20 mL) and MeOH (2 mL), concentrated onto silica and purified by chromatography to give the title compound (982.9 mg, 2.9 mmol) as a light tan solid. MS (ES + ):195.1(M+H) +
[0311] (Intermediate 59 - 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-thiol) [ka]
[0312] (Process 1) To a solution of 4-iodo-1H-pyrazole (80 g, 412 mmol) and 3,4-dihydro-2H-pyran (54 g, 618 mmol) in MeCN (1.2 L) was added TsOH (708 mg, 4.2 mmol) at room temperature. The reaction mixture was stirred at 85° C. for 16 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography to give 4-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (100 g) as a white solid. MS (ES) + ):279.2(M+H) +
[0313] (Process 2) 4-Iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (100 g, 360 mmol), 2-ethylhexyl 3-mercaptopropanoate (94 g, 432 mmol), Pd 2 dba 3 To a solution of (13 g, 14.4 mmol) and Xantphos (16.6 g, 28.8 mmol) was added DIPEA (140 g, 1080 mmol) at room temperature. The reaction mixture was stirred at 100 °C for 16 h. After LCMS showed the reaction was complete, the mixture was extracted with EtOAc (600 mL x 3) and concentrated under reduced pressure at 45 °C. The residue was purified by flash column chromatography to give 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)propanoate (116 g) as a yellow oil. MS (ES) + ):369.3(M+H) +
[0314] (Step 3) To a mixture of 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)propanoate (116 g, 315 mmol) in THF (2 L) was added NaOEt (252 mL, 630 mmol, 2.5 M solution in EtOH) at 0° C. The reaction was stirred at 0° C. for 0.5 h. After LCMS showed the reaction was complete, the reaction mixture was quenched with HCl (1 M) to pH 6. The mixture was extracted with EtOAc (600 mL×3). The organic layer was concentrated under reduced pressure at 40° C. and purified by flash column chromatography to give 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-thiol (45 g) as an oil, which was used in the next step without further purification. MS (ES + ):101.4(M+H) +
[0315] (Intermediate 60 - 5-(chloromethyl)-2,3-dihydrofuro[3,2-b]pyridine) [ka] (Process 1) To a solution of methyl furo[3,2-b]pyridine-5-carboxylate (800 mg, 4.52 mmol) was added 10% Pd / C (320 mg, containing 50% water) in MeOH (10 mL) and the mixture was diluted with H 2 The mixture was stirred at 25° C. for 10 hours. After LCMS showed the reaction was complete, the mixture was diluted with Na 2 SO 4 After drying at 40° C., filtration, and concentration under reduced pressure at 30° C., the residue was purified by flash column chromatography to give methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (750 mg) as a yellow solid. MS (ES + ):180.3(M+H) +
[0316] (Process 2) To a solution of methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (750 mg, 4.19 mmol) in THF (10 mL) was added Red-Al (2.42 g, 8.38 mmol, 70 wt % in toluene) at 0° C. and the reaction mixture was stirred at room temperature for 2 h. After LCMS showed the reaction was complete, the mixture was treated with NH 4 Cl (1 mL) was added. The mixture was diluted with Na 2 SO 4 The mixture was quenched with hexanes, filtered, concentrated under reduced pressure at 30° C., and the residue was purified by flash column chromatography to give (2,3-dihydrofuro[3,2-b]pyridin-5-yl)methanol (360 mg) as a yellow solid. MS (ES + ):152.4(M+H) +
[0317] (Step 3) To a solution of (2,3-dihydrofuro[3,2-b]pyridin-5-yl)methanol (140 mg, 0.93 mmol) in DCM (5 mL) was added SOCl 2 (221 mg, 1.86 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 2 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to obtain DCM and SOCl 2 Removal of 1,2-dihydrofuro[3,2-b]pyridine gave 5-(chloromethyl)-2,3-dihydrofuro[3,2-b]pyridine (150 mg) as a yellow oil which was used directly in the next step. MS (ES + ):170.4(M+H) +
[0318] (Intermediate 61 - 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-iodo-1H-pyrazole) [ka] A mixture of 3-iodopyrazole (300 mg, 1 equiv, 1.55 mmol), (2-bromoethoxy)dimethyl-tert-butylsilane (407 mg, 366 μL, 1.1 equiv, 1.70 mmol) and potassium carbonate (321 mg, 1.5 equiv, 2.32 mmol) in MeCN (10.0 mL) was heated at 85° C. for 24 h. The reaction mixture was cooled to room temperature, diluted with DCM (10 mL), then filtered through Celite, further washed with DCM (20 mL) and MeOH (10 mL). The residue (oil and solid) was partitioned between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (10 mL×2) and diluted with MgSO 4 After drying at 40° C. and concentrating under reduced pressure, the crude product was dissolved in DCM (5 mL), concentrated onto silica and purified by chromatography to give the title compound (108.5 mg) as a clear, colorless oil. [ka]
[0319] (Intermediate 62 - 5-(chloromethyl)furo[3,2-b]pyridine) [ka] (Process 1) To a solution of methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (220 mg, 1.24 mmol) in THF (10 mL) was added Red-Al (536 mg, 1.86 mmol, 70 wt % in toluene) at 0° C., and the reaction mixture was stirred at room temperature for 2 h. After LCMS showed the reaction was complete, the mixture was diluted with H 2 O (1 mL) was added. The mixture was diluted with Na 2 SO 4The residue was purified by flash column chromatography (12 g, petroleum ether / ethyl acetate=100:00 / 50:50) to give furo[3,2-b]pyridin-5-ylmethanol (150 mg, 94.98% purity) as a yellow solid. MS(ES+): 150.3(M+H)+
[0320] (Process 2) To a solution of furo[3,2-b]pyridin-5-ylmethanol (140 mg, 1.00 mmol) in DCM (5 mL) was added SOCl 2 (238 mg, 2.00 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at room temperature for 2 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 30° C. to remove DCM and excess SOCl. 2 Most of the was removed to give 5-(chloromethyl)furo[3,2-b]pyridine (150 mg, 94.83% purity) as a yellow oil which was used directly in the next step. MS (ES+): 168.3 (M+H)+
[0321] Intermediate 63 - 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-thiol [ka] (Process 1) To a solution of 3-iodo-1H-pyrazole (5.0 g, 25.8 mmol) and 3,4-dihydro-2H-pyran (3.3 g, 38.7 mmol) in MeCN (50 mL) was added p-TsOH (43 mg, 0.3 mmol) at room temperature, and the reaction mixture was stirred at 80 °C for 16 h. After LCMS showed the reaction was complete, the reaction mixture was concentrated under reduced pressure at 45 °C. The residue was purified by flash column chromatography (25 g, petroleum ether / tert-butyl methyl ether = 100:0 to 90:10) to give 3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (6.6 g, 100% purity) as a yellow oil. MS (ES + ):279.1(M+H) +
[0322] (Process 2) To a solution of 3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (6.6 g, 23.7 mmol), 2-ethylhexyl 3-mercaptopropanoate (6.7 g, 30.8 mmol), Pd2dba3 (540 mg, 0.59 mmol) and Xantphos (685 mg, 1.19 mmol) in DMF (100 mL) was added DIPEA (9.2 g, 71.1 mmol) at room temperature. The reaction mixture was stirred at 100° C. for 16 h. After LCMS showed the reaction was complete, water (50 mL) was added and the mixture was extracted with EtOAc (50 mL×3). The combined organic layers were concentrated under reduced pressure at 45° C. The residue was purified by flash column chromatography (120 g, petroleum ether / tert-butyl methyl ether=100:00 to 80:20) to give 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)thio)propanoate (7.1 g, 44.18% purity) as a yellow oil. MS (ES) + ):369.3(M+H) +
[0323] (Step 3) To a mixture of 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)thio)propanoate (7.1 g, 19.3 mmol) in THF (150 mL) was added EtONa (15 mL, solution 2.5 M in EtOH) at 0° C. The reaction was stirred at 0° C. for 0.5 h. After LCMS showed the reaction was complete, the pH of the reaction mixture was adjusted by careful addition of aqueous HCl (1 M) until pH=6. The mixture was extracted with EtOAc (800 mL×3). The organic layer was concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography (40 g, petroleum ether / tert-butyl methyl ether = 100:0 to 60:40) to give 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-thiol (2.8 g, 100% purity, 80% yield) as a yellow oil. MS (ES)+ ):185.3(M+H) +
[0324] (Intermediate 64 - 5-(chloromethyl)-2,3-dihydrofuro[3,2-b]pyridine) [ka] (Process 1) H 2 To a mixture of methyl 5-hydroxypicolinate (225 g, 1470 mmol) and sodium carbonate (343 g, 3234 mmol) in 2H2O (3000 mL) was added iodine (373 g, 1470 mmol) at 0 °C. The reaction was stirred at room temperature for 20 h. After LCMS showed the reaction was complete, the reaction mixture was quenched with saturated aqueous sodium thiosulfate (200 mL) and then acidified with 1 M HCl (aq). The mixture was extracted with EtOAc (1000 mL x 3). The organic layer was concentrated under reduced pressure at 40 °C to give methyl 5-hydroxy-6-iodopicolinate (290 g, 67.62% purity) as a yellow oil, which was used directly in the next step without further purification. MS(ES + ):280.2(M+H) +
[0325] (Process 2) Methyl 5-hydroxy-6-iodopicolinate (290 g, 1039 mmol), Pd(PPh 3 ) 2 Cl 2 (95 g, 135 mmol) and CuI (31 g, 166 mmol) were added to a solution of Et 3N (315 mg, 3117 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 5 min. Ethynyltrimethylsilane (265 g, 2701 mmol) was added and the reaction mixture was stirred at 65 °C under nitrogen for 3 h, then allowed to cool to room temperature. After LCMS showed the reaction was complete, water (1000 mL) was added to the mixture and extracted with EtOAc (1000 mL x 3). The organic layer was concentrated under reduced pressure at 40 °C. The residue was purified by flash column chromatography (120 g x 8, petroleum ether / tert-butyl methyl ether = 100:00 to 20:80) to give methyl 2-(trimethylsilyl)furo[3,2-b]pyridine-5-carboxylate (100 g, 84.18% purity) as a yellow solid. MS (ES + ):250.3(M+H) +
[0326] (Step 3) To a solution of methyl 2-(trimethylsilyl)furo[3,2-b]pyridine-5-carboxylate (100 g, 400 mmol) in MeOH (1000 mL) was added KF (70 g, 1200 mmol) at room temperature and the reaction mixture was stirred at 80° C. for 5 h. After LCMS showed the reaction was complete, the mixture was concentrated under reduced pressure at 40° C. to remove MeOH. The residue was quenched with water (1000 mL) and extracted with DCM (3×1000 mL). The organic layer was washed with brine and diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered and concentrated under reduced pressure at 30° C. The residue was purified by flash column chromatography (120 g×8, petroleum ether / tert-butyl methyl ether=100:00 to 60:40) to give methyl furo[3,2-b]pyridine-5-carboxylate (55 g, 91.20% purity) as a yellow oil. MS (ES) + ):178.4(M+H) +
[0327] (Step 4) To a solution of methyl furo[3,2-b]pyridine-5-carboxylate (55 g, 310 mmol) was added 20% Pd / C (11 g, 50% purity) in MeOH (600 mL) and the mixture was stirred at 25° C. under H atmosphere for 10 h. After LCMS showed the reaction was complete, the mixture was dried over Na2SO4, filtered, concentrated under reduced pressure at 30° C. and the residue was purified by flash column chromatography (12 g, petroleum ether / ethyl acetate=100:00 / 50:50) to give methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (49 g, 92.82% purity) as a yellow solid. MS (ES + ):180.4(M+H) +
[0328] (Step 5) To a solution of methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (49 g, 273 mmol) in THF (300 mL) was added Red-Al (150 g, 546 mmol, 70 wt % in toluene) at 0° C. and the reaction mixture was stirred at room temperature for 2 h. After LCMS showed the reaction was complete, the mixture was treated with NH 4 Cl (1000 mL) was added. The mixture was diluted with Na 2 SO 4 The mixture was dried at 40° C., filtered, concentrated under reduced pressure at 30° C., and the residue was purified by flash column chromatography (120 g, petroleum ether / ethyl acetate=100:00 / 50:50) to give the desired compound (22 g, 83% purity) as a yellow solid. MS (ES + ):152.4(M+H) +
[0329] (Intermediate 65 - 3-(chloromethyl)-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole) [ka] (Process 1) To a solution of ethyl 5-methyl-1H-pyrazole-3-carboxylate (530 mg, 3.44 mmol) in DMF (6 mL) was added NaH (130 mg, 3.78 mmol, 70 wt%) at 0° C. and stirred at room temperature for 30 min. To this reaction mixture was added SEMCl (803 mg, 4.82 mmol) and stirred at room temperature overnight. After LCMS showed the reaction was complete, the reaction mixture was washed with saturated NH 4 It was quenched with aqueous Cl (20 mL) and extracted with EtOAc (50 mL×3). The combined organic layers were washed with saturated NH 4 The mixture was washed with Cl water (30 mL × 2), concentrated under reduced pressure at 40 °C, and purified by flash column chromatography (12 g, petroleum ether / tert-butyl methyl ether = 100:00 to 80:20) to give ethyl 5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (520 mg, 95% purity) as a pale yellow oil. MS (ES) + ):285.4(M+H) + . [ka]
[0330] (Process 2) A solution of ethyl 5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-3-carboxylate (440 mg, 1.55 mmol) in THF (6 mL) was cooled to 0° C. and DIBAL-H (6 mL, 6.0 mmol, 1 M in THF) was added. The reaction mixture, protected with nitrogen, was stirred at room temperature for 1 h. After LCMS showed the reaction was complete, the reaction mixture was diluted with Na 2 SO 4 10H 2 The mixture was quenched with 2,4-dichlorophenyl ether (390 mg, 1.21 mmol), stirred for 30 min, and then cooled to 30° C. for an additional 30 min. 2 SO 4was added. The suspension was filtered and the filter cake was washed with MeOH / DCM (1:5). The combined organic layers were concentrated under reduced pressure at 40° C. and purified by flash column chromatography (12 g, petroleum ether / tert-butyl methyl ether=100:00 to 20:80) to give (5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (310 mg, 100% purity) as a white solid. MS (ES) + ):243.3(M+H) +
[0331] (Step 3) To a mixture of (5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol (310 mg, 1.3 mmol) in DCM (4 mL) was added SOCl 2 (238 mg, 2.0 mmol) was added. The reaction mixture was stirred at room temperature for 30 min. After LCMS showed the reaction was complete, the mixture was concentrated to remove SOCl 2 and DCM was removed to give the crude product which was used without further purification.
[0332] Example 1 - 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one [ka] A mixture of 6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (Intermediate 1, 50 mg, 1 eq, 0.16 mmol) and cesium carbonate (0.15 g, 3 eq, 0.47 mmol) in DMF (1 mL) was stirred at 70° C. for 45 min. 3-(Chloromethyl)-1-cyclopropyl-1H-pyrazole hydrochloride (Intermediate 6, 31 mg, 1 eq, 0.16 mmol) was added and the mixture was allowed to cool to room temperature and stirred overnight. Water and DCM were added and the layers were separated. The organic layer was washed with brine and then absorbed onto silica. The crude product was purified by chromatography on silica gel. The product was dissolved in DCM, washed with water, brine and dried (MgSO 4 ), concentrated in vacuo to give the title compound (27.3 mg) as a pale yellow solid. [ka]
[0333] Example 2 - 2-(indolin-4-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one [ka] To a stirred solution of 6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (Intermediate 1, 60 mg, 1 eq, 0.19 mmol) and cesium carbonate (68 mg, 1.1 eq, 0.21 mmol) in dry DMF (6 mL) was added tert-butyl 4-(chloromethyl)indoline-1-carboxylate (Intermediate 4, 90 mg, 85 wt%, 1.5 eq, 0.28 mmol). The reaction mixture was stirred at 20° C. for 18 h. The reaction was allowed to cool to room temperature and then diluted with DCM (10 mL) and washed with water (20 mL). The organic phase was collected, dried (phase separator) and evaporated under reduced pressure. The crude was dissolved in DCM (2 mL) and treated with TFA (0.22 g, 0.15 mL, 10 eq, 1.9 mmol). The resulting mixture was stirred for a few minutes before being diluted with NaHCO 3(2mL) of a saturated solution. The organic phases were collected, dried (phase separator) and evaporated under reduced pressure. The crude product was dissolved in DMSO (0.6mL), filtered and purified by reverse phase preparative HPLC (acidic method (A)). The appropriate fractions were evaporated in a Genevac to give the title compound (6mg) as a pale yellow solid. [ka]
[0334] Example 3 - 2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one [ka] (Process 1) A mixture of 6-((4-methoxyphenyl)sulfinyl)phthalazin-1(2H)-one--6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (Intermediate 1, 100 mg, 66 wt%, 1 eq, 215 μmol) and cesium carbonate (210 mg, 3 eq, 645 μmol) in DMF (1 mL) was stirred at 70° C. for 45 min. 2-Chloro-4-(chloromethyl)pyridine (90.6 mg, 2.6 eq, 559 μmol) was added and the mixture was allowed to cool to room temperature and stirred for 3 days. Water and DCM were added and the layers were separated. The organic layer was washed with brine and then absorbed onto silica. The crude product was purified by chromatography on silica gel to give 2-((2-chloropyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (51 mg) as a white solid. MS (ES + ):442 / 444(M+H) + .
[0335] (Process 2) N 2was bubbled through a mixture of 2-((2-chloropyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (25 mg, 1 equiv, 57 μmol) and 2N KOH (0.28 mL, 2 molar, 10 equiv, 0.57 mmol) in 1,4-dioxane (0.3 mL) for 5 min. 2 dba 3 (2.6 mg, 0.05 equiv, 2.8 μmol) and tBuXPhos (7.2 mg, 0.3 equiv, 17 μmol) were added and the mixture was treated with N 2 The mixture was stirred at under 100° C. for 2 hours, then allowed to cool to room temperature and stirred overnight. 1N HCl (0.3 mL), water, and DCM were added and the layers were separated. The organic layer was washed with brine and then absorbed onto silica. The crude product was purified by chromatography on silica gel to give the title compound (9.2 mg) as a light tan solid. [ka]
[0336] Example 4 - 6-((4-Methoxyphenyl)sulfonyl)-2-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)phthalazin-1(2H)-one [ka] Sodium hydride (2.8 mg, 60 wt%, 2 equiv, 71 μmol) was added to a stirred solution of 2-((2-hydroxypyridin-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (Example 56, 15 mg, 1 equiv, 35 μmol) in dry DMF (2 mL). The reaction mixture was stirred for 5 min and then methyl iodide (10 mg, 4.4 μL, 2 equiv, 71 μmol) was added. The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with EtOAc (10 mL) and washed with water (10 mL), and brine (10 mL). The organic phase was collected and washed with MgSO 4It was dried at 40° C. and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel to give the title compound (15 mg) as a light brown solid. [ka]
[0337] Example 5 - 2-((1-(2-hydroxyethyl)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one [ka] (Process 1) 1-(2-(tert-butyldimethylsilyloxy)ethyl)-3-(chloromethyl)pyridin-2(1H)-one (Intermediate 30, 80 mg, 0.27 mmol) in DMF (5 mL), Cs 2 CO 3 (264 mg, 0.81 mmol) was added with 6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one (Intermediate 1, 161 mg, 1.0 mmol) at 60° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was quenched with water (10 mL) and filtered. The cake was dissolved in EtOAc (5 mL), washed with brine and added with Na 2 SO 4 The filtrate was concentrated under reduced pressure at 30° C., and the residue was triturated with petroleum ether / ethyl acetate=1 / 1, filtered, and dried under reduced pressure at 30° C. to give 2-((1-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one (75 mg) as a yellow solid. MS (ES) + ):582.0(M+H) +
[0338] (Process 2) To a solution of 2-((1-(2-(tert-butyldimethylsilyloxy)ethyl)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one (75 mg, 0.13 mmol) in TFA / DCM (1 / 1) (3 mL), the reaction mixture was stirred at room temperature for 3 h. After LCMS showed the reaction was complete, DCM (5 mL) was added to the mixture and the combined organic layers were washed with NaHCO 3 Wash with water, separate and extract with DCM (3 x 5 mL). 2 SO 4 The mixture was dried at 42° C., filtered and concentrated under reduced pressure at 45° C. The residue was purified by preparative HPLC (Basic Method (B)). The appropriate fractions were concentrated under reduced pressure at 42° C. to remove MeCN and the residue was lyophilized to give the title compound (37.91 mg) as a white solid. [ka]
[0339] Example 6 - 2-((1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one [ka] (Process 1) A mixture of 6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (Intermediate 1, 100 mg, 1 eq, 316 μmol) and cesium carbonate (206 mg, 2 eq, 632 μmol) in DMF (1 mL) was stirred at 70° C. for 45 min. 3-(Chloromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (Intermediate 5, 63.4 mg, 1 eq, 316 μmol) was added and the mixture was allowed to cool to room temperature and stirred overnight. Water and DCM were added and the layers were separated. The organic layer was washed with brine and then absorbed onto silica. The crude product was purified by chromatography on silica gel to give 6-((4-methoxyphenyl)sulfonyl)-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (50 mg) as a pale yellow glass. MS (ES + ):481(M+H) + .
[0340] (Process 2) HCl (4N in dioxane) (56 mg, 0.38 mL, 4 molar, 15 equiv, 1.5 mmol) was added to a solution of 6-((4-methoxyphenyl)sulfonyl)-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (50 mg, 98 wt%, 1 equiv, 0.10 mmol) in MeOH (0.5 mL) and the mixture was stirred for 1 h then concentrated in vacuo. Saturated NaHCO 3 and DCM were added and the layers were separated. The organic layer was washed with brine and then absorbed onto silica. The crude product was purified by chromatography on silica gel to give the title product (29.8 mg) as a white solid. [ka]
[0341] Example 7 - 2-((5-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one [ka] 2-((5-Methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (Example 31, 100 mg, 1 equiv, 245 μmol) was treated with HBr (4.14 g, 2.78 mL, 48 wt%, 100 equiv, 24.5 mmol). The reaction mixture was stirred at 100° C. for 72 hours. The reaction mixture was allowed to cool to room temperature and then diluted with NaHCO 3 until the pH was about 6. 3 Dilute with water and extract with EtOAc (2×10 mL). The organic layer was washed with water (10 mL) and brine (10 mL). The organic phase was collected and diluted with MgSO 4 It was dried at 40° C. and concentrated under reduced pressure. The crude product was purified by chromatography on silica gel to give the title compound (10 mg) as a grey solid. [ka]
[0342] Example 8 - 2-(2-Methoxy-1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one [ka] (Process 1) N 2 To a stirred solution of 6-(phenylsulfonyl)phthalazin-1(2H)-one (Intermediate 2, 0.180 g, 1.0 equiv, 629 μmol) and cesium carbonate (451 mg, 2.2 equiv, 1.38 mmol) in dry DMF (4.0 mL) at 70° C., methyl 2-bromo-2-(6-methoxypyridin-3-yl)acetate (Intermediate 11, 180 mg, 1.1 equiv, 692 μmol) was added. The reaction mixture was stirred for 5 h. The reaction was allowed to cool to room temperature, diluted with water (10 mL) and extracted with DCM (3×15 mL). The combined organic layers were washed with MgSO 4The mixture was dried at 40° C. and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give methyl 2-(6-methoxypyridin-3-yl)-2-(1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)acetate (0.190 g) as a white solid. [ka]
[0343] (Process 2) A solution of methyl 2-(6-methoxypyridin-3-yl)-2-(1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)acetate (0.190 g, 1 equiv, 408 μmol) in THF (4.0 mL) was treated dropwise with lithium borohydride (10.7 mg, 245 μL, 2.00 molar, 1.2 equiv, 490 μmol). The reaction mixture was stirred at room temperature for 4 hours and then washed with saturated NaHCO 3 The mixture was quenched with water (5 mL). The mixture was extracted with EtOAc (2×10 mL) and the combined organic extracts were washed with brine (10 mL) and dried (MgSO 4 ) and concentrated in vacuo. The crude product was purified by chromatography on silica gel to give 2-(2-hydroxy-1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (0.049 g) as a white solid. [ka]
[0344] (Step 3) N 2To a stirred solution of 2-(2-hydroxy-1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (0.035 g, 1 equiv, 80 μmol) in dry DMF (2 mL) below 0° C. was added NaH (4.8 mg, 60 wt%, 1.5 equiv, 0.12 mmol). The reaction mixture was stirred for 10 min, then iodomethane (23 mg, 10 μL, 2.0 equiv, 0.16 mmol) was added dropwise. The resulting yellow suspension was stirred for 2 h while warming to room temperature. The suspension was diluted with water (5 mL) and extracted with EtOAc (2×10 mL). The organic phase was collected, washed with brine (100 mL), dried (MgSO 4 ), and evaporated under reduced pressure to give the title compound (0.020 g) as a white solid. [ka]
[0345] Example 9 - 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide [ka] (Process 1) 6-(phenylsulfonyl)phthalazin-1(2H)-one (Intermediate 2, 200 mg, 0.70 mmol) and K in DMF (5 mL) 2 CO 3 To a solution of (179 mg, 1.4 mmol), methyl 3-(bromomethyl)picolinate (Intermediate 16, 240 mg, 1.05 mmol) was added at room temperature, and the reaction mixture was stirred at 90° C. for 2 h. After LCMS showed that the reaction was complete, the reaction mixture was filtered. To the mixture, EtOAc (10 mL) was added, and the combined organic layers were washed with brine, separated, and extracted with EtOAc (3×10 mL). Na 2 SO 4After drying at 45° C., filtration, and concentration under reduced pressure at 45° C., the residue was purified by flash column chromatography to give methyl 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinate (180 mg) as a yellow solid. MS (ES + ):436.0(M+H) + .
[0346] (Process 2) MeOH (3 mL) and CHCl 3 To a sealed tube of 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinate (180 mg, 0.41 mmol) in 1 mL of 28% aqueous ammonium hydroxide (10 mL) was added and the reaction mixture was stirred at 80° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was concentrated under reduced pressure at 40° C. The residue was purified by preparative HPLC (column: Waters X-SELECT C18 OBD 10 μm 19×250 mm; flow rate: 20 mL / min; solvent system: MeCN / (10 mmol / L NH 4 HCO 3 / water) gradient: MeCN: 40% to 95%; collection wavelength: 214 nm. The appropriate fractions were concentrated under reduced pressure at 42° C. to remove MeCN, and the residue was lyophilized to give the title compound (50.39 mg) as a white solid. [ka]
[0347] Example 10 - 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one [ka] (Process 1) A stirred solution of 2-((1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (Example 68, 100 mg, 98 wt%, 1 eq, 267 μmol) in THF (2 mL) was treated with sodium hydride (60 wt% in mineral oil) (16.0 mg, 60 wt%, 1.5 eq, 401 μmol). The reaction mixture was stirred for 30 min, then a solution of (2-bromoethoxy)(tert-butyl)dimethylsilane (69.1 mg, 62.0 μL, 99 wt%, 1.07 eq, 286 μmol) in THF (1 mL) was added dropwise. The reaction mixture was stirred for 24 h. Sodium iodide (8.02 mg, 0.20 equiv., 53.5 μmol), cesium carbonate (87.1 mg, 1 equiv., 267 μmol), and (2-bromoethoxy)(tert-butyl)dimethylsilane (69.1 mg, 62.0 μL, 99 wt%, 1.07 equiv., 286 μmol) were added and the reaction mixture was stirred for 24 h. The reaction mixture was partitioned between EtOAc (20 mL) and water (20 mL). The organic layer was collected and the aqueous layer was extracted with EtOAc (3×10 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO 4 ) and concentrated in vacuo to give the crude product, which was purified by chromatography on silica gel to give 2-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (32 mg) as a yellow solid. MS (ES + ):525(M+H) + .
[0348] (Process 2) A stirred solution of 2-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (31 mg, 99 wt%, 1 eq, 58 μmol) in THF (1 mL) was treated dropwise with TBAF (46 mg, 0.18 mL, 1.00 molar, 3 eq, 0.18 mmol). The reaction mixture was stirred at room temperature for 2 h, diluted with EtOAc (10 mL) and washed with 50% brine (10 mL). The organic layer was collected and the aqueous layer was extracted with EtOAc (2×10 mL). The combined organic extracts were washed with brine (10 mL) and dried (MgSO 4 ) and concentrated in vacuo to give the crude product as a yellow gum. The crude product was purified by RP Flash C18 (12 g cartridge, 10-80% MeCN / 10 mM NH 3 OH(aq.) to give the title compound (13.5 mg) as a white solid. [ka] (One exchangeable proton was not observed in CDCl3). MS (ES + ):411(M+H)+.
[0349] Example 11 - 2-((1-ethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one [ka] Iodoethane (47 mg, 24 μL, 2.0 equiv, 0.30 mmol) was added to a stirred suspension of 2-((1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (Example 68, 0.055 g, 1 equiv, 0.15 mmol) and cesium carbonate (98 mg, 2.0 equiv, 0.30 mmol) in DMF (2.0 mL) at −10° C. The resulting mixture was stirred overnight while warming to room temperature. The reaction mixture was concentrated under reduced pressure, diluted in DCM (10 mL) and washed with water (2×10 mL). The organic layer was diluted with MgSO 4The crude product was purified by chromatography on silica gel to give the title compound (5.3 mg) as a white solid. 2-((1-ethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one: [ka]
[0350] Example 12 - 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one [ka] (Process 1) Cesium carbonate (546 mg, 1.6 equiv, 1.68 mmol) was added to a stirred solution of 6-(phenylsulfonyl)phthalazin-1(2H)-one (Intermediate 2, 300 mg, 1 equiv, 1.05 mmol) in dry DMF (6 mL). The reaction mixture was stirred for 5 min and then 3-(chloromethyl)-4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole (Intermediate 10, 354 mg, 85 wt%, 1.1 equiv, 1.15 mmol) was added. The resulting mixture was stirred at 70° C. for 3 h. After cooling to room temperature, the reaction mixture was diluted with water (20 mL) and extracted with EtOAc (2×20 mL). The organic phase was collected, dried (MgSO 4 ) and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give 2-((4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (0.57 g, 0.89 mmol, 85%) as a sticky orange oil. MS (ES + ):511(M+H) + .
[0351] (Process 2) TFA (1.0 g, 0.69 mL, 10 equiv, 8.9 mmol) was added dropwise to a suspension of 2-((4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (0.57 g, 80 wt%, 1 equiv, 0.89 mmol) in DCM (10 mL) at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 22 h. The reaction mixture was quenched with saturated aqueous ammonium chloride (30 mL) and extracted with DCM (2×20 mL). The organic phase was collected, dried and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (0.19 g) as a pale yellow solid. [ka]
[0352] Example 13 - 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiophene-2-carboxamide [ka] (Process 1) 6-(phenylsulfonyl)phthalazin-1(2H)-one (Intermediate 2, 200 mg, 0.70 mmol) and K in DMF (5 mL) 2 CO 3 (179 mg, 1.4 mmol) was added with methyl 3-(bromomethyl)thiophene-2-carboxylate (246 mg, 1.05 mmol) at room temperature, and the reaction mixture was stirred at 90° C. for 2 h. After LCMS showed the reaction was complete, the reaction mixture was concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give methyl 3-((1-oxo-6-(phenylsulfonyl)phthalazine-2(1H)-yl)methyl)thiophene-2-carboxylate (200 mg) as a yellow solid. MS (ES + ):440.8(M+H) +.
[0353] (Process 2) H 2 A mixture of methyl 3-((1-oxo-6-(phenylsulfonyl)phthalazine-2(1H)-yl)methyl)thiophene-2-carboxylate (154 mg, 0.35 mmol) and NaOH (42 mg, 1.05 mmol) in 2H2O (5 mL) and MeOH (5 mL) was stirred at 50° C. overnight. After LCMS showed the reaction was complete, the mixture was quenched with 2N HCl. The mixture was concentrated at 40° C. to remove the organic solvent; the residue was separated and extracted with ethyl acetate (3×10 mL). The separated organic layer was washed with brine and Na 2 SO 4 The mixture was dried at 40° C. and filtered. The filtrate was concentrated under reduced pressure at 40° C. to give 3-((1-oxo-6-(phenylsulfonyl)phthalazine-2(1H)-yl)methyl)thiophene-2-carboxylic acid (100 mg, 69%) as a yellow oil. MS (ES + ):427.0(M+H) + .
[0354] (Step 3) 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzoic acid (60 mg, 0.14 mmol), NH 4 Cl (30 mg, 0.56 mmol), HATU (106 mg, 0.28 mmol), and Et 3 A mixture of N (57 mg, 0.56 mmol) was stirred at room temperature for 16 h. After LCMS showed the reaction was complete, the residue was purified by preparative HPLC (basic method (B)). The fractions were concentrated under reduced pressure at 42° C. to remove MeCN, and the residue was lyophilized to give the title compound (48.23 mg) as a white solid. [ka]
[0355] Example 14 - 6-Methoxy-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide [ka] (Process 1) 6-(phenylsulfonyl)phthalazin-1(2H)-one (Intermediate 2, 200 mg, 0.70 mmol) and K in DMF (5 mL) 2 CO 3 To a solution of (179 mg, 1.4 mmol), methyl 3-(bromomethyl)-6-methoxypicolinate (Intermediate 19, 200 mg, 0.77 mmol) was added at room temperature, and the reaction mixture was stirred at 90° C. for 2 h. After LCMS showed that the reaction was complete, the reaction mixture was concentrated under reduced pressure at 40° C. The residue was purified by flash column chromatography to give methyl 6-methoxy-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinate (180 mg) as a yellow solid. MS (ES + ):466.0(M+H) + .
[0356] (Process 2) Methyl 6-methoxy-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinate (180 mg, 0.39 mmol) and CaCl in MeOH (2 mL). 2 (43 mg, 0.39 mmol) in a sealed tube, 3 (7M in MeOH) (8 mL) was added and the reaction mixture was stirred at 80° C. overnight. After LCMS showed the reaction was complete, the reaction mixture was concentrated under reduced pressure at 40° C. The residue was purified by preparative HPLC (column: Waters X-SELECT C18 OBD 10 μm 19×250 mm; flow rate: 20 mL / min; solvent system: MeCN / (10 mmol / L NH 4 HCO 3 / water) gradient: MeCN: 40% to 95%; collection wavelength: 214 nm. The fractions were concentrated under reduced pressure at 42° C. to remove MeCN, and the residue was lyophilized to give the title compound (88.45 mg) as a white solid. [ka]
[0357] Example 15 - 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carboxamide [ka] (Process 1) A stirred suspension of 6-(phenylsulfonyl)phthalazin-1(2H)-one (Intermediate 2, 336 mg, 1 equiv, 1.17 mmol) and cesium carbonate (421 mg, 1.1 equiv, 1.29 mmol) in DMF (5 mL) was heated to 80° C. for 2 h and then allowed to cool to room temperature. A solution of ethyl 3-(chloromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylate (Intermediate 8, 356 mg, 90 wt%, 1 equiv, 1.17 mmol) in DMF (2 mL) was added and the reaction mixture was stirred at room temperature for 20 h. The reaction mixture was concentrated in vacuo and the residue was azeotroped with toluene (twice) to give the crude product. The crude product was purified by chromatography on silica gel to give ethyl 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylate (460 mg) as a pale yellow solid. MS (ES + ):523(M+H) + .
[0358] (Process 2) A mixture of ethyl 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylate (200 mg, 87% by weight, 1 eq., 333 μmol) and lithium hydroxide (15.9 mg, 2 eq., 666 μmol) was dissolved in THF (2 mL) and water (1 mL) and the reaction mixture was stirred at 50° C. for 3 h. The mixture was allowed to stand at room temperature for 18 h. 0.5 M HCl (aq.) (6 mL) was added and the mixture was extracted with EtOAc (2×10 mL). The combined organic extracts were washed with brine (10 mL), dried (MgSO 4 ) and concentrated in vacuo. The residue was dissolved in DCM and concentrated in vacuo. The residue was azeotroped with diethyl ether to give 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylic acid (196 mg) as a pale yellow solid. MS (ES) + ):517(M+Na) + .
[0359] (Step 3) A stirred solution of 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylic acid (196 mg, 80 wt%, 1 equiv, 317 μmol), DIPEA (52 mg, 70 μL, 1.3 equiv, 0.40 mmol), and ammonia (0.5 M in THF) (55.3 mg, 6.50 mL, 0.50 molar, 10.2 equiv, 3.25 mmol) was treated with a solution of HATU (127 mg, 1.05 equiv, 333 μmol) in DMF (2 mL). The reaction mixture was stirred at room temperature for 2 h. Further ammonia (0.5M in THF) (55.3 mg, 6.50 mL, 0.50 molar, 10.2 equiv, 3.25 mmol) was added and the mixture was stirred for 18 h. Ammonium hydroxide (176 mg, 200 μL, 26 wt%, 4.12 equiv, 1.31 mmol) was added and stirred for 3 h. The reaction mixture was diluted with EtOAc (10 mL) and saturated NaHCO 3The organic layer was collected and the aqueous layer was extracted with EtOAc (2×10 mL). The combined organic extracts were washed with brine (10 mL) and dried (MgSO 4 ) and concentrated in vacuo to give the crude product, which was purified by chromatography on silica gel to give 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxamide (165 mg) as a white solid. [ka]
[0360] (Step 4) A solution of 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxamide (70.0 mg, 88 wt%, 1 equiv, 125 μmol) in MeOH (1 mL) was treated with p-toluenesulfonic acid monohydrate (23.7 mg, 1 equiv, 125 μmol). The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was concentrated in vacuo to give the crude product. The crude product was purified by chromatography on silica gel to give the title compound (5.6 mg) as a white solid. [ka] (One exchangeable proton was not observed in DMSO). MS (ES + ):410.1(M+H) + .
[0361] Example 16 - 2-((1-(2-hydroxyethyl)-4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one [ka] (Process 1) A stirred suspension of 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one (Example 12, 40 mg, 95 wt%, 1 equiv, 0.10 mmol) and cesium carbonate (65 mg, 2 equiv, 0.20 mmol) in DMF (3 mL) was treated with methyl bromoacetate (23 mg, 14 μL, 1.5 equiv, 0.15 mmol). The reaction mixture was stirred at 60° C. for 13 h, then allowed to cool to room temperature and absorbed onto silica. The crude product was purified by chromatography on silica gel to give methyl 2-(4-methyl-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazol-1-yl)acetate (35 mg) as a pale yellow solid. MS (ES) + ):453(M+H) + .
[0362] (Process 2) Lithium borohydride (2.9 mg, 66 μL, 2.00 molar, 2 equiv, 0.13 mmol) was added dropwise to a stirred solution of methyl 2-(4-methyl-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazol-1-yl)acetate (30 mg, 1 equiv, 66 μmol) in dry THF (3.0 mL). The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was diluted with water (25 mL) and transferred to a separatory funnel. The layers were extracted with EtOAc (2×25 mL). The combined organic layers were collected and dried (MgSO 4 ), filtered and concentrated in vacuo. The crude product was dissolved in DMSO (1 mL), filtered and purified by reverse phase preparative HPLC (basic method (B)). The appropriate fractions were evaporated in a Genevac to give the title compound (7 mg) as an off-white solid. [ka]
[0363] Example 17 - 3-((6-((4-Methoxyphenyl)sulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)-N-methylfuran-2-carboxamide [ka] (Process 1) To a stirred solution of 6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one (Intermediate 1, 0.10 g, 66 wt%, 1 eq, 0.21 mmol) in dry DMF (8.0 mL) was added cesium carbonate (0.20 g, 3 eq, 0.63 mmol). The reaction mixture was stirred for 5 min and then methyl 3-(bromomethyl)furan-2-carboxylate (Intermediate 18, 91 mg, 2 eq, 0.42 mmol) was added in one portion. The resulting mixture was stirred at 70° C. for 3 h, then it was cooled to room temperature, diluted with water (10 mL) and extracted with DCM (2×10 mL). The organic phase was collected, dried and evaporated under reduced pressure. The crude product was purified by chromatography on silica gel to give methyl 3-((6-((4-methoxyphenyl)sulfonyl)-1-oxophthalazine-2(1H)-yl)methyl)furan-2-carboxylate (75 mg) as an off-white solid. [ka]
[0364] ...
Claims
1. Formula (Ia): [Formula 1] (In the formula, R A is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle; where R A can have one or more R on available atoms. 1A where each R 1A are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , C 1-6 Alkyl-NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2A R 3A , C.H. 2 CONR 2A R 3A , C 3-6 selected from the group consisting of cycloalkyl, oxo, and 4-membered heterocycle, wherein said 4-membered heterocycle is optionally substituted with hydroxy; R 2A and R 3A are independently H and C 1-6 alkyl, or R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; Here, R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A selected from the group consisting of; Here, R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10A R 11A and optionally substituted with one or more groups selected from Here, R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; or Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; Here, R 5A is H or C 1-3 is alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A selected from the group consisting of; Here, R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A and optionally substituted with one or more groups selected from Here, R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Z 1 and Z 2 is independently selected from N and CH, where Z 1 and Z 2 at least one of is CH; R B is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, 5- to 7-membered heterocyclyl, or C 3-6 cycloalkyl; where R B can have one or more R on available atoms. 1B where each R 1B are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B , C 1-6 Alkyl-NR 2B R 3B , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 selected from the group consisting of cycloalkyl, oxo, and 4-membered heterocycle, wherein said 4-membered heterocycle is optionally substituted with hydroxy; R 2B and R 3B are independently H and C 1-6 alkyl, or R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; R C H, Fluoro, C 1-3 Alkyl, C 1-2 Hydroxyalkyl or C 1-2 is methoxyalkyl; R D is H or fluoro; m is 0 or 1; X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -C(R E )(R F )O- or CH 2 NH-; and R E and R F is H or R E and R F is integrated into C 3-5 forming a heterocycloalkyl ring) or a pharma- ceutically acceptable salt and / or solvate thereof.
2. Formula (Ib): [chemical 2] (In the formula, R A is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle; where R A has one or more R on an available carbon or nitrogen atom. 1A where each R 1A are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , C 1-6 Alkyl-NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2A R 3A , C.H. 2 CONR 2A R 3A , C 3-6 cycloalkyl, and oxo; R 2A and R 3A are independently H and C 1-6 alkyl, or R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; Here, R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A selected from the group consisting of; Here, R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10A R 11A and optionally substituted with one or more groups selected from Here, R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11Aare bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; or Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; Here, R 5A is H or C 1-3 is alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A selected from the group consisting of; Here, R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A and optionally substituted with one or more groups selected from Here, R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Z 1 and Z 2is independently selected from N and CH, where Z 1 and Z 2 at least one of is CH; R B is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, 5- to 7-membered heterocyclyl, or C 3-6 cycloalkyl; where R B has one or more R on an available carbon or nitrogen atom. 1B where each R 1B are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B , C 1-6 Alkyl-NR 2B R 3B , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 cycloalkyl, and oxo; R 2B and R 3B are independently H and C 1-6 alkyl, or R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; R C H, Fluoro, C 1-3 Alkyl, C 1-2 Hydroxyalkyl or C 1-2 is methoxyalkyl; R D is H or fluoro; m is 0 or 1; X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -CH 2 O- or CH 2 NH-) 2. The compound of formula (Ia) according to claim 1, which is a compound of the formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof.
3. Formula (I): [C3] (In the formula, R A is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, or 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle; where R A has one or more R on an available carbon atom. 1A where R 1A are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , C 1-6 Alkyl-NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2A R 3A , C.H. 2 CONR 2A R 3A , C 3-6 cycloalkyl, and oxo; R 2A and R 3A are independently H and C 1-6 alkyl, or R 2A and R 3A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; Here, R 4A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 8A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 8A R 9A selected from the group consisting of; Here, R 8A and R 9A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 10A R 11A and optionally substituted with one or more groups selected from Here, R 10A and R 11A are independently H and C 1-6 alkyl, or R 10A and R 11A are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; or Y 2 does not exist and Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; Here, R 5A is H or C 1-3 is alkyl; and R 6A , H, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, OR 12A , halo, cyano, methanesulfonyl, CF 3 , and N.R. 12A R 13A selected from the group consisting of; Here, R 12A and R 13A are independently H and C 1-6 alkyl, wherein C 1-6 Alkyl can be substituted with halo, hydroxy, methoxy, CO on any available carbon atom. 2 H, and NR 14A R 15A and optionally substituted with one or more groups selected from Here, R 14A and R 15A are independently H and C 1-6 alkyl, or R 14A and R 15Aare bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; Z 1 and Z 2 is independently selected from N and CH, where Z 1 and Z 2 at least one of is CH; R B is phenyl, phenyl fused to a 5- to 7-membered heterocycle, 5- to 10-membered heteroaryl, 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, 5- to 7-membered heterocyclyl, or C 3-6 cycloalkyl; where R B has one or more R on an available carbon atom. 1B where R 1B are independent, halo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B , C 1-6 Alkyl-NR 2B R 3B , N.H.C.O.H. 3 , CO 2 H, C.H. 2 CO 2 H, CONR. 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 cycloalkyl, and oxo; R 2B and R 3B are independently H and C 1-6alkyl, or R 2B and R 3B are bonded together with the N atom to which they are attached to form C on an available atom. 1-2 forming a 4- to 7-membered heterocycle optionally substituted with one or more groups selected from alkyl and oxo; R C H, Fluoro, C 1-3 Alkyl, C 1-2 Hydroxyalkyl or C 1-2 is methoxyalkyl; R D is H or fluoro; m is 0 or 1; X is S(=O) 1-2 , -CH 2 S(=O) 1-2 -, S(=O)(=NH), -S(=O) 2 NH-, -NHS(=O) 2 -, CH 2 , -CH 2 O- or CH 2 NH-) 3. The compound of formula (Ia) according to claim 1 or 2, which is a compound of the formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof.
4. R Ais selected from the group consisting of phenyl, phenyl fused to a 5- to 6-membered heterocycle (e.g., selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine), 5- to 6-membered heteroaryl (e.g., pyrrolyl, pyrazolyl, pyrimidinyl, or pyridyl), or phenyl fused to a 5- to 6-membered heterocycle; and 5-6 membered heteroaryl (e.g., 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl, or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl, etc.) and one or more R 1A The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
5. R A has one or more R on an available carbon atom 1A The compound according to any one of claims 1 to 4, wherein R is phenyl optionally substituted by R, R and R, or a pharma- ceutically acceptable salt and / or solvate thereof.
6. R A is phenyl fused to a 5- to 7-membered heterocycle, such as those selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine; and one or more R 1A The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
7. R AThe compound according to claim 6, wherein is 2,3-dihydrobenzofuranyl, benzo-1,4-dioxanyl, or 3,4-dihydro-2H-1,4-benzoxazine, or a pharma- ceutically acceptable salt and / or solvate thereof.
8. R A is a 5-10 membered heteroaryl such as those selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, and quinazolinyl; and one or more R on an available atom (e.g., a carbon or nitrogen atom, especially a carbon atom). 1A The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
9. R A is a 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, such as 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl, or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl; and one or more R 1A The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
10. Each R 1A Independently, Halo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Methoxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2A R 3A , N.H.C.O.H. 3 , CO 2 H, CONR. 2A R 3A , C 3-6 cycloalkyl, oxo, and 4-membered heterocycle, wherein the 4-membered heterocycle is optionally substituted with hydroxy; particularly each R 1A Independently, Halo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Methoxyalkyl, C 1-6 Haloalkyl, Hydroxy, and OC 1-6 Alkyl, e.g., C 1-6 Alkyl, OC 1-6 alkyl, oxo, and oxetane or azetidine, both of which are optionally substituted by hydroxy; for example, each R 1A But OCH 3 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt and / or solvate thereof,
11. R A The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein is unsubstituted.
12. R 2A and R 3A are independently H and C 1-6 The compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein the compound is selected from the group consisting of: alkyl.
13. R 2A and R 3Ais independently selected from the group consisting of H, methyl, and ethyl, a pharma- ceutically acceptable salt, and / or solvate thereof according to any one of claims 1 to 10 or 12.
14. R 2A and R 3A and R are both H, or a pharma- ceutically acceptable salt and / or solvate thereof, according to any one of claims 1 to 10, 12, or 13.
15. R 2A and R 3A are bonded together with the N atom to which they are attached, and C is formed on an available atom. 1-2 The compound according to any one of claims 1 to 10, which forms a 4-7 membered heterocyclic ring optionally substituted by one or more groups selected from alkyl and oxo, or a pharma- ceutically acceptable salt and / or solvate thereof.
16. R 2A and R 3A are combined together with the N atom to which they are attached to form pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-thiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl, 1,4-piperazin-1-yl, or N-methyl-1,4-piperazin-1-yl, or a pharma- ceutically acceptable salt and / or solvate thereof.
17. R Bis phenyl, phenyl fused to a 5- to 7-membered heterocycle (e.g., selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine), pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, pyrazinylin ... aryl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, quinazolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridone, and pyridazinone; and one or more R on an available atom (e.g., a carbon or nitrogen atom, particularly a carbon atom). 1B 17. The compound of any one of claims 1 to 16, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
18. R B has one or more R on an available carbon atom 1B 18. The compound of any one of claims 1 to 17, wherein R is phenyl optionally substituted by R, R and R, or a pharma- ceutically acceptable salt and / or solvate thereof.
19. R Bis phenyl fused to a 5- to 7-membered heterocycle, such as those selected from the group consisting of 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, 1,3-benzodiazole, and 3,4-dihydro-2H-1,4-benzoxazine, in particular 2,3-dihydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, benzo-1,4-dioxanyl, or 1,3-benzodiazole; and one or more R 1B 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
20. R B is a 5-10 membered heteroaryl, for example, pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, oxazolyl, isoxazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazidinyl, pyrazinyl, furo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, indolyl, indazolyl, benzofuranyl, benzimidazo is selected from the group consisting of aryl, benzothiazolyl, benzothiophenyl, quinolinyl, isoquinolinyl, and quinazolinyl; in particular, selected from the group consisting of furanyl, thienyl, pyrazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyrazolo[1,5-a]pyridinyl, imidazo[1,2-a]pyridinyl, and indazolyl, for example pyrazolyl; and one or more R on an available atom (e.g., a carbon or nitrogen atom, in particular a carbon atom). 1B 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
21. R Bis a 5- to 6-membered heteroaryl fused to a 5- to 7-membered heterocycle, such as 2,3-dihydropyrazolo[5,1-b]oxazolyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 2,3-dihydrofuro[3,2-b]pyridinyl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridinyl, or 2,3-dihydro-[1,4]dioxino[2,3-b]pyridinyl; and one or more R 1B 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
22. R B is 5-7 membered heterocyclyl, such as pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridone, or pyridazinone; such as pyridone or pyridazinone, such as pyridone; and one or more R on an available atom (e.g., carbon or nitrogen atom, especially carbon atom). 1B 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
23. R B But, C 3-6 cycloalkyl; and one or more R 1B 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt and / or solvate thereof, optionally substituted by:
24. Each R 1B Independently, Halo, C 1-6 Alkyl, C 1-6 Hydroxyalkyl, C 1-6 Haloalkyl, Hydroxy, OC 1-6 Alkyl, OC 1-6 Hydroxyalkyl, OC 1-6 Haloalkyl, Cyano, NR 2B R 3B ,CONR 2B R 3B , C.H. 2 CONR 2B R 3B , C 3-6 cycloalkyl, oxo, and 4-membered heterocycle, wherein the 4-membered heterocycle is optionally substituted with hydroxy; particularly each R 1B are independently fluoro, chloro, methyl, ethyl, CH 2 OH, CH 2 CH 2 OH, CHF 2 , Hydroxy, OCH 3 , O.C.H. 2 CH 2 OH,OCHF 2 , Cyano, N.H. 2 ,CONH 2 ,CONHCH 3 , C.H. 2 CONH 2 24. The compound according to any one of claims 1 to 23, wherein the compound is selected from the group consisting of oxetane or azetidine, both of which are optionally substituted by cyclopropyl, oxo, and hydroxy, a pharma- ceutically acceptable salt, and / or solvate thereof.
25. R B 24. The compound according to any one of claims 1 to 23, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein: is unsubstituted.
26. R 2B and R 3B are independently H and C 1-6 25. The compound according to any one of claims 1 to 24, a pharma- ceutically acceptable salt, and / or solvate thereof, wherein the compound is selected from the group consisting of alkyl.
27. R 2B and R 3B is independently selected from the group consisting of H, methyl, and ethyl, a pharma- ceutically acceptable salt, and / or solvate thereof according to any one of claims 1 to 24 or 26.
28. R 2B and R 3Band R are both H, or a pharma- ceutically acceptable salt and / or solvate thereof, according to any one of claims 1 to 24, 26, or 27.
29. R 2B and R 3B are bonded together with the N atom to which they are attached, and C is formed on an available atom. 1-2 25. The compound according to any one of claims 1 to 24, a 4-7 membered heterocyclic ring optionally substituted with one or more groups selected from alkyl and oxo, a pharma- ceutically acceptable salt, and / or solvate thereof.
30. R 2B and R 3B are combined together with the N atom to which they are attached to form pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-thiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl, 1,4-piperazin-1-yl, or N-methyl-1,4-piperazin-1-yl, or a pharma-ceutically acceptable salt and / or solvate thereof.
31. Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A where R 4A A compound according to any one of claims 1 to 30, a pharma- ceutically acceptable salt and / or solvate thereof, wherein:
32. Y 1 , Y 2 , and Y 3 All of this is CR 4A where preferably R 4A is H, or a pharma- ceutically acceptable salt, and / or solvate thereof, according to claim 31.
33. Y 2 does not exist and Y 1 and Y 3 One of the groups is S, O, or NR. 5A And the remaining Y 1 Or Y 3 But N or CR 6A where R 5A and CR 6A A compound according to any one of claims 1 to 30, wherein:
34. Z 1 is N and Z 2 The compound according to any one of claims 1 to 33, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein is CH.
35. Z 1 is CH and Z 2 The compound according to any one of claims 1 to 33, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein is N.
36. Z 1 is CH and Z 2 The compound according to any one of claims 1 to 33, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein is CH.
37. R C H, Fluoro, CH 3 , C.H. 2 OH or CH 2 OCH 3 and in particular H, a compound according to any one of claims 1 to 36, a pharma- ceutically acceptable salt and / or solvate thereof.
38. R D A compound according to any one of claims 1 to 37, wherein is H or fluoro, in particular is H, a pharma- ceutically acceptable salt and / or solvate thereof.
39. R Cis H and R D The compound according to any one of claims 1 to 36, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein is fluoro.
40. The compound according to any one of claims 1 to 39, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein m is 0.
41. X is S(=O) 1-2 or S(=O)(=NH), a pharma- ceutically acceptable salt, and / or solvate thereof according to any one of claims 1 to 40.
42. X is S(=O) 2 42. The compound according to any one of claims 1 to 41, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
43. 42. The compound according to any one of claims 1 to 41, wherein X is S(=O), or a pharma- ceutically acceptable salt and / or solvate thereof.
44. X is -CH 2 S(=O) 1-2 -, especially -CH 2 S(=O) 1-2 41. The compound according to any one of claims 1 to 40, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
45. 41. The compound according to any one of claims 1 to 40, wherein X is S(=O)(=NH), or a pharma- ceutically acceptable salt and / or solvate thereof.
46. X is -S(=O) 2 41. The compound according to any one of claims 1 to 40, which is NH-, a pharma- ceutically acceptable salt, and / or solvate thereof.
47. X is -NHS(=O) 2 41. The compound according to any one of claims 1 to 40, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
48. X is CH 2 41. The compound according to any one of claims 1 to 40, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
49. X is -C(R E )(R F )O- and R E and R F is H or R E and R F But it is integrated into C 3-5 Form a heterocycloalkyl ring, e.g., X is -CH 2 The compound according to any one of claims 1 to 40, wherein the compound is O-, a pharma- ceutically acceptable salt, and / or solvate thereof.
50. X is CH 2 41. The compound according to any one of claims 1 to 40, which is NH-, a pharma- ceutically acceptable salt, and / or solvate thereof.
51. The compound of formula (Ia) has the formula (IIa): [C4] (In the formula, Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; R A , R B , R C , R D , m, X, Z 1 , Z 2 and R 4A is as defined in any one of claims 1 to 30 or 32 to 48) or a pharma- ceutically acceptable salt and / or solvate thereof according to any one of claims 1 to 32 or 34 to 50,
52. The compound of formula (Ia) has the formula (IIaA): [C5] (In the formula, Y 1 , Y 2 , and Y 3 Independently, CR 4A and N, where Y 1 , Y 2 , and Y 3 At least two of the 4A and; R A , R B , R C , R D , X and R 4A is as defined in any one of claims 1 to 50) 52. The compound according to claim 51, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
53. The compound of formula (Ia) has the formula (IIaB): [C6] (In the formula, R A , R B , R C , R D and X is as defined in any one of claims 1 to 50.
53. The compound according to claim 52, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
54. The compound of formula (Ia) has the formula (IIaC): [C7] (In the formula, R A , R B and X is as defined in claim 51.
54. The compound according to claim 53, or a pharma- ceutically acceptable salt and / or solvate thereof,
55. The compound of formula (Ia) has the formula (IaD): [C8] (In the formula, R A and R B is as defined in claim 52) 55. The compound according to claim 54, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
56. The compound of formula (Ia) has the formula (IIIa): [C9] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , R C , R D , m, X, Z 1 , Z 2 , R 5A , and R 6A is as defined in any one of claims 1 to 28 or 32 to 48) or a pharma- ceutically acceptable salt and / or solvate thereof according to any one of claims 1 to 30 or 34 to 50,
57. The compound of formula (Ia) has the formula (IIIaA): [C10] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , R C , R D , X, R 5A , and R 6A is as defined in claim 54) 57. The compound according to claim 56, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
58. The compound of formula (Ia) has the formula (IIIaB): [C11] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , X, R 5A , and R 6A is as defined in claim 55) 58. The compound according to claim 57, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein
59. The compound of formula (Ia) has the formula (IIIaC): [C12] (In the formula, Y 1 and Y 3 one of which is S, O, or NR 5A And the remaining Y 1 Or Y 3 is N or CR 6A and; R A , R B , R 5A , and R 6A is as defined in claim 56); 59. The compound according to claim 58, or a pharma- ceutically acceptable salt and / or solvate thereof,
60. 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(indolin-4-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-(2-hydroxyethyl)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((5-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-methoxy-1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-ethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiophene-2-carboxamide; 6-Methoxy-3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)picolinamide; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carboxamide; 2-((1-(2-hydroxyethyl)-4-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((6-((4-methoxyphenyl)sulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)-N-methylfuran-2-carboxamide; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)-1H-pyrazole-4-carbonitrile; 2-(2-hydroxy-1-phenylethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-(hydroxymethyl)benzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-(2-hydroxyethoxy)pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-(hydroxymethyl)thiophen-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazine-2(1H)-yl)methyl)thiophene-2-carbonitrile; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((5-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((4-(hydroxymethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methylthiazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-fluorobenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-fluoro-5-methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(imidazo[1,2-a]pyridin-5-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-indazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-aminopyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-indazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(3-(difluoromethoxy)benzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-(pyridin-3-ylmethyl)phthalazin-1(2H)-one; 2-(2-aminobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-phenethylphthalazin-1(2H)-one; 2-(Isoxazol-5-ylmethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(4-chloro-2-fluorobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrobenzofuran-5-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-indazol-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(4-Methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-Benzyl-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-(2-fluoro-3-methoxybenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(2,6-difluoro-4-methoxybenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-4-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-3-yl)methyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(benzo[d][1,3]dioxol-5-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1H-indazol-6-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methoxypyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)phenyl)acetamide; 2-((6-(difluoromethoxy)pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-(2-hydroxyethyl)benzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methyl-2,3-dihydrobenzofuran-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-(phenylsulfonyl)-2-(pyridin-3-ylmethyl)phthalazin-1(2H)-one; 2-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 2-(2-Methoxy-1-phenylethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-(phenylsulfonyl)-2-(1-(pyridin-3-yl)ethyl)phthalazin-1(2H)-one; 2-((1,3-dimethyl-1H-pyrazol-4-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-Benzyl-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(1-(6-methoxypyridin-3-yl)ethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-methylpyridin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methylthiazol-4-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(difluoro(pyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-Methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methylisoxazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(3-Methoxybenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(2-Methoxy-1-phenylethyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-((1-ethyl-1H-pyrazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 3-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)furan-2-carboxamide; 5-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)furan-2-carboxamide; 2-((5-methoxypyrazin-2-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-methoxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1,4-dimethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-Chloro-6-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 2-Methoxy-6-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)benzamide; 4-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)thiazole-2-carboxamide; 5-Methyl-4-((1-oxo-6-(phenylsulfonyl)phthalazin-2(1H)-yl)methyl)isoxazole-3-carboxamide; 2-((1-isopropyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((3-methylisothiazol-5-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxy-6-methylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxy-4-methylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((5-fluoro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxy-5-isopropylpyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((4-fluoro-2-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 6-((4-methoxyphenyl)sulfonyl)-2-((4-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((3-hydroxypyridin-4-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 5-Methoxy-2-((6-(4-methoxyphenylsulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)benzamide; 2-((4-hydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 6-(Phenylsulfonyl)-2-(pyrazolo[1,5-a]pyridin-2-ylmethyl)phthalazin-1(2H)-one; 2-((2-hydroxy-6-methoxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((4-fluoro-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((5-fluoro-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-(4-Methoxyphenylsulfonyl)-2-((3-(trifluoromethyl)isoxazol-5-yl)methyl)phthalazin-1(2H)-one; 6-(4-Methoxyphenylsulfonyl)-2-((3-(trifluoromethyl)isoxazol-5-yl)methyl)phthalazin-1(2H)-one; 2-((3-hydroxypyridin-2-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(quinolin-8-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(5-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(3-methoxyphenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 3-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)thiophene-2-carboxamide; 4-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)thiophene-2-carboxamide; 2-(3-aminobenzyl)-6-(phenylsulfinyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(pyridin-3-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-1-oxo-N-phenyl-1,2-dihydrophthalazine-6-sulfonamide; 6-((1H-indazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((6-(difluoromethoxy)pyridin-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 3-((6-methoxypyridin-3-yl)methyl)-7-((3-phenyloxetan-3-yl)oxy)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; R)-2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; (S)-2-((6-methoxypyridin-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; 6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(4-(difluoromethoxy)phenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(pyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((5-methylthiophen-2-yl)sulfonyl)phthalazin-1(2H)-one; 6-((4-fluorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(3-methylisothiazol-5-ylsulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-tosylphthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-(3-aminobenzyl)-6-(benzo[d][1,3]dioxol-5-ylsulfonyl)phthalazin-1(2H)-one; 6-(4-(difluoromethoxy)phenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((3-chlorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((4-chlorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((3-fluorophenyl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(4-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(6-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 3-(2-((6-methoxypyridin-3-yl)methyl)-1-oxo-1,2-dihydrophthalazin-6-ylsulfonyl)benzamide; 6-(2-fluorophenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2-chlorophenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2-Methoxyphenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(4-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,2-dimethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(6-methylpyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(3-(difluoromethoxy)phenylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(5-methylthiophen-2-ylsulfonyl)phthalazin-1(2H)-one; 6-(5-methoxypyridin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(2-(difluoromethyl)thiazol-5-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(2-methylthiazol-4-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(6-methoxypyridin-3-ylsulfonyl)phthalazin-1(2H)-one; 2-((6-methoxypyridin-3-yl)methyl)-6-(2-methylbenzo[d]thiazol-4-ylsulfonyl)phthalazin-1(2H)-one; 6-(5-methoxypyrazin-2-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(imidazo[1,2-a]pyridin-5-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1-(difluoromethyl)-1H-pyrazol-3-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(2,3-dihydrobenzofuran-5-sulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydrofuro[2,3-b]pyridin-5-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(imidazo[1,2-a]pyridin-7-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1,2-dimethyl-1H-imidazol-4-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1,5-dimethyl-1H-pyrazol-4-ylsulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; (S)-6-(4-methoxyphenylsulfonimidoyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1-cyclopropyl-1H-pyrazol-4-ylsulfonyl)-2-((2-hydroxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-(1-cyclopropyl-1H-pyrazol-4-ylsulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(benzofuran-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-(3-(difluoromethoxy)benzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-(2-fluoro-5-methoxybenzyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2-hydroxypyridin-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((4-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((6-(1-methyl-1H-pyrazol-3-ylsulfonyl)-1-oxophthalazin-2(1H)-yl)methyl)benzamide; 2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-2-ylsulfonyl)phthalazin-1(2H)-one; 6-((4-(difluoromethoxy)phenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((4-ethoxyphenyl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; (R)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((4-(trifluoromethoxy)phenyl)sulfonyl)phthalazin-1(2H)-one; (S)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((3-methylbenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(benzofuran-6-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(furo[3,2-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-methylbenzofuran-5-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(furo[2,3-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one; 6-((1H-indol-5-yl)sulfonyl)-2-((1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(benzo[b]thiophen-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-indol-5-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-3-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-(1-(2-hydroxyethyl)-1H-pyrazol-3-ylsulfonyl)-2-((2-hydroxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 7-Fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 5-Fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 7-((2-hydroxyethyl)amino)-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 8-Fluoro-2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 7-((2-hydroxyethyl)amino)-2-((2-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 5-((2-hydroxyethyl)amino)-2-((2-hydroxypyridin-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1-methyl-1H-pyrazol-3-yl)methyl)-7-(phenylsulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one; 3-((1-methyl-1H-pyrazol-3-yl)methyl)-7-(phenylsulfinyl)pyrido[3,4-d]pyridazin-4(3H)-one; 7-((1-methyl-1H-pyrazol-3-yl)methyl)-3-(phenylsulfonyl)pyrido[2,3-d]pyridazin-8(7H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-(1H-pyrazol-4-ylsulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(pyridin-4-ylsulfonyl)phthalazin-1(2H)-one; 2-((2,4-dihydroxypyridin-3-yl)methyl)-6-(4-methoxyphenylsulfonyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-(furo[3,2-b]pyridin-5-ylsulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((5-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2,3-dihydrofuro[2,3-c]pyridin-5-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-cyclopropyl-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-(pyrazin-2-ylsulfonyl)phthalazin-1(2H)-one; 2-(imidazo[1,2-a]pyridin-3-ylmethyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((1-methyl-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonimidoyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 3-((1H-pyrazol-3-yl)methyl)-7-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one; 7-((1H-pyrazol-3-yl)methyl)-3-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[2,3-d]pyridazin-8(7H)-one; 2-((1H-pyrazol-3-yl)methyl)-7-((2-hydroxyethyl)amino)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-methylpyridin-2-yl)methyl)-6-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1-(oxetan-3-yl)-1H-pyrazol-3-yl)methyl)-6-(phenylsulfonyl)phthalazin-1(2H)-one; 2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-cyclopropylpyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-(azetidin-3-yl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1-(2-aminoethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; (S)-2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; (R)-2-((6-(1-hydroxyethyl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)sulfonyl)-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((6-(3-hydroxyoxetan-3-yl)pyridin-2-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-cyclopropylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methylpyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((5-methylpyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((6-methylpyridin-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-(1H-pyrazol-4-ylsulfonyl)-2-((5-methoxy-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)methyl)-6-((5-methoxypyridin-2-yl)sulfonyl)phthalazin-1(2H)-one; 6-(1H-pyrazol-4-ylsulfonyl)-2-((2,3-dihydrofuro[2,3-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-3-yl)methyl)phthalazin-1(2H)-one; (R)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; (S)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-(furo[3,2-b]pyridin-5-ylmethyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 7-((1H-pyrazol-4-yl)sulfonyl)-3-((5-methyl-1H-pyrazol-3-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((3-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((6-cyclopropylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((5-fluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((6-cyclopropylpyridin-2-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1,5-dimethyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((4-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((4-fluoro-1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((5-chloro-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((3-chloro-1H-pyrazol-4-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((4-chloro-1H-pyrazol-3-yl)sulfonyl)-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-5,6-dimethylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((5-fluoro-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3-fluoro-6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((2-(1-hydroxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((1-(difluoromethyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((3-fluoro-6-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one; 2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 3-((5-methyl-1H-pyrazol-3-yl)methyl)-7-((1-methyl-1H-pyrazol-4-yl)sulfonyl)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(oxetan-3-yl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-3-yl)sulfonyl)-2-(furo[3,2-b]pyridin-5-ylmethyl)phthalazin-1(2H)-one; 2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((4-chloro-1,5-dimethyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-5-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3,5-difluoro-6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 7-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)-3-((5-methyl-1H-pyrazol-3-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)methyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2-methylfuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-cyclopropylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 7-((1H-pyrazol-4-yl)sulfonyl)-3-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)pyrido[3,4-d]pyridazin-4(3H)-one; 2-((4,5-dimethyl-1H-pyrazol-3-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-(furo[3,2-b]pyridin-5-ylmethyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((3-fluoro-5,6-dimethylpyridin-2-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 6-((1H-pyrazol-4-yl)sulfonyl)-2-((3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methyl)phthalazin-1(2H)-one; 6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-2-((7-methyl-2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((2-(1-methoxyethyl)thiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((5-methyl-1H-pyrazol-3-yl)methyl)-6-((2-methylthiazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((5-methyl-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-methoxyethyl)-1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one; 2-((1H-pyrazol-3-yl)methyl)-6-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one; 2-[(7-methyl-2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl]-6-(1H-pyrazol-4-ylsulfonyl)phthalazin-1-one; (R)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; and (S)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-(1H-pyrazole-4-sulfonimidoyl)phthalazin-1(2H)-one; or a pharma- ceutical acceptable salt and / or solvate thereof according to claim 1, wherein the compound is selected from the group consisting of:
61. 61. A pharmaceutical composition comprising a compound according to any one of claims 1 to 60, a pharma- ceutically acceptable salt and / or solvate thereof, and one or more pharma- ceutically acceptable diluents or carriers.
62. A compound according to any one of claims 1 to 60, a pharma- ceutically acceptable salt and / or solvate thereof, or a pharmaceutical composition according to claim 61, for use as a medicament.
63. A compound according to any one of claims 1 to 60, a pharma- ceutically acceptable salt and / or solvate thereof, or a pharmaceutical composition according to claim 61, for use in the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR.
64. Use of a compound according to any one of claims 1 to 60, a pharma- ceutically acceptable salt and / or solvate thereof, or a pharmaceutical composition according to claim 61, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR.
65. A method for treating or preventing a disease, disorder or condition associated with the function of PK, in particular PKM2 and / or PKLR, comprising administering a compound according to any one of claims 1 to 60, a pharma- ceutically acceptable salt and / or solvate thereof, or a pharmaceutical composition according to claim 61.
66. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or solvate thereof, a use, or a method according to any one of claims 62 to 65 for treating or preventing an inflammatory disease, a disease associated with an undesired immune response, cancer, obesity, a diabetic disease, or a blood disorder.
67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or solvate thereof, a use, or a method according to any one of claims 62 to 66 for treating an inflammatory disease or a disease associated with an undesired immune response.
68. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or a solvate thereof, a use or a method according to any one of claims 62 to 66 for the prophylaxis of an inflammatory disease or a disease associated with an undesired immune response.
69. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or solvate thereof, a use, or a method according to any one of claims 62 to 66 for treating or preventing an inflammatory disease.
70. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or a solvate thereof, a use or a method according to any one of claims 62 to 66 for treating or preventing a disease associated with an undesired immune response.
71. The inflammatory disease or disease associated with an undesired immune response is: psoriasis (including chronic plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis, and nail psoriasis), asthma, chronic obstructive pulmonary disease (including COPD, chronic bronchitis, and emphysema), heart failure (including left ventricular failure), myocardial infarction, angina pectoris, other atherosclerosis and / or atherothrombosis related disorders (including peripheral vascular disease and ischemic stroke), mitochondrial and neurodegenerative diseases (including Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, or mitochondrial encephalomyopathy), autoimmune paraneoplastic retinopathy, transplant rejection (including antibody-mediated and T-cell mediated forms), multiple sclerosis, transverse myelitis, ischemia-reperfusion injury (e.g., during elective surgery such as cardiopulmonary bypass for coronary artery bypass grafting or other cardiac surgery, following percutaneous coronary intervention, treatment of acute ST-segment elevation myocardial infarction or ischemic stroke, organ transplantation, or after acute compartment syndrome), AGE-induced genomic damage, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), primary sclerosing cholangitis (PSC), PSC-autoimmune hepatitis overlap syndrome, nonalcoholic fatty liver disease (nonalcoholic steatohepatitis), rheumatoid, granuloma annulare, cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), lupus nephritis, drug-induced lupus, autoimmune myocarditis or myopericarditis, dread Sluller syndrome, giant cell myocarditis, post-pericardiotomy syndrome, drug-induced hypersensitivity syndrome (including hypersensitivity myocarditis), eczema, sarcoidosis, erythema nodosum, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders (including MOG-EM), optic neuritis, CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), diffuse myelinoclastic sclerosis, Addison's disease, alopecia areata, ankylosing spondylitis, other spondyloarthritis (including peripheral spondyloarthritis associated with psoriasis, inflammatory bowel disease, reactive arthritis, or juvenile-onset forms of spondyloarthritis), antiphospholipid syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, pemphigoid (bullous pemphigoid, mucous membrane pemphigoid, cicatricial pemphigoid,Herpes gestationis or pemphigoid of gestationis, including ophthalmic cicatricial pemphigoid), linear IgA disease, Behcet's disease, celiac disease, Chagas disease, dermatomyositis, type I diabetes mellitus, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome and its subtypes (acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), pharyngeal - including cervicobachial, Miller-Fisher, and Bickerstaff brainstem encephalitis), progressive inflammatory neuropathy, Hashimoto's disease, hidradenitis suppurativa, inclusion body myositis, necrotizing myopathy, Kawasaki disease, IgA nephropathy, Henoch-Schonlein purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), Evans syndrome, interstitial cystitis, mixed connective tissue disease, undifferentiated connective tissue disease, morphea, myasthenia gravis (MuSK antibodies) positive and seronegative types), narcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anemia, psoriatic arthritis, polymyositis, primary biliary cholangitis (also known as primary biliary cirrhosis), rheumatoid arthritis, relapsing rheumatoid arthritis, schizophrenia, autoimmune (meningo)encephalitis syndrome, scleroderma, Sjögren's syndrome, stiff-body syndrome, polymyalgia rheumatica, giant cell arteritis (temporal arteritis), Takayasu's arteritis, polyarteritis nodosa, Kawasaki disease, granulomatous polyangiitis Granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome), microscopic polyarteritis / polyangiitis, hypocomplementemic urticarial vasculitis, hypersensitivity vasculitis, cryoglobulinemia, thromboangiitis obliterans (Buerger's disease), vasculitis, leukocytoclastic vasculitis, vitiligo, acute disseminated encephalomyelitis, adrenoleukodystrophy, Alexander disease, Alper's disease disease), Barro concentric sclerosis or Marburg disease, idiopathic organizing pneumonia (formerly bronchiolitis obliterans organizing pneumonia), Canavan disease, central nervous system vasculitis syndrome, Charcot-Marie-Tooth disease, ataxia of childhood with central nervous system hypomyelination, chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic retinopathy, globoid cell leukodystrophy (Krabbe disease), graft-versus-host disease (GVHD) (including acute and chronic forms and intestinal GVHD), hepatitis C (HCV) infection or complications, herpes simplex virus infection or complications,Human immunodeficiency virus (HIV) infection or complications, lichen planus, Hirayama disease, fibrosis, cystic fibrosis, pulmonary arterial hypertension (PAH, including idiopathic PAH), pulmonary sarcoidosis, idiopathic pulmonary fibrosis, renal fibrosis, childhood asthma, atopic dermatitis, allergic dermatitis, contact dermatitis, allergic rhinitis, rhinitis, sinusitis, conjunctivitis, allergic conjunctivitis, keratoconjunctivitis sicca, dry eye, xerophthalmia, glaucoma, macular edema, diabetic macular edema, central retinal vein occlusion (CRVO), macular degeneration (including dry and / or wet age-related macular degeneration, AMD), inflammation after cataract surgery, uveitis Autoimmune idiopathies (including posterior, anterior, intermediate and panuveitis), iridocyclitis, scleritis, corneal transplant and limbal cell graft rejection, gluten-sensitive enteropathy (celiac disease), dermatitis herpetiformis, eosinophilic esophagitis, esophageal obstruction, autoimmune autonomic neuropathy, autoimmune encephalomyelitis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, aortitis and periaortitis, autoimmune retinopathy, autoimmune urticaria, Behçet's disease, (idiopathic) Castleman's disease, Cogan's syndrome, IgG4-related disease, retroperitoneal fibrosis, juvenile idiopathic arthritis including systemic juvenile idiopathic arthritis (Still's disease), adult Human-onset Still's disease, lignoconjunctivitis, Mooren's ulcer, pityriasis lichenoides varioliformis (PLEVA, also known as Mucha-Habermann disease), multifocal motor neuropathy (MMN), childhood acute-onset neuropsychiatric syndromes (PANS) (including pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS)), paraneoplastic syndromes (including paraneoplastic cerebellar degeneration, Lambert-Eaton myasthenic syndrome, limbic encephalitis, brainstem encephalitis, opsoclonus-myoclonus ataxia syndrome, anti-NMDA receptor encephalitis, and thymoma-associated multisystem autoimmunity), perivenous encephalomyelitis, and reflex sympathetic dystrophy relapsing polychondritis, sperm and testicular autoimmunity, Susac syndrome, Tolosa-Hunt syndrome, Vogt-Koyanagi-Harada disease, antisynthetase syndrome, autoimmune enteropathy, X-linked immunodysregulation-polyendocrinopathy enteropathy (IPEX), microscopic colitis, autoimmune lymphoproliferative syndrome (ALPS), autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APEX), gout, pseudogout, amyloid (including AA or secondary amyloidosis), eosinophilic fasciitis (Schulman syndrome), progesterone hypersensitivity (including progesterone dermatitis),Familial Mediterranean Fever (FMF), Tumor Necrosis Factor (TNF) Receptor-Associated Periodic Fever Syndrome (TRAPS), Hyperglobulin Demia with Periodic Fever Syndrome (HIDS), PAPA (Septic Arthritis, Pyoderma Gangrenosum, and Severe Cystic Acne) Syndrome, Deficiency of Interleukin-1 Receptor Antagonist (DIRA), Deficiency of Interleukin-36-Receptor Antagonist (DITRA), Cryopyrin-Associated Periodic Syndrome (CAPS) (Familial Cold Autoinflammatory Syndrome [FCAS], Mucklewellyn-Wells syndrome) Syndrome, Neonatal-onset multisystem inflammatory disease [NOMID], NLRP12-associated autoinflammatory disorder (NLRP12AD), Periodic febrile aphthous stomatitis (PFAPA), Chronic atypical neutrophilic dermatosis with lipodystrophy and hyperthermia (CANDLE), Majeed syndrome, Blau syndrome (also known as juvenile systemic granulomatosis), Macrophage activation syndrome, Chronic relapsing multifocal osteomyelitis (CRMO), Familial cold autoinflammatory syndrome, Mutant adenosine deaminase 2 and single gene interferon Felonopathy (including Aicardi-Goutieres syndrome, retinal vasculopathy with cerebral leukodystrophy, spinal intrachondrodysplasia, infantile-onset STING [stimulator of interferon genes]-associated vasculopathy, proteasome-associated autoinflammatory syndrome, familial lupus pernio, hereditary symmetrical pigmentary dysplasia), Schnitzler syndrome; familial cylindromatosis, congenital B-cell lymphocytosis, OTULIN-associated autoinflammatory syndrome, type 2 diabetes, insulin resistance and metabolic syndrome (obesity-associated inflammation) 67. The pharmaceutical composition for use, the compound for use, the medicament ...
72. 72. The pharmaceutical composition for use, compound for use, pharma- ceutical acceptable salts and / or solvates thereof, use, or method according to claim 71, wherein the inflammatory disease or disease associated with an undesired immune response is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), atopic dermatitis, fibrosis, uveitis, cryopyrin-associated periodic syndrome, Muckle-Wells syndrome, juvenile idiopathic arthritis, chronic obstructive pulmonary disease, and asthma.
73. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is multiple sclerosis.
74. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is psoriasis.
75. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is asthma.
76. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is chronic obstructive pulmonary disease.
77. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is systemic lupus erythematosus.
78. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is rheumatoid arthritis.
79. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is inflammatory bowel disease (including ulcerative colitis and Crohn's disease).
80. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is atopic dermatitis.
81. 73. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to claim 72, wherein the inflammatory disease or disease associated with an undesired immune response is fibrosis.
82. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt and / or solvate thereof, a use or a method according to any one of claims 1 to 66 for treating cancer.
83. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt and / or solvate thereof, a use or a method according to any one of claims 1 to 66 for preventing cancer.
84. Cancer: acute lymphoblastic leukemia, adult;acute lymphoblastic leukemia, pediatric;acute myeloid leukemia, adult;adrenal cortical carcinoma;adrenal cortical carcinoma, pediatric;AIDS-related lymphoma;AIDS-related malignant tumors;anal cancer;astrocytoma, pediatric cerebellum;astrocytoma, pediatric cerebral;Barrett's esophagus (precancerous syndrome);bile duct cancer, extrahepatic;bladder cancer;bladder cancer, pediatric;bone cancer, osteosarcoma / malignant fibrous histiocytoma;brain stem glioma, pediatric;brain tumor, adult;brain tumor, brain stem glioma, pediatric;brain tumor, cerebellar astrocytoma, pediatric;brain tumor, cerebral astrocytoma / malignant glioma, pediatric;brain tumor, ependymoma, pediatric;brain tumor, medulloblastoma, pediatric;brain Tumors, supratentorial primitive neuroectodermal tumor, children;Brain tumors, optic tract and hypothalamic glioma, children;Brain tumors, children (other);Breast cancer;Breast cancer and pregnancy;Breast cancer, children;Breast cancer, male;Bronchial adenoma / carcinoid, children;Carcinoid tumors, children;Carcinoid tumors, gastrointestinal;Cancer, adrenal cortical;Cancer, islet cell;Carcinoma of unknown primary;Central nervous system lymphoma, primary;Cerebellar astrocytoma, children;Cerebral astrocytoma / malignant glioma, children;Cervical cancer;Childhood cancer;Chronic lymphocytic leukemia;Chronic myeloid leukemia;Chronic myeloproliferative disorder;Clear cell sarcoma of tendon sheath;Colon cancer;Colorectal cancer;Colorectal cancer, children;cutaneous T-cell lymphoma;endometrial cancer;ependymoma, children;epithelial carcinoma, ovarian;esophageal cancer;esophageal cancer, children;Ewing family tumors;extracranial germ cell tumors, children;extragonadal germ cell tumors;extrahepatic bile duct carcinoma;eye cancer, intraocular melanoma;eye cancer, retinoblastoma;gallbladder cancer;gastric cancer;gastric cancer, children;gastrointestinal carcinoid tumors;germ cell tumors, extracranial, children;germ cell tumors, extragonadal;germ cell tumors, ovarian;gestational trophoblastic tumors;glioma, children's brain stem;glioma, children's visual pathway and hypothalamus;hairy cell leukemia;head and neck cancer;hepatocellular (liver) carcinoma;hepatocellular (liver) carcinoma, adult (primary );Hepatocellular (liver) cancer, childhood (primary);Cancer of the esophagus;Hodgkin's lymphoma;Hodgkin's lymphoma, adult;Hodgkin's lymphoma, childhood;Hodgkin's lymphoma, pregnancy;Hypopharyngeal cancer;Hypothalamic and optic tract glioma, childhood;Intraocular melanoma;Islet cell carcinoma (endocrine pancreas);Cancer of the endocrine system (e.g., cancer of the thyroid, pancreas, parathyroid, or adrenal gland);Kaposi's sarcoma;Kidney cancer;Laryngeal cancer;Laryngeal cancer, childhood;Leukemia, acute lymphoblastic, adult;Leukemia, acute lymphoblastic, childhood;Leukemia, acute myeloid, adult;Leukemia, acute myeloid, childhood;Leukemia, chronic lymphocytic;Leukemia, chronic myeloid;Leukemia, hairy cell;Lymphocytic lymphoma;Lip and oral cavity cancer;Liver cancer, adult (primary);Liver cancer, childhood (primary);Lung cancer;Lung cancer, non-small cell;Lung cancer, small cell;Lymphoblastic leukemia, adult acute;Lymphoblastic leukemia, childhood acute;Lymphocytic leukemia, chronic;Lymphoma, AIDS-related;Lymphoma, central nervous system (primary);Lymphoma, cutaneous T-cell;Lymphoma, Hodgkin, adult;Lymphoma, Hodgkin, childhood;Lymphoma, Hodgkin, pregnancy;Lymphoma, non-Hodgkin, adult;Lymphoma, non-Hodgkin, childhood;Lymphoma, non-Hodgkin, pregnancy;Lymphoma, primary central nervous system;macroglobulinemia, Waldenström;male breast cancer;malignant mesothelioma, adult;malignant mesothelioma, childhood;malignant thymoma;medulloblastoma, childhood;melanoma;melanoma, intraocular;Merkel cell carcinoma;mesothelioma, malignant;metastatic squamous neck cancer of unknown primary;multiple endocrine neoplasia syndrome, childhood;multiple myeloma / plasma cell neoplasm;mycosis fungoides;myelodysplastic syndrome;myeloid leukemia, chronic;myeloid leukemia, childhood acute;myeloma, multiple;myeloproliferative disorder, chronic;nasal and paranasal sinus cancer;nasopharyngeal carcinoma;nasopharyngeal carcinoma, childhood;neoplastic skin disease;neuroblastoma;non-Hodgkin's lymphoma, adult;non-Hodgkin's Lymphoma, childhood;Non-Hodgkin's lymphoma, pregnancy;Non-small cell lung cancer;Neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumor, medulloblastoma, brain stem glioma, or pituitary adenoma);Oat cell carcinoma;Oral cavity cancer, childhood;Cancer of the oral cavity and lip;Oropharyngeal cancer;Osteosarcoma / malignant fibrous histiocytoma of bone;Ovarian cancer;Ovarian cancer, childhood;Ovarian epithelial cancer;Ovarian germ cell tumor;Ovarian low malignant potential tumor;Childhood malignant tumors;Pancreatic cancer;Pancreatic cancer, childhood;Pancreatic islet cell cancer;Sino-nasal and nasal cancer;Parathyroid cancer;Penile cancer;Pheochromocytoma;Pineal and supratentorial primitive neuroectodermal tumors, childhood;Pituitary gland Tumors;Plasma cell neoplasms / multiple myeloma;Pleuropulmonary blastoma;Pregnancy and breast cancer;Pregnancy and Hodgkin's lymphoma;Pregnancy and non-Hodgkin's lymphoma;Primary central nervous system lymphoma;Primary liver cancer, adult;Primary liver cancer, pediatric;Prostate cancer (especially hormone refractory);Chronic or acute leukemia;Solid tumors of childhood;Hypereosinophilia;Rectal cancer;Renal cell (kidney) cancer;Renal cell carcinoma, pediatric;Renal pelvis and ureter, transitional cell carcinoma;Retinoblastoma;Rhabdomyosarcoma, pediatric;Salivary gland cancer;Salivary gland cancer, pediatric;Sarcoma, Ewing family tumors;Sarcoma, Kaposi;Sarcoma (osteosarcoma) / malignant fibrous histiocytoma of bone;Sarcoma, rhabdomyosarcoma, childhood;Sarcoma of soft tissue;Sarcoma, soft tissue, adult;Sarcoma, soft tissue, childhood;Sezary syndrome;Skin cancer;Skin cancer, childhood;Skin cancer (melanoma);Skin cancer, Merkel cell;Small cell lung cancer;Dermatofibrosarcoma protuberans;Small intestine cancer;Soft tissue sarcoma, adult;Soft tissue sarcoma, childhood;Head and neck cancer;Squamous cell neck carcinoma of unknown primary, metastatic;Gastric cancer;Gastric cancer, childhood;Supratentorial primitive neuroectodermal tumor, childhood;T-cell lymphoma, skin;Testicular cancer;Thymoma, childhood;Thymoma, malignant;Thyroid cancer;Thyroid cancer, childhood;Transitional cell carcinoma of the renal pelvis and ureter;Chloroblastic tumor, gestational;Origin 83. The pharmaceutical composition for use, the compound for use, the pharma- ceutical acceptable salts and / or solvates thereof, the use, or the method according to any one of claims 66, 82, or 83, selected from the group consisting of cancer of unknown origin, pediatric; rare cancers of childhood; ureter and renal pelvis, transitional cell carcinoma; urethral cancer; cancer of the ureter (e.g., renal cell carcinoma, renal pelvis cancer); cancer of the penis; gynecological tumors; uterine cancer; uterine sarcoma; cancer of the fallopian tube; cancer of the endometrium; vaginal cancer; cancer of the vagina; cancer of the vulva; optic tract and hypothalamic glioma, pediatric; vulvar cancer; Waldenstrom's macroglobulinemia; and Wilms' tumor.
85. Cancers include, but are not limited to, lung cancer; NSCLC (non-small cell lung cancer); oat cell carcinoma; bone cancer; pancreatic cancer; skin cancer; dermatofibrosarcoma protuberans; cancer of the head and neck; cutaneous or intraocular melanoma; uterine cancer; ovarian cancer; colorectal cancer; anal cancer; gastric cancer; colon cancer; breast cancer; gynecological tumors (e.g., uterine sarcoma, cancer of the fallopian tubes, cancer of the endometrium, cancer of the cervix, cancer of the vagina, or cancer of the vulva); Hodgkin's disease; hepatocellular carcinoma; cancer of the esophagus; small intestine cancer; cancer of the endocrine system (e.g., cancer of the thyroid, pancreas, parathyroid, or adrenal gland); sarcoma of soft tissue; cancer of the urethra; cancer of the penis; prostate cancer (e.g., 85. The pharmaceutical composition for use, the compound for use, its pharmacologic acceptable salts, and / or solvates thereof, the use, or the method according to claim 84, wherein the cancer is selected from the group consisting of: chronic or acute leukemia; childhood solid tumors; hypereosinophilia; lymphocytic lymphoma; bladder cancer; kidney cancer; cancer of the ureter (e.g., renal cell carcinoma, renal pelvis carcinoma); childhood malignancies; neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumor, medulloblastoma, brain stem glioma, or pituitary adenoma); Barrett's esophagus (precancerous syndrome), and neoplastic skin diseases.
86. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or solvate thereof, a use or a method according to claim 66 for treating obesity.
87. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or a solvate thereof, a use or a method according to claim 66 for preventing obesity.
88. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or a solvate thereof, a use or a method according to claim 66 for treating a diabetic disease.
89. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or a solvate thereof, a use or a method according to claim 66 for preventing a diabetic disease.
90. 90. The pharmaceutical composition for use, compound for use, pharma- ceutically acceptable salts thereof, and / or solvates thereof, use or method according to any one of claims 66, 88 or 89, wherein the diabetic disease is selected from diabetes and diabetic complications.
91. 91. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts and / or solvates, the use or the method according to claim 90, wherein diabetes is type 1 diabetes.
92. 91. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts and / or solvates, the use or the method according to claim 90, wherein diabetes is type 2 diabetes.
93. 91. The pharmaceutical composition for use, the compound for use, its pharma- ceutical acceptable salts, and / or solvates thereof, the use, or the method according to claim 90, wherein the diabetic complication is selected from the group consisting of coronary artery disease, peripheral artery disease, stroke, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic kidney disease, and NASH.
94. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or solvate thereof, a use, or a method according to claim 66 for treating a blood disorder.
95. 67. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or a solvate thereof, a use or a method according to claim 66 for preventing a blood disorder.
96. 96. The pharmaceutical composition for use, compound for use, pharma- ceutical acceptable salts and / or solvates thereof, use, or method of any one of claims 66, 94, or 95, wherein the blood disorder is selected from the group consisting of thalassemia (e.g., β-thalassemia), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemia (e.g., enzymopathies)), and anemia of chronic disease.
97. 97. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts, and / or solvates, the use, or the method according to any one of claims 62 to 96, wherein said compound is for administration to a human subject.
98. A pharmaceutical composition for use, a compound for use, a pharma- ceutically acceptable salt thereof, and / or solvate thereof, a use or a method according to any one of claims 62 to 97 for use in combination with a further therapeutic agent.
99. Corticosteroids (glucocorticoids), retinoids (e.g., acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogues (e.g., cacitriol, calcipotriol), calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g., psoralen ultraviolet radiation, PUVA) or other forms of ultraviolet light radiation therapy, cyclosporine, thiopurines (e.g., azathioprine, 6-mercaptopurine), methotrexate, anti-TNFα agents (e.g., infliximab, etanercept, adalimumab , certolizumab, golimumab, or biosimilars), phosphodiesterase-4 (PDE4) inhibitors (e.g., apremilast, crisaborole), anti-IL-17 agents (e.g., brodalumab, ixekizumab, secukinumab), anti-IL12 / IL-23 agents (e.g., ustekinumab, briakinumab), anti-IL-23 agents (e.g., guselkumab, tildrakizumab), JAK (Janus kinase) inhibitors (e.g., tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasmapheresis, intravenous immunoglobulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agents (e.g., rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogues (e.g., mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulators or sphingosine analogues (e.g., fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparations (interferon beta 1b / 1a), glatiramer, anti-CD3 therapy (e.g., OKT3), anti-CD52 targeted agents (e.g., alemtuzumab), leflunomide, teriflunomide, gold compounds, laquinimod, potassium channel blockers (e.g., dalfampridine / 4-aminopyridine), mycophenolic acid, mycophenolate mofetil, purine analogs (e.g., pentostatin), mTOR (target of rapamycin) pathway inhibitors (e.g., sirolimus, everolimus), anti-thymocyte globulin (ATG), IL-2 receptor (CD25) inhibitors (e.g., basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agents (e.g., tocilizumab,Other B cell targeted therapies, including B-cell activating factor (BAFF, also known as BlyS) inhibitors (e.g., belimumab, blissibimod), fusion proteins targeting both APRIL (proliferative ligand) and BlyS (e.g., atacicept), pan inhibitors or agents targeting p110δ and / or p110γ-containing isoforms (e.g., rituximab), Bruton's tyrosine kinase (BTK) inhibitors (e.g., ibrutinib), tyrosine kinase inhibitors (e.g., imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B-cell activating factor (BAFF, also known as BlyS) inhibitors (e.g., belimumab, blissibimod), fusion proteins targeting both APRIL (proliferative ligand) and BlyS (e.g., atacicept), pan inhibitors or agents targeting p110δ and / or p110γ-containing isoforms (e.g., rituximab ... PI3K inhibitors (e.g., idelalisib, copanlisib, duvelisib), interferon alpha receptor inhibitors (e.g., anifrolumab, sifalimumab), T cell costimulatory blockers (e.g., abatacept, belatacept), thalidomide and its derivatives (e.g., lenalidomide), dapsone, clofazimine, leukotriene antagonists (e.g., montelukast), theophylline, anti-IgE therapy (e.g., omalizumab), anti-IL-5 agents (e.g., mepolizumab, reslizumab), long-acting muscarinic agents (e.g., thiotoxin, thiol ... thiazide, ... , vedolizumab), anti-CD11-α agents (e.g., efalizumab), nonsteroidal anti-inflammatory drugs (NSAIDs) including salicylates (e.g., aspirin), propionic acids (e.g., ibuprofen, naproxen), acetates (e.g., indomethacin, diclofenac, etodolac), oxicams (e.g., meloxicam), and fenamates (e.g., mefenamic acid), selective or relatively selective COX-2 inhibitors (e.g., celecoxib, etroxicoxib, valdecoxib, and etodolac, meloxicam, nabumetone),Colchicine, IL-4 receptor inhibitors (e.g., dupilumab), local / contact immunotherapy (e.g., diphenylcyclopropenone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g., anakinra), IL-1β inhibitors (e.g., canakinumab), IL-1 neutralizing therapy (e.g., rilonacept), chlorambucil, certain antibiotics with immunomodulatory properties and / or the ability to modulate NRF2 (e.g., minocycline, tetracyclines including clindamycin, macrolide antibiotics), antiandrogen therapy (e.g., cyproterone, spironolactone, fumarate, 82. The pharmaceutical composition for use, the compound for use, the pharma- ceutical acceptable salts and / or solvates thereof, the use, or the method according to any one of claims 67 to 81, for use in combination with a further therapeutic agent selected from the group consisting of: finasteride, pentoxifylline, ursodeoxycholic acid, obeticholic acid, fibrates, cystic fibrosis transmembrane conductance regulator (CFTR) modulators, VEGF (vascular endothelial growth factor) inhibitors (e.g., bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone, or mizoribine.
100. 86. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts and / or solvates thereof, the use or the method according to any one of claims 82 to 85 for use in combination with a further therapeutic agent selected from the group consisting of antiemetics, drugs intended to relieve pain such as opioids, drugs used to lower high blood uric acid levels such as allopurinol or rasburicase, palliative treatments such as those selected from the group consisting of antidepressants, sedatives, anticonvulsants, laxatives, antidiarrheals, and / or antacids.
101. 86. The pharmaceutical composition for use, the compound for use, its pharma- ceutically acceptable salts and / or solvates, the use or the method according to any one of claims 82 to 85 for use in combination with an additional cancer treatment selected from the group consisting of chemotherapy, targeted therapy, immunotherapy, and hormonal therapy.
102. The chemotherapeutic agent is aclarubicin, actinomycin, alitretinone, altretamine, aminopterin, aminolevulinic acid, amrubicin, amsacrine, anagrelide, arsenic trioxide, asparaginase, atrasentan, belotecan, bexarotene, endamustine, bleomycin, bortezomib, busulfan, camptothecin, capecitabine, carboplatin, carboquone, carmofur, carmustine, celecoxib, chlorambucil, chlormethine, cisplatin, cladrivir , clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, demecolcine, docetaxel, doxorubicin, efaproxiral, elesclomol, elsamitrucin, enocitabine, epirubicin, estramustine, etoglucide, etoposide, floxuridine, fludarabine, fluorouracil (5FU), fotemustine, gemcitabine, gliadel implant, hydroxycarbamide, hydroxyurea, idarubicin, ifosfamide, irinotecan, Irofulven, ixabepilone, larotaxel, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lonidamine, lomustine, lucantone, mannosulfan, masoprocol, melphalan, mercaptopurine, mesna, methotrexate, methyl aminolevulinate, mitobronitol, mitoguazone, mitotane, mitomycin, mitoxantrone, nedaplatin, nimustine, oblimersen, omacetaxine, ortataxel, oxaliplatin, paclitaxel, pegaspargase, pemetrexed, pentostatin, Pirarubicin, pixantrone, plicamycin, porfimer sodium, prednimustine, procarbazine, raltitrexed, ranimustine, rubitecan, sapacitabine, semustine, sitimagene seradenovec, satraplatin, streptozocin, talaporfin, tegafur-uracil, temoporfin, temozolomide, teniposide, tesetaxel, testolactone, tetranitrate, thiotepa, tiazofurin, thioguanine, tipifarnib, topotecan, trabectedin, triazicon, triethylenemelamine, triplatin,The pharmaceutical composition for use, the compound for use, the pharma- ceutically acceptable salts and / or solvates thereof, the use, or the method according to claim 101, selected from the group consisting of tretinoin, treosulfan, trofosfamide, uramustine, valrubicin, verteporfin, vinblastine, vincristine, vindesine, vinfhmine, vinorelbine, vorinostat, and zorubicin.
103. The pharmaceutical composition for use, the compound for use, its pharmaceutically acceptable salts and / or solvates, the use, or the method according to claim 101, wherein the targeted therapy is selected from the group consisting of axitinib, bosutinib, cediranib, dasatinib, erlotinib, imatinib, gefitinib, lapatinib, lestaurtinib, nilotinib, semaxanib, sorafenib, sunitinib, vandetanib, alvocidib, seliciclib, herceptin, rituximab, tositumomab, cetuximab, panitumumab, trastuzumab, alemtuzumab, bevacizumab, edrecolomab, gemtuzumab, aflibercept, denileukin diftitox, and bexar.
104. Gastric or pancreatic lipase inhibitors (such as orlistat); lipid lowering agents (such as statins, fibrates, niacin or its derivatives (such as acipimox), lecithin, bile acid sequestrants, ezetimibe, lomitapide, phytosterols, omega-3 supplements, PCSK9 inhibitors); CB-1 antagonists; lipoxygenase inhibitors; somostatin analogs; insulin compounds or insulin analogs (human insulin, insulin lispro, insulin aspart, insulin lispro ... insulin glulisine, insulin glargine, insulin degludec, etc.; insulin sensitizers such as PPAR-gamma agonists, PPAR-alpha agonists, or mixed PPAR-gamma / alpha agonists (such as metformin, pioglitazone, or rosiglitazone); insulin secretagogues (such as nateglinide or repaglinide, or sulfonylureas such as gliclazide, glimeperide, limepiride, and glyburide). SGLT2 inhibitors (such as dapagliflozin, canagliflozin, or empagliflozin); amylin analogs (such as pramlintide); DPPIV inhibitors (such as sitagliptin, saxagliptin, linagliptin, alogliptin, or vildagliptin); GLP-1 agonists (such as albiglutide, dulaglutide, exenatide, liraglutide, semaglutide, or lixisenatide); α-glucosidase inhibitors (such as acarbose, miglitol, or voglibose) 88. A pharmaceutical composition for use, a compound for use, a pharma- ceutical acceptable salt thereof, and / or solvate thereof, use, or method as described in claim 86 or 87 for use in combination with an inhibitor of serotonin, phosphodiesterase (such as pentoxifylline), glycogen phosphorylase inhibitor, MCH-1 antagonist, glucokinase activator, glucagon antagonist, insulin signaling agonist, PTP1B inhibitor, gluconeogenesis inhibitor, GSK inhibitor or galanin receptor agonist.
105. Gastric or pancreatic lipase inhibitors (such as orlistat); lipid lowering agents (such as statins, fibrates, niacin or its derivatives (such as acipimox), lecithin, bile acid sequestrants, ezetimibe, lomitapide, phytosterols, omega-3 supplements, PCSK9 inhibitors); CB-1 antagonists; lipoxygenase inhibitors; somostatin analogs; insulin compounds or insulin analogs (human insulin, insulin lispro, insulin aspart, insulin insulin glulisine, insulin glargine, insulin degludec, etc.; insulin sensitizers such as PPAR-gamma agonists, PPAR-alpha agonists, or mixed PPAR-gamma / alpha agonists (such as metformin, pioglitazone, or rosiglitazone); insulin secretagogues (such as nateglinide or repaglinide, or sulfonylureas such as gliclazide, glimeperide, limepiride, and glyburide); SG LT2 inhibitors (such as dapagliflozin, canagliflozin, or empagliflozin); amylin analogs (such as pramlintide); DPPIV inhibitors (such as sitagliptin, saxagliptin, linagliptin, alogliptin, or vildagliptin); GLP-1 agonists (such as albiglutide, dulaglutide, exenatide, liraglutide, semaglutide, or lixisenatide); α-glucosidase inhibitors (such as acarbose, miglitol, or voglibose); A pharmaceutical composition for use, a compound for use, a pharma- ceutical acceptable salt and / or solvate thereof, use or method according to any one of claims 88 to 93 for use in combination with a phosphodiesterase inhibitor (such as pentoxifylline); a glycogen phosphorylase inhibitor; an MCH-1 antagonist; a glucokinase activator; a glucagon antagonist; an insulin signaling agonist; a PTP1B inhibitor; a gluconeogenesis inhibitor; a GSK inhibitor or a galanin receptor agonist.
106. 6-((4-methoxyphenyl)sulfonyl)phthalazin-1(2H)-one; 6-(phenylsulfonyl)phthalazin-1(2H)-one; 6-Bromo-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; 6-mercapto-2-((6-methoxypyridin-3-yl)methyl)phthalazin-1(2H)-one; tert-Butyl (3-((6-bromo-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate; tert-Butyl (3-((6-mercapto-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate; 2-((2-chloropyridin-3-yl)methyl)-6-mercaptophthalazin-1(2H)-one; 6-mercapto-2-((1-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-mercapto-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)-6-mercaptophthalazin-1(2H)-one; 6-Bromo-2-((4-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-Bromo-2-((5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; 6-Mercaptophthalazin-1(2H)-one; 6-Mercapto-2-((6-methylpyridin-2-yl)methyl)phthalazin-1(2H)-one; 5-Fluoro-6-(phenylthio)phthalazin-1(2H)-one; 7-Fluoro-6-(phenylthio)phthalazin-1(2H)-one; and 6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one; A compound or a salt thereof selected from the group consisting of:
107. Formula (IIa-S): [C13] or a salt thereof; Formula (IIIa-S): [C14] Compound (In the formula, R A , R B , R C , R D , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 , X and m are as defined in any one of claims 1 to 40, and LG 2 is a leaving group such as halo (e.g., chloro, bromo, or iodo), OMs, or OTs); 61. A process for preparing a compound of formula (Ia) according to any one of claims 1 to 60, or a salt such as a pharma- ceutically acceptable salt and / or solvate thereof, comprising reacting with
108. Formula (IIa-S): [C15] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , Z 2 and X is defined in any one of claims 1 to 16, 31 or 34 to 50. or a salt and / or solvate thereof.
109. Formula (IVa): [C16] (In the formula, Y 1 , Y 2 , Y 3 , Z 1 , and Z 2is defined in any one of claims 1 to 60, and LG is a leaving group such as halo, OMs, or OTs. or a salt and / or solvate thereof.
110. Formula (Va): [C17] (In the formula, R A , Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined in any one of claims 1 to 60) or a salt and / or solvate thereof.
111. Formula (VIa): [C18] (In the formula, R B , R C , R D , m, Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined in any one of claims 1 to 60, and LG 1 is a leaving group such as halo (e.g., chloro, bromo, or iodo), OMs, or OTs). or a salt and / or solvate thereof.
112. Formula (VIIa): [C19] (In the formula, R A , R B , R C , R D , m, Y 1 , Y 2 , Y 3 , Z 1 , and Z 2 is defined in any one of claims 1 to 60) or a salt and / or solvate thereof.
113. 66. The compound according to any one of claims 1 to 65, which is a pharma- ceutically acceptable salt of the compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof.
114. 66. The compound according to any one of claims 1 to 65, which is a compound of formula (Ia) or a pharma- ceutically acceptable salt and / or solvate thereof.
Citation Information
Patent Citations
Fatty amino substituted quinazolinone derivative and preparation method and application thereof
CN103833646A
Histone histone deacetylase inhibitor and application thereof
CN107879975A
M2 type pyruvate kinase small molecule activator and application thereof
CN112156095A
γ-Secretase Modulator
JP2011506461A
Benzazepine derivatives, their preparation, pharmaceutical compositions and uses
JP2019518728A
